N-(hydroxyalkyl(hetero)aryl)tetrahydrofurancarboxamide as a modulator of sodium channels

N-(hydroxyalkyl(hetero)aryl)tetrahydrofurancarboxamide compounds selectively target NaV1.8 sodium channels to address the limitations of existing inhibitors, offering improved pain relief for neuropathic and chronic pain conditions.

JP7948970B2Active Publication Date: 2026-11-11VERTEX PHARMACEUTICALS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023574395
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-06-04
Filing Date
2022-06-03
Publication Date
2026-11-11
Estimated Expiration
2042-06-03

AI Technical Summary

Technical Problem

Existing voltage-gated sodium channel inhibitors lack isoform selectivity, potency, and therapeutic window, limiting their effectiveness in treating neuropathic pain and other chronic pain conditions.

Method used

Development of N-(hydroxyalkyl(hetero)aryl)tetrahydrofurancarboxamide compounds that selectively target voltage-gated sodium channels, particularly NaV1.8, to inhibit pain signaling.

Benefits of technology

The compounds effectively reduce neuropathic pain and other chronic pain conditions by selectively inhibiting sodium channels, providing a broader therapeutic window and improved efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007948970000187
    Figure 0007948970000187
  • Figure 0007948970000188
    Figure 0007948970000188
  • Figure 0007948970000189
    Figure 0007948970000189
Patent Text Reader

Abstract

Compounds of formula I and pharma- ceutically acceptable salts thereof are provided that are useful as inhibitors of sodium channels.Also provided are pharmaceutical compositions comprising the compounds or pharma- ceutically acceptable salts, and methods of using the compounds, pharma- ceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.In yet another aspect, the invention relates to a method of inhibiting voltage-gated sodium channels in a subject by administering a compound, a pharma- ceutically acceptable salt, or a pharmaceutical composition to the subject. JPEG2024522292000158.jpg5870
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 63 / 196,946, filed on 4 June 2021, which is incorporated herein by reference in its entirety. [Background technology]

[0002] Pain is a protective mechanism that allows healthy animals to avoid tissue damage and prevent further damage to damaged tissue. Nevertheless, there are many conditions in which pain persists beyond its usefulness, or in which the patient would benefit from pain suppression. Neuropathic pain is a form of chronic pain caused by damage to sensory nerves (Dieleman, JP, et al., Incidence rates and treatment of neuropathic pain conditions in the general population. Pain, 2008. 137(3): p.681-8). Neuropathic pain can be divided into two categories: pain caused by systemic metabolic damage to nerves, and pain caused by discrete nerve damage. Metabolic neuropathy includes postherpetic neuropathy, diabetic neuropathy, and drug-induced neuropathy. Indications for discrete nerve damage include pain after amputation, postoperative nerve injury pain, and nerve compression injuries such as neuropathic back pain.

[0003] Voltage-gated sodium channels (Na V ) is involved in pain signaling. V Sodium is a biological mediator of electrical signaling, mediating the rapid rise in action potentials in many excitable cell types (e.g., neurons, skeletal muscle cells, cardiomyocytes). Evidence for the role of these channels in normal physiological function, pathological conditions arising from mutations in sodium channel genes, preclinical studies in animal models, and the clinical pharmacology of known sodium channel modulators all support the role of Na in pain perception. VThis suggests a central role (Rush, A.M. and TRCummins, Painful Research: Identification of a Small-Molecule Inhibitor that Selectively Targets Na). V 1.8 Sodium Channels.Mol.Interv.,2007.7(4):p.192-5), England, S., Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin. Investig. Drugs 17(12), p.1849-64 (2008), Krafte, DSand Bannon, AW, Sodium channels and Nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol.8(1), p.50-56(2008)). Na V Na mediated the rapid increase in action potentials in many excitable cell types (e.g., neurons, skeletal muscle cells, cardiomyocytes) and was therefore involved in the initiation of signal transduction in those cells (Hille, Bertil, Ion Channels of Excitable Membranes, Third ed. (Sinauer Associates, Inc., Sunderland, MA, 2001)). Na mediated the initiation and propagation of neuronal signals. V Due to the role that Na plays, V Antagonists that reduce current can prevent or reduce nerve signaling, Na VChannels have been considered to have high potential to reduce pain in states where high excitability is observed (Chahine, M., Chatelier, A., Babich, O., and Krupp, J.J., Voltage-gated sodium channels in neurological disorders. CNS Neurol. Disord. Drug Targets 7 (2), p.144-58(2008)). Several clinically useful analgesics are Na V have been identified as channel inhibitors. Local anesthetics such as lidocaine block pain by inhibiting Na V channels, and other compounds such as carbamazepine, lamotrigine, and tricyclic antidepressants, which have proven effective in reducing pain, have also been suggested to act via sodium channel inhibition (Soderpalm, B., Anticonvulsants: aspects of their mechanisms of action. Eur. J. Pain 6 Suppl. A, p.3-9(2002), Wang, G.K., Mitchell, J., and Wang, S.Y., Block of persistent late Na + currents by antidepressant sertraline and paroxetine. J. Membr. Biol. 222(2), p.79-90(2008)).

[0004] Na V form a subfamily of the voltage-gated ion channel superfamily, and include 9 isoforms designated as Na V 1.1 to Na V 1.9. The tissue localization of the 9 isoforms differs. Na V 1.4 is the primary sodium channel in skeletal muscle, and Na V 1.5 is the primary sodium channel in cardiomyocytes. Na V 1.7, 1.8, and 1.9 are mainly localized in the peripheral nervous system, and Na V1.1, 1.2, 1.3, and 1.6 are neuronal channels found in both the central and peripheral nervous systems. While the functional behavior of the nine isoforms is similar, they are distinct in the details of their voltage-gated and dynamic behavior (Catterall, WA, Goldin, AL, and Waxman, SG, International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57(4), p. 397 (2005)).

[0005] When they were discovered, Na V Channel 1.8 was identified as a likely target for analgesia (Akopian, AN, L. Sivilotti, and J.N. Wood, A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature, 1996. 379(6562): p.257-62). Subsequently, Na V 1.8 has been shown to be the carrier of sodium current that maintains action potential firing in small dorsal root ganglion (DRG) neurons in nociceptive sensory neurons (Blair, NT and BPBean, Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+). + current, and Ca 2+ current in the action potentials of nociceptive sensory neurons.J.Neurosci.,2002.22(23):p.10277-90). Na V 1.8 is involved in spontaneous firing in damaged neurons, such as those that cause neuropathic pain (Roza, C., et al., The tetrodotoxin-resistant Na+ channel Na V 1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice.J.Physiol.,2003.550(Pt 3):p.921-6、Jarvis,M.F.,et al.,A-803467,a potent and selective Na V 1.8 sodium channel blocker,attenuates neuropathic and inflammatory pain in the rat.Proc.Natl.Acad.Sci.U S A,2007.104(20):p.8520-5、Joshi,S.K.,et al.,Involvement of the TTX-resistant sodium channel Na V 1.8 in inflammatory and neuropathic,but not post-operative,pain states.Pain,2006.123(1-2):pp.75-82、Lai,J.,et al.,Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel,Na V 1.8.Pain,2002.95(1-2):p.143-52、Dong,X.W.,et al.,Small interfering RNA-mediated selective knockdown of Na V1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats.Neuroscience,2007.146(2):p.812-21、Huang,H.L.,et al.,Proteomic profiling of neuromas reveals alterations in protein composition and local protein synthesis in hyper-excitable nerves.Mol.Pain,2008.4:p.33、Black,J.A.,et al.,Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann. Neurol.,2008.64(6):p.644-53、Coward,K.,et al.,Immunolocalization of SNS / PN3 and NaN / SNS2 sodium channels in human pain states. Pain,2000.85(1-2):p.41-50、Yiangou,Y.,et al.,SNS / PN3 and SNS2 / NaN sodium channel-like immunoreactivity in human adult and neonate injured sensory nerves.FEBS Lett.,2000.467(2-3):p.249-52、Ruangsri,S.,et al.,Relationship of axonal voltage-gated sodium channel 1.8(Na V 1.8)mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats.J.Biol.Chem.286(46):p.39836-47)。Na VSmall DRG neurons expressing 1.8 contain nociceptors involved in pain signaling. V 1.8 mediates large-amplitude action potentials in small neurons of the dorsal root ganglia (Blair, NT and BPBean, Roles of tetrodotoxin (TTX)-sensitive Na + current, TTX-resistant Na + current, and Ca 2+ current in the action potentials of nociceptive sensory neurons.J.Neurosci.,2002.22(23):p.10277-90). Na V 1.8 is necessary for rapid, repetitive action potentials in nociceptors and for spontaneous activity in damaged neurons. (Choi, JS and SG Waxman, Physiological interactions between Na V 1.7 and Na V 1.8 sodium channels: a computer simulation study.J.Neurophysiol.106(6):p.3173-84, Renganathan, M., TRCummins, and SGWaxman, Contribution of Na( V )1.8 sodium channels to action potential electrogenesis in DRG neurons.J.Neurophysiol.,2001.86(2):p.629-40, Roza,C.,et al.,The tetrodotoxin-resistant Na + channel Na V 1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J. Physiol., 2003. 550 (Pt 3): p. 921-6). In depolarized or damaged DRG neurons, Na V1.8 appears to be a driving factor for hyperexcitability (Rush, AM, et al., A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. USA, 2006. 103(21): p. 8245-50). In some animal pain models, Na V 1.8 mRNA expression levels have been shown to increase in DRGs (Sun, W., et al., Reduced conduction failure of the main axon of polymodal nociceptive C-fibers contributes to painful diabetic neuropathy in rats. Brain, 135 (Pt 2): p.359-75; Strickland, IT, et al., Changes in the expression of Na V 1.7,Na V 1.8 and Na V 1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain.Eur.J.Pain,2008.12(5):p.564-72, Qiu,F.,et al.,Increased expression of tetrodotoxin-resistant sodium channels Na V 1.8 and Na V 1.9 within dorsal root ganglia in a rat model of bone cancer pain.Neurosci.Lett.,512(2):p.61-6). The inventors of this invention believe that some voltage-gated sodium channel inhibitors may have an insufficient therapeutic window (e.g., Na VIt was discovered that it has limitations as a therapeutic agent due to a lack of isoform selectivity, low potency, and / or other reasons. Therefore, selective Na V The need to develop selective voltage-gated sodium channel inhibitors, such as 1.8 inhibitors, remains. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Dieleman,JP,et al.,Incidence rates and treatment of neuropathic pain conditions in the general population.Pain,2008.137(3):p.681-8 [Non-Patent Document 2] Rush, AMand TRCummins, Painful Research:Identification of a Small-Molecule Inhibitor that Selectively Targets NaV1.8 Sodium Channels.Mol.Interv.,2007.7(4):p.192-5) [Non-Patent Document 3] England, S., Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin. Investig. Drugs 17(12), p.1849-64 (2008) [Non-Patent Document 4] Krafte, DSand Bannon, AW, Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol.8(1), p.50-56(2008) [Non-Patent Document 5] Hille, Bertil, Ion Channels of Excitable Membranes, Third ed. (Sinauer Associates, Inc., Sunderland, MA, 2001) [Non-Patent Document 6] Chahine, M., Chatelier, A., Babich, O., and Krupp, JJ, Voltage-gated sodium channels in neurological disorders.CNS Neurol.Disord.Drug Targets 7 (2), p.144-58(2008) [Non-Patent Document 7] Soderpalm, B., Anticonvulsants: aspects of their mechanisms of action.Eur.J.Pain 6 Suppl.A, p.3-9(2002) [Non-Patent Document 8] Wang, GK, Mitchell, J., and Wang, SY, Block of persistent late Na+ currents by antidepressant sertraline and paroxetine.J.Membr.Biol.222(2),p.79-90(2008) [Non-Patent Document 9] Catterall, WA, Goldin, AL, and Waxman, SG, International Union of Pharmacology.XLVII.Nomenclature and structure-function relationships of voltage-gated sodium channels.Pharmacol.Rev.57(4), p.397(2005) [Non-Patent Document 10] Akopian, A.N., L. Sivilotti, and J.N. Wood, A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature, 1996. 379(6562): p. 257-62 Non-Patent Document 11 Blair, N.T. and B.P. Bean, Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons. J. Neurosci., 2002. 22(23): p. 10277-90 Non-Patent Document 12 Roza, C., et al., The tetrodotoxin-resistant Na+ channel NaV1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J. Physiol., 2003. 550(Pt 3): p. 921-6 Non-Patent Document 13 Jarvis, M.F., et al., A-803467, a potent and selective NaV1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. U S A, 2007. 104(20): p. 8520-5 Non-Patent Document 14 Joshi, S.K., et al., Involvement of the TTX-resistant sodium channel NaV1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain, 2006. 123(1-2): pp.75-82 Non-Patent Document 15 Lai, J., et al., Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain, 2002. 95(1-2): p.143-52 Non-Patent Document 16 Dong, X.W., et al., Small interfering RNA-mediated selective knockdown of NaV1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience, 2007. 146(2): p.812-21 Non-Patent Document 17 Huang, H.L., et al., Proteomic profiling of neuromas reveals alterations in protein composition and local protein synthesis in hyper-excitable nerves. Mol. Pain, 2008. 4: p.33 Non-Patent Document 18 Black, J.A., et al., Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann. Neurol., 2008. 64(6): p.644-53 [Non-Patent Document 19] Coward, K., et al., Immunolocalization of SNS / PN3 and NaN / SNS2 sodium channels in human pain states. Pain, 2000. 85(1-2): p.41-50 [Non-Patent Document 20] Yiangou, Y., et al., SNS / PN3 and SNS2 / NaN sodium channel-like immunoreactivity in human adult and neonate injured sensory nerves. FEBS Lett., 2000. 467(2-3): p.249-52 [Non-Patent Document 21] Ruangsri, S., et al., Relationship of axonal voltage-gated sodium channel 1.8 (NaV1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats. J. Biol. Chem. 286(46): p.39836-47 [Non-Patent Document 22] Blair, N.T. and B.P. Bean, Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons. J. Neurosci., 2002. 22(23): p.10277-90 [Non-Patent Document 23] Choi, J.S. and S.G. Waxman, Physiological interactions between NaV1.7 and NaV1.8 sodium channels: a computer simulation study. J. Neurophysiol. 106(6): p.3173-84 [Non-Patent Document 24] Renganathan, M., TRCummins, and SGWaxman, Contribution of Na(V)1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol., 2001.86(2):p.629-40 [Non-Patent Document 25] Roza, C., et al., The tetrodotoxin-resistant Na+ channel NaV1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice.J.Physiol.,2003.550(Pt 3):p.921-6 [Non-Patent Document 26] Rush, AM, et al., A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. USA, 2006.103(21):p.8245-50 [Non-Patent Document 27] Sun, W., et al., Reduced conduction failure of the main axon of polymodal nociceptive C-fibers contributes to painful diabetic neuropathy in rats.Brain, 135(Pt 2):p.359-75 [Non-Patent Document 28] Strickland, IT, et al., Changes in the expression of NaV1.7,NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain.Eur.J.Pain,2008.12(5):p.564-72 [Non-Patent Document 29] Qiu, F., et al., Increased expression of tetrodotoxin-resistant sodium channels NaV1.8 and NaV1.9 within dorsal root ganglia in a rat model of bone cancer pain.Neurosci.Lett.,512(2):p.61-6 [Overview of the project] [Means for solving the problem]

[0007] In one embodiment, the present invention relates to compounds described herein, or pharmaceutically acceptable salts thereof.

[0008] In another embodiment, the present invention relates to a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or vehicles.

[0009] In yet another aspect, the present invention relates to a method for inhibiting voltage-gated sodium channels in a subject by administering a compound, a pharmaceutically acceptable salt, or a pharmaceutical composition to the subject.

[0010] In yet another aspect, the present invention relates to a method for treating or reducing the severity of various diseases, disorders, or conditions, including but not limited to chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., pain from aponeurosis resection, hernia repair, or abdominal wall reconstruction), visceral pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or cardiac arrhythmia, by administering a compound, a pharmaceutically acceptable salt, or a pharmaceutical composition to a subject. [Brief explanation of the drawing]

[0011] [Figure 1] The XRPD pattern characteristics of amorphous compound 1 are shown. [Figure 2] The XRPD pattern characteristics of amorphous compound 7 are shown. [Figure 3] The XRPD pattern characteristics of amorphous compound 8 are shown. [Figure 4] The XRPD pattern characteristics of compound 16 in its crystalline form are shown. [Figure 5] The XRPD pattern characteristics of amorphous compound 21 are shown. [Figure 6] The XRPD pattern characteristics of amorphous compound 35 are shown. [Modes for carrying out the invention]

[0012] In one embodiment, the present invention relates to a compound of formula (I), [ka] , Or with respect to the pharmaceutically acceptable salt thereof, X 2a is N, N + -O - , or CR 2a And, X 3a is N or N + -O - And, X 5a is N, N +-O - , or CR 5a And, X 6a is N, N + -O - , or CR 6a And, R d (CH2) m (CHR e ) n (CH2) p H is, m, n, and p are each independently either 0 or 1. R e is H, OH, halo, C1-C6 alkoxy, or C1-C6 haloalkoxy. R 2a and R 6a Each of these is independently H, halo, C1-C6 alkyl, or C1-C6 haloalkyl. R 5a is H, halo, CH2OH, C1-C6 alkyl, or C1-C6 haloalkyl, R 4b1 and R 4b2 Each of these is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl. R 5b1 and R 5b2 Each of these is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl. X 3c is N or CR 3c And, X 4c is N or CR 4c And, X 5c is N or CR 5c And, X 6c is N or CR 6c And, R 2c This refers to H, OH, halo, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2-(C3-C6 cycloalkyl), wherein said cycloalkyl is optionally substituted with 1 to 2 halo groups, L 1 is a bond or O, L 2 is a bond or C1-C6 alkylene, R 3c is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl, or X 3c is C-R 3c , and R 2c and R 3c together with the carbon atom to which they are attached form a ring of the following formula, [Chemical Formula] ; Z1 and Z2 are each independently O or CH2, each R is independently H or halo, R 4c is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, R 5c is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl, R 6c is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl, provided that, X 2a , X 3a , X 5a , and X 6a no more than 2 of them are N or N + -O - , and X 3c , X 4c , X 5c , and X 6c no more than 1 of them is N.

[0013] For the purpose of the present invention, chemical elements are defined according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th The general principles of organic chemistry are identified according to Ed. Furthermore, “Organic Chemistry,” Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry,” 5 th This is described in Ed., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001, and its entire contents are incorporated herein by reference.

[0014] As used herein, the term “compounds of the present invention” refers to the compounds of formula (I) described herein, all of its embodiments (e.g., formula (IA), etc.), and the compounds specified in Table A.

[0015] As described herein, the compounds of the present invention have a plurality of variable groups (for example, R 1 , X 3a , R 5b This includes, for example. As those skilled in the art will recognize, the combinations of groups envisioned by the present invention are combinations that result in the formation of stable or chemically viable compounds. In this context, “stable” means a compound that remains substantially unchanged when subjected to conditions that enable their formation, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable or chemically viable compound is a compound that remains substantially unchanged when held at a temperature of 40°C or less for at least one week in the absence of moisture or other chemically reactive conditions.

[0016] The chemical structures illustrated herein will be understood by those skilled in the art, and are therefore intended to be understood. For example, with respect to formulas (I), (IA), (IB), and (IC), X 2a and X 3a They are joined by a single bond, X 5a and X 6aThey are joined by a double bond, X 4c and X 5c Although they are joined by single bonds, the bonds between these groups can be hidden by atomic labels in the chemical structure. Using different ChemDraw styles, equation (I) can be drawn as follows to illustrate the bonds in question. [ka] Furthermore, substituents represented as "CF3" or "F3C" in the chemical structure refer to trifluoromethyl substituents, regardless of whether their representation appears in the chemical structure.

[0017] As used herein, the term "halo" means F, Cl, Br, or I.

[0018] As used herein, the term "alkyl" refers to a linear or branched hydrocarbon radical group consisting only of carbon and hydrogen atoms, which is unsaturated and has a specified number of carbon atoms, and is bonded to the rest of the molecule by a single bond. For example, a "C1-C6 alkyl" group is an alkyl group having 1 to 6 carbon atoms.

[0019] As used herein, the term “alkenyl” refers to a linear or branched hydrocarbon chain radical group consisting only of carbon and hydrogen atoms, having one or more carbon-carbon double bonds and a specified number of carbon atoms, which are bonded to the rest of the molecule by single bonds. For example, a “C2-C6 alkenyl” group is an alkenyl group having 2 to 6 carbon atoms.

[0020] As used herein, the term “cycloalkyl” refers to a stable, non-aromatic monocyclic or bicyclic (condensed, cross-linked, or spiro) saturated hydrocarbon radical consisting only of carbon and hydrogen atoms, having a specified number of carbon ring atoms, which are bonded to the rest of the molecule by single bonds. For example, a “C3-C8 cycloalkyl” group is a cycloalkyl group having 3 to 8 carbon atoms.

[0021] As used herein, the term "haloalkyl" refers to an alkoxy group having a specified number of carbon atoms, in which one or more hydrogen atoms of the alkyl group are replaced by a halo group. For example, a "C1-C6 haloalkyl" group is an alkyl group having 1 to 6 carbon atoms, in which one or more hydrogen atoms of the alkyl group are replaced by a halo group.

[0022] As used herein, the term "alkoxy" refers to the formula -OR a This refers to the radical of the expression, where R is located in the formula. a This is an alkyl group having a specified number of carbon atoms. For example, a "C1-C6 alkoxy" group is defined by the formula -OR a It is a radical of, and in the formula, R a It is an alkyl group having 1 to 6 carbon atoms.

[0023] As used herein, the term "haloalkoxy" refers to an alkoxy group having a specified number of carbon atoms, wherein one or more hydrogen atoms of the alkyl group are replaced by a halo group.

[0024] As used herein, the term "alkylene" refers to a divalent linear or branched hydrocarbon radical group consisting only of carbon and hydrogen atoms, which is unsaturated and has a specified number of carbon atoms, and is bonded to the rest of the molecule by two single bonds. For example, a "C1-C6 alkylene" group is an alkylene group having 1 to 6 carbon atoms.

[0025] As used herein, the term “optionally substituted” refers to a group that is either unsubstituted or substituted with a substituent that is subsequently identified. For example, “optionally substituted with one or two halos” means either unsubstituted, substituted with one halo group, or substituted with two halo groups.

[0026] When used herein, "*2" and "*3" in the following structures refer to R 2c Base and R3c This indicates the carbon atom to which the group is bonded. [ka]

[0027] Unless otherwise specified, the compounds of the present invention include all stereoisomers (e.g., enantiomers and diastereomers), double bond isomers (e.g., (Z) and (E)), structural isomers, and tautomers of the compounds specified herein by their chemical name and chemical structure, whether or not they are specified by their chemical name or chemical structure. Furthermore, monoisomers, double bond isomers, structural isomers, and tautomers, as well as mixtures of stereoisomers, double bond isomers, structural isomers, and tautomers, are within the scope of the present invention.

[0028] As used herein, in any chemical structure or formula, a straight bond that is not a thick line attached to the stereocenter of a compound, as in the following formula, is: [ka] , This indicates that the stereochemistry of the stereocenter is unspecified. The compound may have any stereochemistry, or a mixture of stereochemistrys, at its stereocenter.

[0029] When used herein, in any chemical structure or formula, a straight bond between a stereocenter of a compound, represented by a thick or dashed line, as in the following formula, is: [ka] , The relative stereochemistry of the chiral center with respect to other stereocenters to which it is attached by a thick or dashed linear bond is shown.

[0030] When used herein, in any chemical structure or formula, a wedge-shaped bond, indicated by a thick or dashed line, attached to the stereocenter of a compound, as in the following formula, [ka] , The wedge-shaped bonds, indicated by thick or dashed lines, show the absolute stereochemistry of the stereocenter relative to other stereocenters to which they are bonded, as well as the relative stereochemistry of the stereocenter.

[0031] As used herein, the prefix "rac-" refers to a racemic mixture of compounds when used in relation to chiral compounds. In compounds with the "rac-" prefix, the (R)- and (S)- designations in the chemical name reflect the relative stereochemistry of the compound.

[0032] As used herein, the prefix "rel-" refers to a single enantiomer of an unknown absolute configuration when used in relation to chiral compounds. In compounds with the "rel-" prefix, the (R) and (S)- designators in the chemical name reflect the relative stereochemistry of the compound, but not necessarily the absolute stereochemistry. If the relative stereochemistry of a given stereocenter is unknown, no stereochemical designator is provided. In some examples, the absolute configurations of some stereocenters are known, while only the relative configurations of others are known. In these examples, stereochemical designators related to stereocenters with known absolute configurations are marked with an asterisk (*), e.g., (R*)- and (S*)-, while stereochemical designators related to stereocenters with unknown absolute configurations are not marked in this way. Unmarked stereochemical specifiers associated with stereocenters of an unknown absolute configuration reflect the relative stereochemistry of those stereocenters with respect to other stereocenters of the unknown absolute configuration, but do not necessarily reflect the relative stereochemistry with respect to stereocenters of known absolute configurations.

[0033] As used herein, the term “compound” refers to a collection of molecules having the same chemical structure, except that isotopic variations may exist between the constituent atoms of the molecules, when referring to the compounds of the present invention. The term “compound” includes such collections of molecules regardless of the purity of a given sample containing such collections of molecules. Accordingly, the term “compound” includes such collections of molecules in their pure form, in a mixture with one or more other substances (e.g., a solution, suspension, colloid, or pharmaceutical composition or dosage form), or in the form of hydrates, solvates, or cocrystals.

[0034] As used herein, the term “amorphous” refers to a solid material that does not possess long-range order in its molecular positioning. Amorphous solids are generally glassy or supercooled liquids in which molecules are randomly arranged, such that there is no clearly defined arrangement, e.g., no molecular packing and no long-range order. Amorphous solids are generally rather isotropic, meaning they exhibit similar properties in all directions and do not have a distinct melting point. Instead, they typically exhibit a glass transition temperature, indicating a transition from a glassy amorphous state to a supercooled liquid amorphous state upon heating. For example, an amorphous material is a solid material that does not have a sharp, characteristic crystalline peak in its X-ray powder diffraction (XRPD) pattern (i.e., is not crystalline as determined by XRPD). Instead, one or more broad peaks (e.g., halos) are observed in its XRPD pattern. Broad peaks are characteristic of amorphous solids. For a comparison of XRPDs of amorphous and crystalline materials, see US2004 / 0006237. In some embodiments, the solid material may contain amorphous compounds, for example, the solid material may be characterized by the absence of sharp, characteristic crystalline peaks in its XRPD spectrum (i.e., the solid material is not crystalline but amorphous as determined by the XRPD). Instead, one or more broad peaks (e.g., halos) may be observed in the XRPD pattern of the solid material. For a typical comparison of XRPDs of amorphous and crystalline materials, see US2004 / 0006237. Solid materials containing amorphous compounds may be characterized by a broader temperature range of melting of the solid material compared to, for example, the melting range of a pure crystalline solid. Other techniques, such as solid-state NMR, may be used to characterize the crystalline or amorphous form.

[0035] As used herein, the term "crystalline" refers to a crystalline structure (or polymorph) having a specific molecular packing arrangement within the crystal lattice. Crystalline forms can be determined, for example, by X-ray powder diffraction (XRPD), single-crystal X-ray diffraction, and solid-state nuclear magnetic resonance (e.g., 13 C, 19 F, 15 N, and 31They can be identified and distinguished from one another by one or more characterization techniques, including P-SSNMR.

[0036] In this specification and in the claims, unless otherwise specified, any atom not specifically designated as a particular isotope of any compound of the present invention is intended to represent any stable isotope of the specified element. In the examples, if an atom is not specifically designated as a particular isotope of any compound of the present invention, no effort is made to enrich that atom in a particular isotope, and therefore, a person skilled in the art will understand that such an atom likely existed in the isotopic composition of the specified element at approximately its natural abundance.

[0037] As used herein, the term “stable” means, when referring to an isotope, that the isotope is not known to undergo spontaneous radioactive decay. Stable isotopes include, but are not limited to, those whose decay modes are not identified in the Table of Nuclides (January 1980) by V.S. Shirley & C.M. Lederer, Isotopes Project, Nuclear Science Division, Lawrence Berkeley Laboratory.

[0038] As used herein and in the claims, "H" refers to hydrogen, any stable isotope of hydrogen, i.e. 1 This includes H and D. In the examples, when an atom is designated as "H", no attempt is made to concentrate that atom in a specific isotope of hydrogen, and therefore, those skilled in the art will understand that such hydrogen atoms likely existed in the approximately naturally occurring isotopic composition of hydrogen.

[0039] When used herein, 1 "H" refers to protium. When an atom in the compound of the present invention or a pharmaceutically acceptable salt thereof is designated as protium, protium is present at the designated position at least at the naturally occurring concentration of protium.

[0040] As used herein, "D", "d", and " 2 "H" refers to deuterium.

[0041] In some embodiments, the compounds of the present invention and their pharmaceutically acceptable salts contain each constituent atom in an approximately naturally occurring isotopic composition of the specified elements.

[0042] In some embodiments, the compounds of the present invention and their pharmaceutically acceptable salts contain one or more atoms having an atomic mass or mass number different from the atomic mass or mass number of the most abundant isotope of the specified element ("isotope-labeled" compound and salt). Examples of commercially available stable isotopes suitable for the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, and phosphorus, for example, respectively. 2 H, 13 C, 15 N, 18 O, 17 O, and 31 P is one example, but it is not limited to these.

[0043] Isotope-labeled compounds and salts can be used in several beneficial ways, including as pharmaceuticals. In some embodiments, the isotope-labeled compounds and salts contain deuterium ( 2 H) Labeled. Deuterium ( 2 H) Labeled compounds and salts are therapeutically useful and non 2 It has potential therapeutic advantages over H-labeled compounds. Generally speaking, deuterium ( 2 H) Labeled compounds and salts may have higher metabolic stability compared to unlabeled compounds due to the kinetic isotope effect described below. This higher metabolic stability translates directly to an increased in vivo half-life or lower doses, which in most circumstances represents a preferred embodiment of the present invention. Isotopically labeled compounds and salts can typically be prepared by performing the procedures disclosed in the synthesis scheme, examples, and related descriptions, and by replacing unisotopically labeled reactants with readily available isotopely labeled reactants.

[0044] deuterium( 2 H) Labeled compounds and salts can manipulate the oxidative metabolic rate of compounds through first-order kinetic isotope effects. First-order kinetic isotope effects are changes in the rate of chemical reactions resulting from the exchange of isotopic nuclei, which are then caused by changes in the ground state energy of the covalent bonds involved in the reaction. The exchange of heavier isotopes usually results in a decrease in the ground state energy of the chemical bond, and therefore a decrease in the rate-determining bond cleavage. If the bond cleavage occurs within or near the saddle point region along the coordination of a multi-product reaction, the product distribution ratio can change significantly. For example, if deuterium is bonded to a carbon atom in a non-exchangeable position, k H / k D A typical velocity difference is 2 to 7. For further consideration, see S.L. Harbeson and R.D. Tung, Deuterium In Drug Discovery and Development, Ann. Rep. Med. Chem. 2011, 46, 403-417, which is incorporated herein by reference in its entirety.

[0045] The concentration of an isotope (e.g., deuterium) incorporated at a given position in the isotope-labeled compound or a pharmaceutically acceptable salt thereof of the present invention may be defined by an isotope enrichment factor. As used herein, the term “isotope enrichment factor” means the ratio between the abundance of the isotope at a given position in the isotope-labeled compound (or salt) and the natural abundance of the isotope.

[0046] When the atom in the compound of the present invention or a pharmaceutically acceptable salt thereof is designated as deuterium, such compound (or salt) has an isotopic enrichment factor for such atom of at least 3000 (approximately 45% deuterium incorporated). In some embodiments, the isotopic enrichment factors are at least 3500 (approximately 52.5% deuterium incorporated), at least 4000 (approximately 60% deuterium incorporated), at least 4500 (approximately 67.5% deuterium incorporated), at least 5000 (approximately 75% deuterium incorporated), at least 5500 (approximately 82.5% deuterium incorporated), at least 6000 (approximately 90% deuterium incorporated), at least 6333.3 (approximately 95% deuterium incorporated), at least 6466.7 (approximately 97% deuterium incorporated), at least 6600 (approximately 99% deuterium incorporated), or at least 6633.3 (approximately 99.5% deuterium incorporated).

[0047] In some embodiments, the present invention relates to compounds of formula (IA), [ka] , Or, with respect to its pharmaceutically acceptable salt, in the formula, X 2a , X 3a , X 5a , X 6a , R d , R 4b1 , R 4b2 , R 5b1 , R 5b2 , X 3c , X 4c , X 5c , X 6c , and R 2c It is defined as shown above in relation to equation (I).

[0048] In some embodiments, the present invention relates to a compound of formula (IA-1), [ka] , Or, with respect to a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b1 , R 4b2, R 5b1 , R 5b2 , R 2c , R 3c , and R 4c It is defined as shown above in relation to equation (I).

[0049] In some embodiments, the present invention relates to a compound of formula (IA-2), [ka] , Or, with respect to a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b1 , R 4b2 , R 5b1 , R 5b2 , R 2c , R 3c , and R 4c It is defined as shown above in relation to equation (I).

[0050] In some embodiments, the present invention relates to a compound of formula (IA-3), [ka] , or having a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b2 , R 2c , R 3c , and R 4c It is defined as shown above in relation to equation (I).

[0051] In some embodiments, the present invention relates to a compound of formula (IB), [ka] , Or, with respect to its pharmaceutically acceptable salt, in the formula, X 2a , X 3a , X 5a , X 6a , R d , R 4b1 , R 4b2 , R 5b1 , R 5b2, X 3c , X 4c , X 5c , X 6c , and R 2c It is defined as shown above in relation to equation (I).

[0052] In some embodiments, the present invention relates to a compound of formula (IB-1), [ka] , Or, with respect to a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b1 , R 4b2 , R 5b1 , R 5b2 , R 2c , R 3c , and R 4c It is defined as shown above in relation to equation (I).

[0053] In some embodiments, the present invention relates to a compound of formula (IB-2), [ka] , Or, with respect to a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b1 , R 4b2 , R 5b1 , R 5b2 , R 2c , R 3c , and R 4c It is defined as shown above in relation to equation (I).

[0054] In some embodiments, the present invention relates to a compound of formula (IB-3), [ka] , or having a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b2 , R 2c , R 3c , and R 4cIt is defined as shown above in relation to equation (I).

[0055] In some embodiments, the present invention relates to a compound of formula (IC), [ka] , Or, with respect to its pharmaceutically acceptable salt, in the formula, X 2a , X 3a , X 5a , X 6a , R d , R 4b1 , R 4b2 , R 5b1 , R 5b2 , X 3c , X 4c , X 5c , X 6c , and R 2c It is defined as shown above in relation to equation (I).

[0056] In some embodiments, the present invention relates to a compound of formula (IC-1), [ka] , Or, with respect to a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b1 , R 4b2 , R 5b1 , R 5b2 , R 2c , R 3c , and R 4c It is defined as shown above in relation to equation (I).

[0057] In some embodiments, the present invention relates to a compound of formula (IC-2), [ka] , Or, with respect to a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b1 , R 4b2 , R 5b1 , R 5b2 , R2c , R 3c , and R 4c It is defined as shown above in relation to equation (I).

[0058] In some embodiments, the present invention relates to a compound of formula (IC-3), [ka] , or having a pharmaceutically acceptable salt thereof, in the formula, R d , R 4b2 , R 2c , R 3c , and R 4c It is defined as shown above in relation to equation (I).

[0059] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 2a CR 2a In other embodiments, X 2a CR 2a And R 2a H is H.

[0060] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 3a In other embodiments, X 3a is, N + -O - That is the case.

[0061] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 5a is N or CR 5a And R 5a is H, halo, or CH2OH. In other embodiments, X 5a In other embodiments, X 5a CR5a In other embodiments, X 5a CR 5a And R 5a is H, halo, or CH2OH. In other embodiments, X 5a CR 5a And R 5a is H, F, or CH2OH. In other embodiments, X 5a CR 5a And R 5a In other embodiments, X 5a CR 5a And R 5a In other embodiments, X 5a CR 5a And R 5a In other embodiments, X 5a CR 5a And R 5a It is CH2OH.

[0062] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 6a is N or CR 6a And R 6a In other embodiments, X 6a In other embodiments, X 6a CR 6a In other embodiments, X 6a CR 6a And R 6a H is H.

[0063] In some embodiments, the present invention relates to any one compound from formula (I), (IA), (IA-1), (IA-2), (IB), (IB-1), (IB-2), (IC), (IC-1), and (IC-2), or a pharmaceutically acceptable salt thereof, R 4b1 is H or C1-C6 alkyl. In other embodiments, R 4b1 In other embodiments, R 4b1is a C1-C6 alkyl group. In other embodiments, R 4b1 is H or CH3. In other embodiments, R 4b1 This is CH3.

[0064] In some embodiments, the present invention relates to any one compound from formula (I), (IA), (IA-1), (IA-2), (IA-3), (IB), (IB-1), (IB-2), (IB-3), (IC), (IC-1), (IC-2), and (IC-3), or a pharmaceutically acceptable salt thereof, R 4b2 is H or C1-C6 alkyl. In other embodiments, R 4b2 In other embodiments, R 4b2 is a C1-C6 alkyl group. In other embodiments, R 4b2 is H or CH3. In other embodiments, R 4b2 This is CH3.

[0065] In some embodiments, the present invention relates to any one compound from formula (I), (IA), (IA-1), (IA-2), (IB), (IB-1), (IB-2), (IC), (IC-1), and (IC-2), or a pharmaceutically acceptable salt thereof, wherein R 5b1 is a C1-C6 alkyl or C1-C6 haloalkyl. In other embodiments, R 5b1 is a C1-C6 alkyl group. In other embodiments, R 5b1 is a C1-C6 haloalkyl. In other embodiments, R 5b1 is CH3 or CF3. In other embodiments, R 5b1 In other embodiments, R 5b1 This is CF3.

[0066] In some embodiments, the present invention relates to any one compound from formula (I), (IA), (IA-1), (IA-2), (IB), (IB-1), (IB-2), (IC), (IC-1), and (IC-2), or a pharmaceutically acceptable salt thereof, wherein R 5b2is a C1-C6 alkyl or C1-C6 haloalkyl. In other embodiments, R 5b2 is a C1-C6 alkyl group. In other embodiments, R 5b2 is a C1-C6 haloalkyl. In other embodiments, R 5b2 is CH3 or CF3. In other embodiments, R 5b2 In other embodiments, R 5b2 This is CF3.

[0067] In some embodiments, the present invention relates to any one compound from formula (I), (IA), (IA-1), (IA-2), (IA-3), (IB), (IB-1), (IB-2), (IB-3), (IC), (IC-1), (IC-2), and (IC-3), or a pharmaceutically acceptable salt thereof, wherein R 2c is OH, halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 2c In other embodiments, R 2c In other embodiments, R 2c is a C1-C6 alkyl group. In other embodiments, R 2c is a C1-C6 alkoxy. In other embodiments, R 2c In other embodiments, R 2c is OH, Cl, CH3, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCH2CH2F, or OCH2CHF2. In other embodiments, R 2c In other embodiments, R 2c In other embodiments, R 2c In other embodiments, R 2c In other embodiments, R 2c In other embodiments, R 2c In other embodiments, R 2c In other embodiments, R 2c It is OCH2CHF2.

[0068] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 3c is N or CR 3c And R 3c is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl. In other embodiments, X 3c In other embodiments, X 3c CR 3c In other embodiments, X 3c CR 3c And R 3c In other embodiments, X 3c CR 3c And R 3c In other embodiments, X 3c CR 3c And R 3c is a C1-C6 alkyl group. In other embodiments, X 3c CR 3c And R 3c is a C1-C6 haloalkyl. In other embodiments, X 3c CR 3c And R 3c is H, F, CH3, CHF2, or CF3. In other embodiments, X 3c CR 3c And R 3c In other embodiments, X 3c CR 3c And R 3c In other embodiments, X 3c CR 3c And R 3c In other embodiments, X 3c CR 3c And R 3c This is CF3.

[0069] In some embodiments, the present invention relates to any one compound of formulas (IA-1), (IA-2), (IA-3), (IB-1), (IB-2), (IB-3), (IC-1), (IC-2), and (IC-3), or a pharmaceutically acceptable salt thereof, wherein R 3c is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl. In other embodiments, R 3c In other embodiments, R 3c In other embodiments, R 3c is a C1-C6 alkyl group. In other embodiments, R 3c is a C1-C6 haloalkyl. In other embodiments, R 3c is H, F, CH3, CHF2, or CF3. In other embodiments, R 3c In other embodiments, R 3c In other embodiments, R 3c In other embodiments, R 3c This is CF3.

[0070] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 3c CR 3c And R 2c and R 3c These, together with the carbon atoms to which they are bonded, form a ring as shown in the following equation. [ka] . In other embodiments, the ring is of the following formula: [ka] .

[0071] In some embodiments, the present invention relates to any one compound of formulas (IA-1), (IA-2), (IA-3), (IB-1), (IB-2), (IB-3), (IC-1), (IC-2), and (IC-3), or a pharmaceutically acceptable salt thereof, wherein R 2c and R 3c These, together with the carbon atoms to which they are bonded, form a ring as shown in the following equation. [ka] . In other embodiments, the ring is of the following formula: [ka] .

[0072] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 4c CR 4c And R 4c is H, halo, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, X 4c CR 4c In other embodiments, X 4c CR 4c And R 4c In other embodiments, X 4c CR 4c And R 4c In other embodiments, X 4c CR 4c And R 4c is a C1-C6 haloalkyl. In other embodiments, X 4c CR 4c And R 4c In other embodiments, X 4c CR 4c And R 4c In other embodiments, X4c CR 4c And R 4c These are H, F, CHF2, OCH2CH3, OCHF2, and OCF3. In other embodiments, X 4c CR 4c And R 4c In other embodiments, X 4c CR 4c And R 4c In other embodiments, X 4c CR 4c And R 4c In other embodiments, X 4c CR 4c And R 4c In other embodiments, X 4c CR 4c And R 4c This is OCF3.

[0073] In some embodiments, the present invention relates to any one compound of formulas (IA-1), (IA-2), (IA-3), (IB-1), (IB-2), (IB-3), (IC-1), (IC-2), and (IC-3), or a pharmaceutically acceptable salt thereof, wherein R 4c is H, halo, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy. In other embodiments, R 4c In other embodiments, R 4c In other embodiments, R 4c is a C1-C6 haloalkyl. In other embodiments, R 4c is a C1-C6 alkoxy. In other embodiments, R 4c In other embodiments, R 4c These are H, F, CHF2, OCH2CH3, OCHF2, and OCF3. In other embodiments, R 4c In other embodiments, R 4c In other embodiments, R 4c In other embodiments, R4c In other embodiments, R 4c This is OCF3.

[0074] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 5c CR 5c And R 5c H is H.

[0075] In some embodiments, the present invention relates to one compound from formulas (I), (IA), (IB), and (IC), or a pharmaceutically acceptable salt thereof, wherein X 6c CR 6c And R 6c H is H.

[0076] In some embodiments, the present invention relates to any one compound from formula (I), (IA), (IA-1), (IA-2), (IA-3), (IB), (IB-1), (IB-2), (IB-3), (IC), (IC-1), (IC-2), and (IC-3), or a pharmaceutically acceptable salt thereof, R d (CH2) p In other embodiments, R d is H or CH3. In other embodiments, R d (CHR e ) n (CH2) p In other embodiments, R d is CH2F, CH2OH, or CH(OH)CH3. In other embodiments, R d (CH2) m (CHR e ) n In other embodiments, R d This is CH2OCH3 or CH2CH2OCH3.

[0077] In some embodiments, the present invention relates to any one compound from formula (I), (IA), (IA-1), (IA-2), (IA-3), (IB), (IB-1), (IB-2), (IB-3), (IC), (IC-1), (IC-2), and (IC-3), or any embodiment thereof, i.e., a non-salt form of the compound.

[0078] In some embodiments, the present invention relates to compounds selected from Table A, or pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to compounds selected from Table A, i.e., compounds in non-salt forms.

[0079] Table A. Compound structure and name. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15]

[0080] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0081] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0082] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, the compound has absolute and relative stereochemistry corresponding to the first eluting isomer when the two diastereoisomers of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide are separated by SFC, as described in step 15 of Example 1. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0083] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, the compound has absolute and relative stereochemistry corresponding to a second eluting isomer when the two diastereoisomers of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide are separated by SFC, as described in step 15 of Example 1. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0084] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0085] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0086] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, the compound has the absolute and relative stereochemistry of the first eluting isomer when rac-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-(hydroxymethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide is separated by SFC, as described in Example 6. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0087] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, the compound has the absolute and relative stereochemistry of a second eluting isomer when rac-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-(hydroxymethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide is separated by SFC, as described in Example 6. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0088] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0089] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0090] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0091] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, as described in Example 6, when two enantiomers of rac-(5-((2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide)pyrimidine-2-yl)methylbenzo are separated by SFC, they have the absolute and relative stereochemistry corresponding to the first eluting isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0092] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, as described in Example 6, when two enantiomers of rac-(5-((2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide)pyrimidine-2-yl)methylbenzo are separated by SFC, they have absolute and relative stereochemistry corresponding to the second eluting isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0093] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0094] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0095] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0096] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0097] In some embodiments, the present invention relates to the compound rel-(2S,3R,4R,5S)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound is a two diastereoisomer rel-(2S,3R,4R,5S)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3- When rel-(2R,3S,4S,5R)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide is separated by SFC, it has the absolute and relative stereochemistry corresponding to the first eluted isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0098] In some embodiments, the present invention relates to the compound rel-(2R,3S,4S,5R)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound is a two diastereoisomer rel-(2S,3R,4R,5S)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine- When 3-yl)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2R,3S,4S,5R)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide are separated by SFC, the second eluting isomer has absolute and relative stereochemistry. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0099] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0100] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0101] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0102] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, the compound has absolute and relative stereochemistry corresponding to the first eluting isomer when the two enantiomers of rac-(2R,3S,4S,5R)-N-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridine-3-yl)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide are separated by SFC, as described in Example 9. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0103] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, the compound has absolute and relative stereochemistry corresponding to a second eluting isomer when the two enantiomers of rac-(2R,3S,4S,5R)-N-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridine-3-yl)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide are separated by SFC, as described in Example 9. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0104] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0105] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0106] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, the compound has absolute and relative stereochemistry corresponding to the first eluting isomer when the two diastereoisomers of (2R,3S,4S,5R)-N-(6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide are separated by SFC, as described in step 2 of Example 2. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0107] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , With respect to the pharmaceutically acceptable salt thereof, the compound had absolute and relative stereochemistry corresponding to the second eluting isomer when the two diastereoisomers of (2R,3S,4S,5R)-N-(6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide were separated by SFC, as described in step 2 of Example 2. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0108] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0109] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0110] In some embodiments, the present invention relates to the compound rel-(2R*,3S*,4S*,5R*)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((1R,2R)-1,2-dihydroxypropyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound is a two diastereoisomer rel-(2R*,3S*,4S*,5R*)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, as described in Example 1. When rel-((4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)tetrahydrofuran-2-carboxamide and rel-(2R*,3S*,4S*,5R*)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)-N-(6-((4S,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)tetrahydrofuran-2-carboxamide are separated by SFC, they have absolute and relative stereochemistry corresponding to the first eluted isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0111] In some embodiments, the present invention relates to the compound rel-(2R*,3S*,4S*,5R*)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((1S,2S)-1,2-dihydroxypropyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound is as described in Example 1, rel-(2R*,3S*,4S*,5R*)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)-N-(6-((4 When the two diastereoisomers of R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)tetrahydrofuran-2-carboxamide and rel-(2R*,3S*,4S*,5R*)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)-N-(6-((4S,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)tetrahydrofuran-2-carboxamide are separated by SFC, they have absolute and relative stereochemistry corresponding to the second eluting isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0112] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0113] In some embodiments, the present invention relates to compounds of the following formulas: [ka] , The present invention relates to pharmaceutically acceptable salts thereof. In other embodiments, the present invention relates to non-salt forms of the aforementioned compounds. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0114] In some embodiments, the present invention relates to the compound rel-(2S,3R,5S)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound is two diastereomers, as described in Example 8, rel-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2- When dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2S,3R,5S)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide are separated by SFC, they have absolute and relative stereochemistry corresponding to the first eluted isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0115] In some embodiments, the present invention relates to the compound rel-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound is two diastereomers rel-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2- When dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2S,3R,5S)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide are separated by SFC, they have absolute and relative stereochemistry corresponding to the second eluting isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt forms. Such compounds are considered to be “compounds of the present invention” as the term is used herein.

[0116] Salts, compositions, uses, formulations, administration, and additional agents pharmaceutically acceptable salts and compositions As discussed herein, the present invention provides compounds and pharmaceutically acceptable salts thereof that are inhibitors of voltage-gated sodium channels, and thus the compounds and pharmaceutically acceptable salts thereof are useful in treating diseases, disorders and conditions including, but are not limited to, chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., pain from aponeurosis resection, hernia repair, or abdominal wall reconstruction), visceral pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or cardiac arrhythmias. Accordingly, in another aspect of the present invention, pharmaceutical compositions are provided, which comprise the compounds described herein or pharmaceutically acceptable salts thereof, and optionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents. In some embodiments, the additional therapeutic agents are sodium channel inhibitors.

[0117] As used herein, the term “pharmaceutically acceptable” means a salt that, within the bounds of sound medical judgment, is suitable for use in contact with human and lower animal tissues without excessive toxicity, irritation, allergic reactions, etc., and that is commensurate with a reasonable benefit / risk ratio. A “pharmaceutically acceptable salt” of the compound of the present invention includes any non-toxic salt that can be used to provide the compound of the present disclosure or an inhibitory metabolite or residue thereof, either directly or indirectly, at the time of administration to the recipient. The salt may be in pure form, a mixture with one or more other substances (e.g., a solution, suspension, or colloid), or in the form of a hydrate, solvate, or cocrystal. As used herein, the term “inhibitory metabolite or residue thereof” means that the metabolite or residue thereof is also an inhibitor of voltage-gated sodium channels.

[0118] Pharmacopoeia-acceptable salts are well known in the art. For example, SMBerge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmacopoeia-acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipine, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, and 2-hydroxyethane. Examples include sulfonates, lactobionates, lactates, laurates, lauryl sulfates, malates, maleates, malons, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oleates, oxalates, palmitates, pamoates, pectins, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propions, stearates, succinates, sulfates, tartrates, thiocyanates, p-toluenesulfonates, undecanoates, and valersates. Salts derived from suitable bases include alkali metals, alkaline earth metals, ammonium, and N + (C 1-4This includes alkyl) tetrasalts. Typical alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium. Further pharmaceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfons, and aryl sulfons.

[0119] As used herein, the pharmaceutically acceptable compositions of the present invention also include, as used herein, all solvents, diluents, or other liquid vehicles suitable for the desired specific dosage form, including pharmaceutically acceptable carriers, adjuvants, or vehicles, such as dispersing or suspending aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc. Remington's Pharmaceutical Sciences, Sixteenth Edition, EW Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in the formulation of pharmaceutically acceptable compositions and known techniques for their preparation. Unless any conventional carrier medium becomes incompatible with the compounds of the present invention, for example, by producing any undesirable biological effect or otherwise interacting in a detrimental manner with any other component of the pharmaceutically acceptable composition, its use is intended to be within the scope of this disclosure.Some examples of materials that can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffers (e.g., phosphates, glycine, sorbic acid, and potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, lanolin, sugars (e.g., lactose, glucose, and sucrose), starches (e.g., corn starch and potato starch), cellulose and its derivatives (e.g., carboxymethylcellulose). Examples of ingredients include sodium, ethylcellulose, and cellulose acetate), powdered tragacanth, malt, gelatin, talc, excipients (e.g., cocoa butter and suppository wax), oils (e.g., peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil), glycols (e.g., propylene glycol and polyethylene glycol), esters (e.g., ethyl oleate and ethyl laurate), agar, buffers (e.g., magnesium hydroxide and aluminum hydroxide), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, phosphate buffer solution, and other non-toxic compatible lubricants (e.g., sodium lauryl sulfate and magnesium stearate), as well as colorants, release agents, coating agents, sweeteners, flavoring agents, and fragrances. Preservatives and antioxidants may also be present in the composition at the discretion of the compounder.

[0120] In another embodiment, the present invention is characterized by a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0121] In another embodiment, the present invention is characterized by a pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or vehicles.

[0122] Use of compounds and pharmaceutically acceptable salts and compositions In another embodiment, the present invention is characterized by a method for inhibiting voltage-gated sodium channels in a subject, the method comprising administering the compound of the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to the subject. In another embodiment, voltage-gated sodium channels are Na V It is 1.8.

[0123] In yet another aspect, the present invention features a method for treating or reducing the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., pain from aponeurosis resection, hernia repair, or abdominal wall reconstruction), visceral pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or cardiac arrhythmia, the method comprising administering an effective amount of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0124] In yet another aspect, the present invention is characterized by a method for treating or reducing the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, hernia repair pain, aponeurosis resection pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, or cardiac arrhythmias, the method comprising administering an effective amount of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0125] In yet another embodiment, the present invention is characterized by a method for treating or reducing the severity of intestinal pain in a subject, the intestinal pain including inflammatory bowel disease pain, Crohn's disease pain, or interstitial cystitis pain, and the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0126] In yet another embodiment, the present invention features a method for treating neuropathic pain or reducing its severity in a subject, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some embodiments, neuropathic pain includes postherpetic neuralgia, small-diameter fiber neuropathy, diabetic neuropathy, or idiopathic small-diameter fiber neuropathy. In some embodiments, neuropathic pain includes diabetic neuropathy (e.g., diabetic peripheral neuropathy). As used herein, the term "idiopathic small-diameter fiber neuropathy" shall be understood to include any small-diameter fiber neuropathy.

[0127] In yet another aspect, the present invention is characterized by a method for treating neuropathic pain or reducing its severity in subjects, wherein neuropathic pain includes postherpetic neuralgia, diabetic neuropathy, painful HIV-related sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radiculopathy, sciatica; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy-induced neuralgia, cancer chemotherapy-induced neuralgia, antiretroviral therapy-induced neuralgia; pain after spinal cord injury, small fiber neuropathy, idiopathic small fiber neuropathy, idiopathic sensory neuropathy, or trigeminal-autonomic headache, wherein the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0128] In yet another embodiment, the present invention features a method for treating musculoskeletal pain or reducing its severity in a subject, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some embodiments, musculoskeletal pain includes osteoarthritis.

[0129] In yet another aspect, the present invention is characterized by a method for treating musculoskeletal pain or reducing its severity in a subject, wherein musculoskeletal pain includes osteoarthritis, back pain, cold pain, burn pain, or toothache, and the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0130] In yet another aspect, the present invention is characterized by a method for treating inflammatory pain or reducing its severity in a subject, wherein the inflammatory pain includes rheumatoid arthritis pain or vulvodynia, and the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0131] In yet another aspect, the present invention is characterized by a method for treating inflammatory pain or reducing its severity in a subject, wherein the inflammatory pain includes pain of rheumatoid arthritis, and the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0132] In yet another aspect, the present invention is characterized by a method for treating idiopathic pain or reducing its severity in a subject, wherein idiopathic pain includes pain of fibromyalgia, and the method comprises administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0133] In yet another embodiment, the present invention is characterized by a method for treating a pathological cough or reducing its severity in a subject, the method comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0134] In yet another embodiment, the present invention features a method for treating acute pain or reducing its severity in a subject, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some embodiments, acute pain includes acute postoperative pain.

[0135] In yet another aspect, the present invention is characterized by a method for treating or reducing the severity of postoperative pain (e.g., pain from joint replacement, pain from soft tissue surgery, pain from hernia repair, pain from aponeurosis resection, or pain from abdominal wall reconstruction) in a subject, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0136] In yet another aspect, the present invention is characterized by a method for treating a fasciotomy or reducing the severity of pain in a subject of a fasciotomy, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0137] In yet another aspect, the present invention is characterized by a method for treating hernia repair or reducing the severity of pain in an object, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0138] In yet another aspect, the present invention is characterized by a method for treating abdominoplasty or reducing the severity of pain in an object thereof, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0139] In yet another embodiment, the present invention features a method for treating visceral pain or reducing its severity in a subject, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some embodiments, visceral pain includes visceral pain resulting from abdominoplasty.

[0140] In yet another embodiment, the present invention features a method for treating a neurodegenerative disease or reducing its severity in a subject, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some embodiments, the neurodegenerative disease includes multiple sclerosis. In some embodiments, the neurodegenerative disease includes Pitt-Hopkins syndrome (PTHS).

[0141] In yet another embodiment, the present invention is characterized by a method in which a subject is treated simultaneously with one or more additional therapeutic agents administered before or after treatment with an effective amount of a compound, a pharmaceutically acceptable salt, or a pharmaceutical composition. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0142] In another embodiment, the present invention is characterized by a method for inhibiting voltage-gated sodium channels in a biological sample, the method comprising contacting the biological sample with an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In another embodiment, the voltage-gated sodium channels are Na V It is 1.8.

[0143] In another aspect, the present invention relates to acute pain, subacute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, dysalgesic pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpes zoster neuralgia, general neuralgia, epilepsy, epileptic states, neurodegenerative disorders, psychiatric disorders, anxiety, depression, bipolar disorder, myotonia, arrhythmia, motor disorders, neuroendocrine disorders, ataxia, central neuropathic pain and irritable bowel syndrome associated with multiple sclerosis, incontinence, pathological cough, visceral pain, osteoarthritis, postherpetic neuralgia, diabetic neuralgia Lopathies, radiculopathy, sciatica, back pain, unspecified chronic back pain, headache, neck pain, moderate pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postoperative pain (e.g., pain from joint replacement, soft tissue surgery, hernia repair, aponeurosis excision, or abdominal wall reconstruction), cancer pain including chronic cancer pain and cancer breakthrough pain, stroke (e.g., central neuropathic pain after stroke), traumatic cervical syndrome, fragility fracture, vertebral fracture, ankylosing spondylitis, pemphigus, Raynaud's disease, scleroderma, systemic lupus Matodes, epidermolysis bullosa, gout, juvenile idiopathic arthritis, venous osteopathy, polymyalgia rheumatica, pyoderma gangrenosum, chronic widespread pain, diffuse idiopathic osteoproliferative disorder, intervertebral disc degeneration / hernia pain, nerve root compression, facet joint syndrome, spinal surgery failure syndrome, burns, carpal tunnel syndrome, Paget's disease pain, spinal stenosis, spondylodiscitis, transverse myelitis, Ehlers-Danlos syndrome, Fabry disease, mastocytosis, neurofibromatosis, ophthalmic neuropathy, sarcoidosis, spondylolysis, spondylolisthesis, chemotherapy-induced osteopathy The present invention is characterized by a method for treating or reducing the severity of the following conditions in a subject: sacral mucositis, Charcot arthritis, temporomandibular joint disorder, painful total knee replacement, noncardiac chest pain, genital pain, renal colic, biliary tract disease, vascular lower extremity ulcers, pain in Parkinson's disease, pain in Alzheimer's disease, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise-induced angina, palpitations, hypertension, or abnormal gastrointestinal motility, the method comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0144] In another aspect, the present invention relates to pain from femoral cancer; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, abdominal pain; splenic pain; IBS pain; chronic and acute headache pain; migraine; tension headache; cluster headache; chronic and acute neuropathic pain, postherpetic neuralgia; diabetic neuropathy; HIV-related neuropathy; trigeminal neuralgia; Charcot-Marie-Tooth neuropathy; hereditary sensory neuropathy; peripheral Nerve injury; painful neuroma; ectopic proximal and distal discharge; radiculopathy; chemotherapy-induced neuropathic pain; radiation-induced neuropathic pain; persistent / chronic postoperative pain (e.g., post-amputation, post-thoracotomy, post-cardiac surgery), post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; phantom limb pain (e.g., post-lower limb, upper limb, or mastectomy); intractable pain; acute pain, acute postoperative pain; acute musculoskeletal pain; arthralgia; mechanical low back pain; neck pain; tenosynovitis; injury pain; movement pain; acute visceral pain; Pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernia; chest pain, cardiac pain; pelvic pain, renal colic pain, acute obstetric pain, labor pains; cesarean section pain; acute inflammatory pain, burn pain, traumatic pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain; sinusitis pain; toothache; multiple sclerosis (MS) pain; depression pain; leprosy pain; Behçet's disease pain; painful steatosis; phlebitis pain; Guillain-Barré syndrome pain; painful leg and mobile toes; Haglund The present invention is characterized by a method for treating or reducing the severity of widespread pain, paroxysmal severe pain, pruritus, tinnitus, or angina-induced pain in subjects, comprising administering an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0145] Compounds for use, pharmaceutically acceptable salts, and compositions In another embodiment, the present invention is characterized by the compound of the present invention for use as a pharmaceutical agent, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0146] In another aspect, the present invention features a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition for use in a method of inhibiting voltage-gated sodium channels in a subject. In another aspect, the voltage-gated sodium channel is Na V It is 1.8.

[0147] In another aspect, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for use in a method of treating or reducing the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., pain from hernia repair, pain from aponeurosis resection, or pain from abdoplasty), visceral pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or cardiac arrhythmias.

[0148] In another aspect, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for use in a method of treating or reducing the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, hernia repair pain, aponeurosis resection pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, or cardiac arrhythmias.

[0149] In another embodiment, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating or reducing the severity of intestinal pain in a subject, wherein intestinal pain includes pain of inflammatory bowel disease, pain of Crohn's disease, or pain of interstitial cystitis.

[0150] In other embodiments, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating neuropathic pain or reducing its severity in a subject thereof. In some embodiments, neuropathic pain includes postherpetic neuralgia, small fiber neuropathy, diabetic neuropathy, or idiopathic small fiber neuropathy. In some embodiments, neuropathic pain includes diabetic neuropathy (e.g., diabetic peripheral neuropathy). As used herein, the term "idiopathic small fiber neuropathy" shall be understood to include any small fiber neuropathy.

[0151] In another aspect, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for use in a method of treating neuropathic pain or reducing its severity in subjects thereof, wherein neuropathic pain includes postherpetic neuralgia, diabetic neuropathy, painful HIV-related sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radiculopathy, sciatica; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy-induced neuralgia, cancer chemotherapy-induced neuralgia, antiretroviral therapy-induced neuralgia; pain after spinal cord injury, small fiber neuropathy, idiopathic small fiber neuropathy, idiopathic sensory neuropathy, or trigeminal-autonomic headache.

[0152] In another embodiment, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating musculoskeletal pain or reducing its severity in a subject thereof. In some embodiments, musculoskeletal pain includes osteoarthritis.

[0153] In another aspect, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in treating musculoskeletal pain or reducing its severity in subjects thereof, musculoskeletal pain including osteoarthritis, back pain, cold pain, burn pain, or toothache.

[0154] In another embodiment, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating inflammatory pain or reducing its severity in a subject thereof, wherein inflammatory pain includes pain of rheumatoid arthritis or vulvodynia.

[0155] In another embodiment, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating inflammatory pain or reducing its severity in a subject thereof, wherein inflammatory pain includes pain of rheumatoid arthritis.

[0156] In another embodiment, the present invention features a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition for use in a method of treating idiopathic pain or reducing its severity in a subject thereof, wherein idiopathic pain includes pain of fibromyalgia.

[0157] In another aspect, the present invention features a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition for use in a method of treating a pathological cough or reducing its severity in a subject thereof.

[0158] In another embodiment, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating acute pain or reducing its severity in a subject thereof. In some embodiments, acute pain includes acute postoperative pain.

[0159] In yet another aspect, the present invention features the compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating or reducing the severity of postoperative pain (for example, pain from joint replacement surgery, pain from soft tissue surgery, pain from hernia repair surgery, pain from aponeurosis excision surgery, or pain from abdominal wall reconstruction surgery).

[0160] In another aspect, the present invention features the compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating aponeurosis resection or reducing the severity of pain in the subject thereof.

[0161] In another aspect, the present invention features the compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating hernia repair or reducing the severity of pain in a subject thereof.

[0162] In another aspect, the present invention features the compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating abdominal wall reconstruction or reducing the severity of pain in a subject thereof.

[0163] In another embodiment, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in a method of treating visceral pain or reducing its severity in a subject thereof. In some embodiments, visceral pain includes visceral pain resulting from abdominoplasty.

[0164] In other embodiments, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in treating neurodegenerative diseases or reducing their severity in subjects thereof. In some embodiments, neurodegenerative diseases include multiple sclerosis. In some embodiments, neurodegenerative diseases include Pitt-Hopkins syndrome (PTHS).

[0165] In another embodiment, the present invention features a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof for use in a manner in which the subject is treated simultaneously with treatment by an effective amount of the compound, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof, or with one or more additional therapeutic agents administered before or after such treatment. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0166] In another embodiment, the present invention features a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition for use in a method of inhibiting voltage-gated sodium channels in a biological sample, the method comprising contacting the biological sample with an effective amount of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In another embodiment, voltage-gated sodium channels are Na V It is 1.8.

[0167] In another aspect, the present invention relates to acute pain, subacute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, dysalgesic pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpes zoster neuralgia, general neuralgia, epilepsy, epileptic states, neurodegenerative disorders, psychiatric disorders, anxiety, depression, bipolar disorder, myotonia, arrhythmia, motor disorders, neuroendocrine disorders, ataxia, central neuropathic pain and irritable bowel syndrome associated with multiple sclerosis, incontinence, pathological cough, visceral pain, osteoarthritis, postherpetic neuralgia, diabetic neuralgia - Pain disorders, radiculopathy, sciatica, back pain, unspecified chronic back pain, headache, neck pain, moderate pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postoperative pain (e.g., pain from joint replacement, soft tissue surgery, hernia repair, aponeurosis excision, or abdominal wall reconstruction), cancer pain including chronic cancer pain and cancer breakthrough pain, stroke (e.g., central neuropathic pain after stroke), traumatic cervical syndrome, fragility fracture, vertebral fracture, ankylosing spondylitis, pemphigus, Raynaud's disease, scleroderma, systemic Lupus erythematosus, epidermolysis bullosa, gout, juvenile idiopathic arthritis, venous osteopathy, polymyalgia rheumatica, pyoderma gangrenosum, chronic widespread pain, diffuse idiopathic osteoproliferative disorder, intervertebral disc degeneration / hernia pain, nerve root compression, facet joint syndrome, spinal surgery failure syndrome, burns, carpal tunnel syndrome, Paget's disease pain, spinal stenosis, spondylodiscitis, transverse myelitis, Ehlers-Danlos syndrome, Fabry disease, mastocytosis, neurofibromatosis, ophthalmic neuropathy, sarcoidosis, spondylolysis, spondylolisthesis, chemotherapy The present invention is characterized by the compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions, for use in a method of treating or reducing the severity of stress-induced oral mucositis, Charcot arthritis, temporomandibular joint disorder, painful total knee replacement, noncardiac chest pain, genital pain, renal colic, biliary tract disease, vascular lower extremity ulcers, pain in Parkinson's disease, pain in Alzheimer's disease, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise-induced angina, palpitations, hypertension, or abnormal gastrointestinal motility.

[0168] In another aspect, the present invention relates to pain from femoral cancer; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, abdominal pain; splenic pain; IBS pain; chronic and acute headache pain; migraine; tension headache; cluster headache; chronic and acute neuropathic pain, postherpetic neuralgia; diabetic neuropathy; HIV-related neuropathy; trigeminal neuralgia; Charcot-Marie-Tooth neuropathy; hereditary sensory neuropathy; and other conditions. Peripheral nerve injury; painful neuroma; ectopic proximal and distal discharge; radiculopathy; chemotherapy-induced neuropathic pain; radiation-induced neuropathic pain; persistent / chronic postoperative pain (e.g., post-amputation, post-thoracotomy, post-cardiac surgery), post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; phantom limb pain (e.g., post-lower limb, upper limb, or mastectomy); intractable pain; acute pain, acute postoperative pain; acute musculoskeletal pain; arthralgia; mechanical low back pain; neck pain; tenosynovitis; injury pain; movement pain; acute internal Visceral pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernia; chest pain, cardiac pain; pelvic pain, renal colic pain, acute obstetric pain, labor pains; cesarean section pain; acute inflammatory pain, burn pain, traumatic pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain; sinusitis pain; toothache; multiple sclerosis (MS) pain; depression pain; leprosy pain; Behçet's disease pain; painful steatosis; phlebitis pain; Guillain-Barré syndrome pain; painful leg and mobile toes; The present invention features compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for use in treating or reducing the severity of widespread pain, paroxysmal severe pain, pruritus, tinnitus, or angina-induced pain in subjects with Haglund's syndrome; erythromelalgia pain; Fabry disease pain; bladder and genitourinary disorders; urinary incontinence, pathological cough; overactive bladder; bladder pain syndrome; interstitial cystitis (IC); prostatitis; regional pain syndrome (CRPS) type I, complex regional pain syndrome (CRPS) type II; widespread pain, paroxysmal severe pain, pruritus, tinnitus, or angina-induced pain.

[0169] In another aspect, the present invention features compounds of the present invention, or pharmaceutically acceptable salts or pharmaceutical compositions thereof, for use in a method of treating or reducing the severity of trigeminal neuralgia, Botox-treated migraine, cervical spondylotic radiculopathy, occipital neuralgia, axillary neuropathy, radial neuropathy, ulnar neuropathy, brachial plexus disorder, thoracic radiculopathy, intercostal neuralgia, lumbosacral radiculopathy, ilioinguinal neuralgia, pudendal neuralgia, femoral neuropathy, paresthesia of femoral pain, saphenous neuropathy, sciatic neuropathy, fibular neuropathy, tibial neuropathy, lumbosacral plexus disorder, stump pain of traumatic neuroma, or pain after amputation surgery.

[0170] Pharmaceutical manufacturing In another aspect, the present invention provides the use of the compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for the manufacture of pharmaceuticals.

[0171] In another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the inhibition of voltage-gated sodium channels. In another aspect, voltage-gated sodium channels are Na V It is 1.8.

[0172] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of or reduction of the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., pain from hernia repair, pain from aponeurosis resection, or pain from abdoplasty), visceral pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or cardiac arrhythmias.

[0173] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of or reduction of the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, hernia repair pain, aponeurosis resection pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, or cardiac arrhythmias.

[0174] In yet another aspect, the present invention provides the use of the compounds, pharmaceutically acceptable salts, or pharmaceutical compositions described herein for the manufacture of agents for use in the treatment of intestinal pain or in reducing the severity thereof, wherein intestinal pain includes pain of inflammatory bowel disease, pain of Crohn's disease, or pain of interstitial cystitis.

[0175] In yet another embodiment, the present invention provides compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of neuropathic pain or in reducing the severity of such pain in subjects. In some embodiments, neuropathic pain includes postherpetic neuralgia, small fiber neuropathy, diabetic neuropathy, or idiopathic small fiber neuropathy. In some embodiments, neuropathic pain includes diabetic neuropathy (e.g., diabetic peripheral neuropathy).

[0176] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of neuropathic pain or in reducing the severity in subjects thereof, the neuropathic pain including postherpetic neuralgia, diabetic neuropathy, painful HIV-related sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radiculopathy, sciatica; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy-induced neuralgia, cancer chemotherapy-induced neuralgia, antiretroviral therapy-induced neuralgia; pain after spinal cord injury, small fiber neuropathy, idiopathic small fiber neuropathy, idiopathic sensory neuropathy, or trigeminal autonomic neuropathy.

[0177] In yet another embodiment, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of musculoskeletal pain or in reducing the severity thereof in subjects. In some embodiments, musculoskeletal pain includes osteoarthritis.

[0178] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of musculoskeletal pain or the reduction of its severity in subjects thereof, musculoskeletal pain including osteoarthritis, back pain, cold pain, burn pain, or toothache.

[0179] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of pharmaceuticals for use in the treatment of inflammatory pain or the reduction of its severity in subjects thereof, wherein inflammatory pain includes rheumatoid arthritis pain or vulvodynia.

[0180] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of pharmaceuticals for use in the treatment of inflammatory pain or the reduction of its severity in subjects thereof, wherein inflammatory pain includes pain of rheumatoid arthritis.

[0181] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of pharmaceuticals for use in the treatment of idiopathic pain or in reducing the severity thereof, wherein idiopathic pain includes pain of fibromyalgia.

[0182] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of pathological cough or in reducing the severity thereof in subjects.

[0183] In yet another embodiment, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of acute pain or in reducing the severity of such pain in subjects. In some embodiments, acute pain includes acute postoperative pain.

[0184] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of postoperative pain (e.g., pain from joint replacement surgery, pain from soft tissue surgery, pain from hernia repair surgery, pain from aponeurosis resection surgery, or pain from abdominal wall reconstruction surgery) or for reducing the severity of such pain in subjects.

[0185] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in treating pain in hernia repair or reducing the severity in such patients.

[0186] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in treating pain in aponeurosis resection or reducing the severity in such subjects.

[0187] In yet another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents used for the treatment of pain in abdominoplasty or for reducing the severity in such patients.

[0188] In yet another embodiment, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents for use in the treatment of visceral pain or in reducing the severity thereof in subjects. In some embodiments, visceral pain includes visceral pain resulting from abdominoplasty.

[0189] In other embodiments, the present invention features compounds of the present invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions for the manufacture of agents for use in the treatment of neurodegenerative diseases or in reducing the severity of such diseases. In some embodiments, neurodegenerative diseases include multiple sclerosis. In some embodiments, neurodegenerative diseases include Pitt-Hopkins syndrome (PTHS).

[0190] In yet another embodiment, the present invention provides the use of the compound, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof for the manufacture of a drug to be used in combination with one or more additional therapeutic agents administered before or after treatment with the compound or pharmaceutical composition. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0191] In another aspect, the present invention relates to acute pain, subacute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, dysalgesic pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpes zoster neuralgia, general neuralgia, epilepsy, epileptic states, neurodegenerative disorders, psychiatric disorders, anxiety, depression, bipolar disorder, myotonicis, arrhythmia, motor disorders, neuroendocrine disorders, ataxia, central neuropathic pain and irritable bowel syndrome associated with multiple sclerosis, incontinence, pathological cough, visceral pain, osteoarthritis, postherpetic neuralgia, and diabetic neuropathy. Neuropathy, radiculopathy, sciatica, back pain, unspecified chronic back pain, headache, neck pain, moderate pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postoperative pain (e.g., pain from joint replacement, soft tissue surgery, hernia repair, aponeurosis excision, or abdominal wall reconstruction), cancer pain including chronic cancer pain and cancer breakthrough pain, stroke (e.g., central neuropathic pain after stroke), traumatic cervical syndrome, fragility fracture, vertebral fracture, ankylosing spondylitis, pemphigus, Raynaud's disease, scleroderma, systemic Lupus erythematosus, epidermolysis bullosa, gout, juvenile idiopathic arthritis, venous osteopathy, polymyalgia rheumatica, pyoderma gangrenosum, chronic widespread pain, diffuse idiopathic osteoproliferative disorder, intervertebral disc degeneration / hernia pain, nerve root compression, facet joint syndrome, spinal surgery failure syndrome, burns, carpal tunnel syndrome, Paget's disease pain, spinal stenosis, spondylodiscitis, transverse myelitis, Ehlers-Danlos syndrome, Fabry disease, mastocytosis, neurofibromatosis, ophthalmic neuropathy, sarcoidosis, spondylolysis, spondylolisthesis, The present invention provides for the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents used for the treatment or reduction of the severity of the following conditions: arteriovenous-induced oral mucositis, Charcot joint disorder, temporomandibular joint disorder, painful total knee replacement, noncardiac chest pain, genital pain, renal colic, biliary tract disease, vascular lower extremity ulcers, pain in Parkinson's disease, pain in Alzheimer's disease, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise-induced angina, palpitations, hypertension, or abnormal gastrointestinal motility.

[0192] In another aspect, the present invention relates to pain from femoral cancer; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, abdominal pain; splenic pain; IBS pain; chronic and acute headache pain; migraine; tension headache; cluster headache; chronic and acute neuropathic pain, postherpetic neuralgia; diabetic neuropathy; HIV-related neuropathy; trigeminal neuralgia; Charcot-Marie-Tooth neuropathy; hereditary sensory neuropathy; Peripheral nerve injury; painful neuroma; ectopic proximal and distal discharge; radiculopathy; chemotherapy-induced neuropathic pain; radiation-induced neuropathic pain; persistent / chronic postoperative pain (e.g., post-amputation, post-thoracotomy, post-cardiac surgery), post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; phantom limb pain (e.g., post-lower limb, upper limb, or mastectomy); intractable pain; acute pain, acute postoperative pain; acute musculoskeletal pain; arthralgia; mechanical low back pain; neck pain; tenosynovitis; injury pain; movement pain; acute Visceral pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernia; chest pain, cardiac pain; pelvic pain, renal colic pain, acute obstetric pain, labor pains; cesarean section pain; acute inflammatory pain, burn pain, traumatic pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain; sinusitis pain; toothache; multiple sclerosis (MS) pain; depression pain; leprosy pain; Behçet's disease pain; painful steatosis; phlebitis pain; Guillain-Barré syndrome pain; painful leg and mobile foot The present invention provides for the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for the manufacture of agents used for the treatment or reduction of the severity of widespread pain, paroxysmal severe pain, pruritus, tinnitus, or angina-induced pain.

[0193] In another aspect, the present invention provides the use of the compounds of the present invention, pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for the manufacture of agents used for the treatment of trigeminal neuralgia, Botox-treated migraine, cervical spondylotic radiculopathy, occipital neuralgia, axillary neuropathy, radial neuropathy, ulnar neuropathy, brachial plexus disorder, thoracic radiculopathy, intercostal neuralgia, lumbosacral radiculopathy, ilioinguinal neuralgia, pudendal neuralgia, femoral neuropathy, paresthesia of femoral pain, saphenous neuropathy, sciatic neuropathy, fibular neuropathy, tibial neuropathy, lumbosacral plexus disorder, stump pain of traumatic neuroma, or post-amputation treatment or reduction of the severity of pain thereof.

[0194] Administration of compounds, pharmaceutically acceptable salts, and compositions In certain embodiments of the present invention, an "effective amount" of the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is an amount effective in treating or reducing the severity of one or more of the conditions listed above.

[0195] The compounds, salts, and compositions produced by the methods of the present invention may be administered in any amount and via any route of administration that is effective in treating or alleviating the severity of one or more of the painful or non-painful conditions listed herein. The exact amount required will vary among subjects, depending on the species, age, and general condition of the subject, the severity of the condition, the specific drug, and its mode of administration. The compounds, salts, and compositions of the present invention are preferably formulated in unit dosage forms for ease of administration and uniformity of dosage. As used herein, the term "unit dosage form" refers to a physically distinct drug unit that is appropriate for the subject being treated. However, it will be understood that the total daily dose of the compounds, salts, and compositions of the present invention should be determined by the attending physician within the bounds of sound medical judgment. The specific effective dose level for any particular subject or organism will depend on a variety of factors, including the disorder being treated and its severity; the activity of the specific compound or salt used; the specific composition used; the subject's age, weight, general health, sex, and diet; the timing, route of administration, and rate of excretion of the specific compound or salt used; the duration of treatment; the agents used in combination with or concurrently with the specific compound or salt used; and similar factors well known in the medical technology. As used herein, the terms “subject” or “patient” mean an animal, preferably a mammal, and most preferably a human.

[0196] The pharmaceutically acceptable compositions of the present invention can be administered to humans and other animals orally, rectally, parenterally, intracisional, vaginally, intraperitoneally, topically (as powder, ointment, or droplets), orally or as a nasal spray to the cheek, etc., depending on the severity of the condition being treated. In certain embodiments, the compounds, salts, and compositions of the present invention may be administered orally or parenterally once or twice a day at a dosage level of about 0.001 mg / kg to about 1000 mg / kg, which is effective in obtaining the desired therapeutic effect.

[0197] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound or salt, the liquid dosage form may include, for example, inert diluents commonly used in the art, such as water or other solvents; solubilizers and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, as well as mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and fragrances.

[0198] Preparations for injection, such as sterile aqueous or oily suspensions for injection, may be formulated according to known techniques using suitable dispersants or wetting agents and suspending agents. Sterile preparations for injection may also be sterile solutions, suspensions, or emulsions for injection in non-toxic, parenterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution (United States Pharmacopeia), and isotonic sodium chloride solution. Furthermore, sterile fixatives have traditionally been used as solvents or suspension media. For this purpose, any non-irritating fixative, including synthetic monoglycerides or diglycerides, can be used. Additionally, fatty acids such as oleic acid are used in the preparation of injectable preparations.

[0199] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable media before use.

[0200] To extend the effects of the compounds of the present invention, it is often desirable to delay the absorption of the compounds from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material with poor water solubility. The absorption rate of the compound then depends on its dissolution rate, which may depend on the crystal size and crystalline form. Alternatively, delaying the absorption of parenterally administered compound forms is achieved by dissolving or suspending the compound in an oil vehicle. Depot formulations for injection are prepared by forming a microencapsulation matrix of the compound in a biodegradable polymer such as polylactide-polyglycolide. The compound release rate can be controlled depending on the compound-to-polymer ratio and the properties of the specific polymer used. Other examples of biodegradable polymers include poly(orthoester) and poly(anhydrous). Depot injection formulations are also prepared by encapsulating the compound in liposomes or microemulsions compatible with body tissues.

[0201] A composition for rectal or vaginal administration is preferably a suppository that can be prepared by mixing the compound or salt of the present invention with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol, or suppository wax, which is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity to release the active compound.

[0202] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound or salt is at least one inert, pharmaceutically acceptable excipient or carrier, e.g., sodium citrate or dicalcium phosphate, and / or a) fillers or bulking agents, e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders, e.g., carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants, e.g., glycerol; d) disintegrants, e.g., agar, carbonate It is mixed with calcium, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarders, e.g., paraffin; f) absorption enhancers, e.g., quaternary ammonium compounds; g) wetting agents, e.g., cetyl alcohol and glycerol monostearate; h) absorbents, e.g., kaolin and bentonite clay; i) lubricants, e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also contain buffers.

[0203] Similar types of solid compositions may also be used as fillers in soft and rigid gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol. Solid dosage forms of tablets, sugar-coated tablets, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in pharmaceutical formulation technology. They may optionally contain opacifying agents and may optionally be compositions that release the active ingredient in a delayed manner, only in or preferentially in a specific part of the intestinal tract. Examples of embedding compositions that can be used include polymer substances and waxes. Similar types of solid compositions may also be used as fillers in soft and rigid gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol.

[0204] The active compound or salt may also be in the form of microcapsules having one or more of the excipients described above. Solid dosage forms of tablets, sugar-coated tablets, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, controlled-release coatings, and other coatings well known in pharmaceutical formulation technology. In such solid dosage forms, the active compound or salt may be mixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also contain additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose, as is common practice. In the case of capsules, tablets, and pills, the dosage forms may also contain buffers. These may optionally contain opacifiers and may optionally be compositions that release the active ingredient in a delayed manner, only in a specific part of the intestinal tract, or preferentially. Examples of embedding compositions that may be used include polymeric substances and waxes.

[0205] Dosage forms for topical or transdermal administration of the compounds or salts of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredient is mixed under sterile conditions with a pharmaceutically acceptable carrier and, if necessary, any required preservatives or buffers. Ophthalmic formulations, ear drops, and eye drops are also intended to be within the scope of the present invention. Furthermore, the present invention intends to utilize transdermal patches, which have the additional advantage of providing controlled delivery of the compound into the body. Such dosage forms are prepared by dissolving or dispersing the compound in a suitable medium. Absorption enhancers may also be used to increase the flow of the compound across the skin. The rate can be controlled by providing a rate-controlled membrane or by dispersing the compound in a polymer matrix or gel.

[0206] Generally as described above, the compounds of the present invention are useful as inhibitors of voltage-gated sodium channels. In one embodiment, the compound is Na V1.8 is an inhibitor, and therefore does not wish to be bound by any particular theory, but the compound, salt, and composition are Na V 1.8 is particularly useful for treating or reducing the severity of diseases, conditions, or disorders in which activation or hyperactivity is involved. V 1.8 If the activation or hyperactivity of Na is involved in a particular disease, condition, or disorder, then the disease, condition, or disorder may also be Na V 1.8 A disease, condition, or disorder may be referred to as a mediated disease. Therefore, in another embodiment, the present invention is Na V 1.8 The present invention provides a method for treating or reducing the severity of a disease, condition, or disorder in which activation or hyperactivity of the substance is involved in the disease state.

[0207] Na V The activity of the compounds used in the present invention as inhibitors of 1.8 may be assayed in accordance with methods generally described in International Publication No. 2014 / 120808A9 and U.S. Publication No. 2014 / 0213616A1 (both of which are incorporated in their entirety by reference), the methods described herein, and other methods known and available to those skilled in the art.

[0208] Additional medications The compounds, salts, and pharmaceutically acceptable compositions of the present invention can be used in combination therapy, that is, the compounds, salts, and pharmaceutically acceptable compositions can be administered simultaneously with, before, or after one or more other desired treatments or medical procedures. The specific combination of therapies (treatments or procedures) used in a combination regimen will take into account the suitability of the desired therapeutic agent and / or procedure, as well as the desired therapeutic effect to be achieved. Naturally, the therapies used may achieve the desired effect against the same disorder (for example, the compounds of the present invention may be administered simultaneously with another agent used to treat the same disorder) or they may achieve different effects (for example, control of any adverse effects). As used herein, additional therapeutic agents that are typically administered to treat or prevent a particular disease or condition are known to be appropriate for the disease or condition being treated. For example, exemplary additional therapeutic agents include, but are not limited to, non-opioid analgesics (indoles, e.g., etodolac, indomethac, sulindac, tolmetine; naphthyl alkanones, e.g., nabumetone; oxicam, e.g., piroxicam; para-aminophenol derivatives, e.g., acetaminophen; propionic acids, e.g., fenoprofen, fluviprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium, oxaprozine; salicylates, e.g., aspirin, choline magnesium trisalicylate, diflunisal; fenamet, e.g., Examples include meclofenamic acid, mefenamic acid; and pyrazoles (e.g., phenylbutazone), or opioid (anesthetic) agonists (e.g., codeine, fentanyl, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, propoxyfen, buprenorphine, butorphanol, dezosine, nalbufine, and pentazocine). Furthermore, non-pharmacological analgesic approaches may be used in conjunction with the administration of one or more compounds of the present invention. For example, anesthesiological (spinal injection, nerve block), neurosurgical (nerve decompression of CNS pathways), neurostimulation (percutaneous electroneural stimulation, spinal cord posterior column stimulation), physical therapy (physiotherapy, orthostatic devices, diathermy), or psychiatric (cognitive methods - hypnosis, biofeedback, or behavioral methods) approaches may also be used.Additional appropriate therapeutic agents or approaches are generally described in The Merck Manual, Nineteenth Edition, Ed. Robert S. Porter and Justin L. Kaplan, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), 2011, and the Food and Drug Administration (website www.fda.gov), the entire contents of which are incorporated herein by reference.

[0209] In another embodiment, additional suitable therapeutic agents are selected from the following:

[0210] (1) Opioid analgesics, such as morphine, heroin, hydromorphone, oxymorphone, levorphanol, levorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyfene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbufine, pentazocine, or diferikephalin; (2) Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen, flufenisal, fluviprofen, ibuprofen (but not limited to intravenous ibuprofen (e.g., Caldolor®)), indomethacin, ketoprofen, ketrolac (but not limited to ketrolactromethamine (e.g., Toradol®)), meclofenamic acid, mefenamic acid, meloxicam, IV meloxicam (e.g., Anjeso®), nabumetone, naproxen, nimeslide, nitroflurbiprofen, orsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin, or zomepirac; (3) Barbiturate sedatives, such as amobarbital, aprobarbital, butabarbital, butarbital, mefobarbital, metalbital, methhexital, pentobarbital, phenobarbital, secobarbital, tarbutal, thiamylal, or thiopental; (4) Benzodiazepines having a sedative effect, such as chlordiazepoxide, chlorazepic acid, diazepam, furazepam, lorazepam, oxazepam, temazepam, or triazolam; (5) Histamine (H1) antagonists having a sedative effect, such as diphenhydramine, pyriramine, promethazine, chlorpheniramine, or chlorcyclidine; (6) Sedatives, such as glutethimide, meprobamate, methacaron, or dichlorphenazone; (7) Skeletal muscle relaxants, such as baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol, or orphenadrine; (8) NMDA receptor antagonists, such as dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) or its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), ketamine, memantine, pyrroloquinoline kinin, cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, budipine, EN-3231 (MorphiDex®), combination preparations of morphine and dextromethorphan), topiramate, neramexane, or perzinfotel (NR2B antagonists, such as ifenprodil, traxoprodil, or (-)-(R)-6-{2-[4-(3-fluorophenyl)-4-hydroxy-l-piperidinyl]-l-hydroxyethyl-3,4-dihydro-2(lH)-quinolinone); (9) Alpha-adrenergic agonists, such as doxazosin, tamsulosin, clonidine, guanfacine, dexmedetomidine, modafinil, or 4-amino-6,7-dimethoxy-2-(5-methanesulfonamide-1,2,3,4-tetrahydroisoquinoline-2-yl)-5-(2-pyridyl)quinazoline; (10) Tricyclic antidepressants, such as desipramine, imipramine, amitriptyline, or nortriptyline; (11) Anticonvulsants, such as carbamazepine (Tegretol®), lamotrigine, topiramate, lacosamide (Vimpat®), or valproate; (12) Tachykinin (NK) antagonists, especially NK-3, NK-2, or NK-1 antagonists, for example, (alpha-R,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[l,4]diazosino[2,1g][l,7]-naphthyridine-6-13-dione (TAK-637), 5-[[(2R,3S) -2-[(lR)-l-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]-methyl]-l,2-dihydro-3H-l,2,4-triazole-3-one (MK-869), aprepitant, ranepitant, dapitant, or 3-[[2-methoxy-5-(trifluoromethoxy)phenyl]-methylamino]-2-phenylpiperidine (2S,3S); (13) Muscarinic antagonists, such as oxybutynin, tolterodine, propiverine, tropsium chloride, dalifenacin, solifenacin, temiverine, and ipratropium; (14) COX-2 selective inhibitors, e.g., celecoxib, rofecoxib, parecoxib, valdecoxib, delacoxib, etoricoxib, or lumiracoxib; (15) Coal-tar analgesics, especially paracetamol; (16) Neuroleptics, such as droperidol, chlorpromazine, haloperidol, perphenazine, thioridazine, mesolidazine, trifluoperazine, fluphenazine, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, certindol, aripiprazole, sonepiprazole, blonanserin, iloperidone, perospirone, lacloprid, zotepine, bifepurnox, asenapine, lurasidone, amisulpride, paraperidone, palindore, eprivanserin, osanetan, limonabant, meclinertan, Miraxion®, or sarizotan; (17) Vanilloid receptor agonists (e.g., resiniferatoxin or cibamide) or antagonists (e.g., capsazepine, GRC-15300); (18) Beta-adrenaline, e.g., propranolol; (19) Local anesthetics, e.g., mexiletine; (20) Corticosteroids, e.g., dexamethasone; (21) 5-HT receptor agonists or antagonists, in particular 5-HT 1B / 1D Agonists, such as eletriptan, sumatriptan, naratriptan, zolmitriptan, or rizatriptan; (22)5-HT 2A Receptor antagonists, e.g., R(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL-100907); (23) Cholinergic (nicotinic) analgesics, for example isopronicline (TC-1734), (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403), (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), or nicotine; (24) Tramadol®, Tramadol ER (Ultram ER®), IV Tramadol, Tapentador ER (Nucynta®); (25) PDE5 inhibitors, e.g., 5-[2-ethoxy-5-(4-methyl-l-piperazinyl-sulfonyl)phenyl]-l-methyl-3-n-propyl-l,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one (sildenafil), (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',l':6,l]-pyrido[3,4-b ]Indole-l,4-dione (IC-351 or tadalafil), 2-[2-ethoxy-5-(4-ethyl-piperazine-l-yl-l-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,lf][l,2,4]triazine-4-one (vardenafil), 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(l-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4, 3-d]pyrimidine-7-one, 5-(5-acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(l-isopropyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one, 5-[2-ethoxy-5-(4-ethylpiperazine-l-ylsulfonyl)pyridine-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine- 7-ONE, 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidine-l-yl]-N-(pyrimidine-2-ylmethyl)pyrimidine-5-carboxamide, 3-(l-methyl-7-oxo-3-propyl-6,7-dihydro-lH-pyrazolo[4,3-d]pyrimidine-5-yl)-N-[2-(l-methylpyrrolidine-2-yl)ethyl]-4-propoxybenzenesulfonamide; (26) Alpha-2-delta ligands, e.g., gabapentin (Neurontin®), gabapentin GR (Gralise®), gabapentin, enacarbil (Horizant®), pregabalin (Lyrica®), 3-methylgabapentin, (l[alpha],3[alpha],5[alpha])(3-amino-methyl-bicyclo[3.2.0]hepta-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methylheptanoic acid, (3S,5R)-3-amino-5-methylheptanoic acid, (3S,5R)-3-amino-5-methyloctanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline, (2S,4S)-4-(3-fluorobenzyl)- Proline, [(lR,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hepta-6-yl]acetic acid, 3-(l-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazole-5-one, C-[1-(1H-tetrazole-5-ylmethyl)-cycloheptayl]-methylamine, (3S,4S)-(l-aminomethyl-3,4-dimethylcyclopentyl)acetic acid, (3S,5R)-3-aminomethyl-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylnonanoic acid, (3S,5R)-3-amino-5-methyloctanoic acid, (3R,4R,5R)-3-amino-4,5-dimethylheptanoic acid, and (3R,4R,5R)-3-amino-4,5-dimethyloctanoic acid; (27) Cannabinoids, e.g., KHK-6188; (28) Metabotropic glutamate subtype 1 receptor (mGluRl) antagonists; (29) Serotonin reuptake inhibitors, such as sertraline, sertraline metabolite demethylsertraline, fluoxetine, norfluoxetine (fluoxetine desmethyl metabolite), fluvoxamine, paroxetine, citalopram, citalopram metabolite desmethylcitalopram, esitalopram, d,l-fenfluramine, femoxetine, ioxetine, cyanodothiopine, ritoxetine, dapoxetine, nefazodone, sericlamine, and trazodone; (30) Norepinephrine reuptake inhibitors, e.g., maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, bupropion, bupropion metabolite hydroxybupropion, nomifensin, and biloxazine (Vivalan®), in particular selective norepinephrine reuptake inhibitors, e.g., reboxetine, in particular (S,S)-reboxetine; (31) Dual serotonin-norepinephrine reuptake inhibitors, e.g., venlafaxine, venlafaxine metabolite O-desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, duloxetine (Cymbalta®), milnacipran, and imipramine; (32) Inducible nitric oxide synthase (iNOS) inhibitors, e.g., S-[2-[(l-iminoethyl)amino]ethyl]-L-homocysteine, S-[2-[(l-iminoethyl)amino]ethyl]-4,4-dioxo-L-cysteine, S-[2-[(l-iminoethyl)amino]ethyl]-2-methyl-L-cysteine, (2S,5Z)-2-amino-2-methyl-7-[(l-iminoethyl)amino]-5-heptenoic acid, 2-[[(lR,3S)-3-amino-4-hydroxy-l-(5-thiazolyl)-butyl]thio]-S-chloro-S-pyridinecarbonitride; 2-[[(lR,3S)-3-amino-4-hydroxy-l-(5- [Thiazolyl)butyl]thio]-4-chlorobenzonitrile, (2S,4R)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol, 2-[[(lR,3S)-3-amino-4-hydroxy-l-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitride, 2-[[(lR,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chlorobenzonitrile, N-[4-[2-(3-chlorobenzylamino)ethyl]phenyl]thiophene-2-carboxamidine, NXN-462, or guanidinoethyl disulfide; (33) Acetylcholinesterase inhibitors, e.g., donepezil; (34) Prostaglandin E2 subtype 4 (EP4) antagonists, e.g., N-[({2-[4-(2-ethyl-4,6-dimethyl-lH-imidazo[4,5-c]pyridine-l-yl)phenyl]ethyl}amino)-carbonyl]-4-methylbenzenesulfonamide or 4-[(15)-l-({[5-chloro-2-(3-fluorophenoxy)pyridine-3-yl]carbonyl}amino)ethyl]benzoic acid; (35) Leukotriene B4 antagonists, e.g., l-(3-biphenyl-4-ylmethyl-4-hydroxychroman-7-yl)-cyclopentanecarboxylic acid (CP-105696), 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl]oxyphenoxy]valeric acid (ONO-4057), or DPC-11870; (36) 5-lipoxygenase inhibitors, e.g., dileuton, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxymethyl]-1-methyl-2-quinolone (ZD-2138), or 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504); (37) Sodium channel blockers, e.g., lidocaine, lidocaine + tetracaine cream (ZRS-201), or eslicarbazepine acetate; (38) Na V1.7 Blockers, e.g., XEN-402, XEN403, TV-45070, PF-05089771, CNV1014802, GDC-0276, RG7893, BIIB-074 (Vixotrigine), BIIB-095, ASP-1807, DSP-3905, OLP-1002, RQ-00432979, FX-301, DWP-1706, DWP-17061, IMB-110, IMB-111, IMB-112, and WO2011 / 140425 (US2011 / 306607); WO2012 / 106499 (US2012 / 196869); WO2012 / 112743 (US2012 / 245) 136); as disclosed in WO2012 / 125613 (US2012 / 264749), WO2012 / 116440 (US2014 / 187533), WO2011 / 026240 (US2012 / 220605), US8883840, US8466188, WO2013 / 109521 (US2015 / 005304), WO2020 / 117626, and CN111217776 (the entire contents of each application are incorporated herein by reference); (38a)Na V1.7 Blockers, e.g., (2-benzylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl)-(4-isopropoxy-3-methylphenyl)methanone, 2,2,2-trifluoro-1-[1'-[3-methoxy-4-[2-(trifluoromethoxy)ethoxy]benzoyl]-2,4-dimethylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydro Ropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]-(4-isobutoxy-3-methoxyphenyl)methanone, 1-(4-benzhydrylpiperazine-1-yl)-3-[2-(3,4-dimethylphenoxy)ethoxy]propan-2-ol, (4-butoxy-3-methoxyphenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[ 3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]-(5-isopropoxy-6-methyl-2-pyridyl)methanone, (4-isopropoxy-3-methylphenyl)-[2-methyl-6-(1,1,2,2,2-pentafluoroethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone, 5-[2-methyl-4-[2-methyl-6-(2,2,2-trifluoroacetyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4 '-piperidine]-1'-carbonyl]phenyl]pyridine-2-carbonilicate, (4-isopropoxy-3-methylphenyl)-[6-(trifluoromethyl)spiro[3,4-dihydro-2H-pyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone, 2,2,2-trifluoro-1-[1'-[3-methoxy-4-[2-(trifluoromethoxy)ethoxy]benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, 2,2,2-Trifluoro-1-[1'-(5-isopropoxy-6-methylpyridine-2-carbonyl)-3,3-dimethyl-spiro[2,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, 2,2,2-Trifluoro-1-[1'-(5-isopentyloxypyridine-2-carbonyl)-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, (4-isopropoxy-3-methoxyphenyl)-[2-methyl-6-(trifluoromethyl (L)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone, 2,2,2-trifluoro-1-[1'-(5-isopentyloxypyridine-2-carbonyl)-2,4-dimethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, 1-[(3S)-2,3-dimethyl-1'-[4-(3,3,3-trifluoropropoxymethyl)benzoyl]spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6- [Iyl]-2,2,2-trifluoro-ethanone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]-[3-methoxy-4-[(1R)-1-methylpropoxy]phenyl]methanone, 2,2,2-trifluoro-1-[1'-(5-isopropoxy-6-methylpyridine-2-carbonyl)-2,4-dimethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, 1-[1'-[ 4-Methoxy-3-(trifluoromethyl)benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]-2,2-dimethyl-propan-1-one, (4-isopropoxy-3-methylphenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone, [2-methyl-6-(1-methylcyclopropanecarbonyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-Piperidine]-1'-yl]-[4-(3,3,3-trifluoropropoxymethyl)phenyl]methanone, 4-Bromo-N-(4-bromophenyl)-3-[(1-methyl-2-oxo-4-piperidyl)sulfamoyl]benzamide, or (3-chloro-4-isopropoxy-phenyl)-[2-methyl-6-(1,1,2,2,2-pentafluoroethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone. (39) Na V 1.8 Blockers, e.g., PF-04531083, PF-06372865, and e.g., WO2008 / 135826 (US2009048306), WO2006 / 011050 (US2008312235), WO2013 / 061205 (US2014296313), US2013 / 0303535, WO2013 / 131018, US8466188, WO2013 / 114250(US2013 / 274243), WO2014 / 120808(US2014 / 213616), WO2014 / 120815(US2014 / 228371), WO20 14 / 120820(US2014 / 221435), WO2015 / 010065(US20160152561), WO2015 / 089361(US20150166589), WO2 019 / 014352(US2019 / 0016671), WO2018 / 213426, WO2020 / 146682, WO2020 / 146612, WO2020 / 014243, WO 2020 / 014246, WO2020 / 092187, WO2020 / 092667(US2020140411), WO2020 / 261114, WO2020 / 140959, WO20 Disclosed in 20 / 151728, WO2021 / 032074, CN112390745, CN111808019, CN112225695, CN112457294, CN112300051, CN112300069, CN112441969, and CN112479996 (WO2021 / 047622) (the entire contents of each application are incorporated herein by reference); (39a)Na V1.8 Blockers, e.g., 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)-4-(perfluoroethyl)benzamide, 4,5-dichloro-2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)benzamide, 4,5-dichloro-2-(3-fluoro-4-methoxyphenoxy)-N-(2- Xo-1,2-dihydropyridine-4-yl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)-5-(trifluoromethyl)benzamide, N-(2-oxo-1,2-dihydropyridine-4-yl)-2-(4-(trifluoromethoxy)phenoxy)-4-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)-4-(perfluoroethyl)benzamide, 5-chloro-2-(4 -Fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)benzamide, N-(2-oxo-1,2-dihydropyridine-4-yl)-2-(4-(trifluoromethoxy)phenoxy)-5-(trifluoromethyl)benzamide, 2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)-5-(trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)- 5-(trifluoromethyl)benzamide, 5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)benzamide, 4-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)benzamide, 5-chloro-2-(2-chloro-4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)benzamide, 2-((5-fluoro-2-hydroxybenzyl)oxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)-4-(trifluoromethyl)benzamide, N-(2-oxo-1,2-dihydropyridine-4-yl)-2-(o-tolyloxy)-5-(trifluoromethyl)benzamide, 2-(2,4-difluorophenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)-4-(trifluoromethyl)benzamide, N-(2-oxo-1,2-dihydropyridine-4-yl)-2-(2-(trifluoromethoxy)phenoxy)-5-(trifluoromethyl)benzamide, 2-(4-fluoro Phenoxy)-N-(2-oxo-1,2-dihydropyridine-4-yl)-5-(trifluoromethyl)benzamide, 2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1H-pyridine-4-yl)-4-(trifluoromethyl)benzamide, [4-[[2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoyl]amino]-2-oxo-1-pyridyl]methyl dihydrogen phosphate, 2-(4-fluoro-2-(methyl-d3)phenoxy)-N-(2-oxo-1,2-dihydropyridine-4- (Iyl)-4-(trifluoromethyl)benzamide, (4-(2-(4-fluoro-2-(methyl-d3)phenoxy)-4-(trifluoromethyl)benzamide)-2-oxopyridine-1(2H)-yl)methyl dihydrogen phosphate, 3-(4-fluoro-2-methoxyphenoxy)-N-(3-(methylsulfonyl)phenyl)quinoxaline-2-carboxamide, 3-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide, 3-(2-chloro-4-methoxyphenoxy)-N-( 3-Sulfamoylphenyl)Quinoxaline-2-Carboxamide, 3-(4-Chloro-2-Methoxyphenoxy)-N-(3-Sulfamoylphenyl)Quinoxaline-2-Carboxamide, 4-(3-(4-(Trifluoromethoxy)phenoxy)Quinoxaline-2-Carboxamide)Picolinic Acid, 2-(2,4-Difluorophenoxy)-N-(3-Sulfamoylphenyl)Quinoline-3-Carboxamide, 2-(4-Fluoro-2-Methoxyphenoxy)-N-(3-Sulfamoylphenyl)Quinoline-3-Carboxamide, 3-(2,4-Difluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide, N-(3-sulfamoylphenyl)-2-(4-(trifluoromethoxy)phenoxy)quinoline-3-carboxamide, N-(3-sulfamoylphenyl)-3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamide, 3-(4-chloro-2-methylphenoxy)-N-(3-sulfamoylphenyl)quinoxaline- 2-Carboxamide, 5-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamide)picolinic acid, 3-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-yl)quinoxaline-2-carboxamide, 3-(4-fluoro-2-methoxyphenoxy)-N-(pyridine-4-yl)quinoxaline-2-carboxamide, 3-(4-fluorophenoxy)-N -(3-sulfamoylphenyl)quinoxaline-2-carboxamide, N-(3-cyanophenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide, N-(4-carbamoylphenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide, 4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamide)benzoic acid, N-(4-cyanophenyl)-3-(4 -Fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide, 5-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamide)picolinic acid, 5-(2-(2,4-dimethoxyphenoxy)-4,6-bis(trifluoromethyl)benzamide)picolinic acid, 4-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamide)benzoic acid, 5-(2-(4-fluoro-2-methoxyphenoxy)-4,6-Bis(trifluoromethyl)benzamide) picolinic acid, 4-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)benzamide) benzoic acid, 5-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)benzamide) picolinic acid, 4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide) benzoic acid, 5-(4,5-Dichloromethyl 4-(4-fluoro-2-methoxyphenoxy)benzamide) picolinic acid, 4-(2-(2-chloro-4-fluorophenoxy)-4-(perfluoroethyl)benzamide) benzoic acid, 4-(2-(4-fluoro-2-methylphenoxy)-4-(perfluoroethyl)benzamide) benzoic acid, 4-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamide) benzoic acid, 4-(4, 5-Dichloro-2-(4-chloro-2-methylphenoxy)benzamide)benzoic acid, 5-(4-(tert-butyl)-2-(4-fluoro-2-methoxyphenoxy)benzamide) picolinic acid, 5-(4,5-Dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamide) picolinic acid, 4-(4,5-Dichloro-2-(4-fluoro-2-methylphenoxy)benzamide)benzoic acid, 5-(4,5- Dichloro-2-(2,4-dimethoxyphenoxy)benzamide) picolinic acid, 5-(4,5-dichloro-2-(2-chloro-4-fluorophenoxy)benzamide) picolinic acid, 5-(4,5-dichloro-2-(4-fluoro-2-methylphenoxy)benzamide) picolinic acid, 4-(4,5-dichloro-2-(4-chloro-2-methoxyphenoxy)benzamide) benzoic acid, 5-(4,5-dichloro-2-(2,4-Difluorophenoxy)benzamide)picolinic acid, 2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)-5-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)-4-(trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)-5-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(3-s Sulfamoylphenyl)-4-(trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)-6-(trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-5-(difluoromethyl)-N-(3-sulfamoylphenyl)benzamide, 2-(4-fluorophenoxy)-4-(perfluoroethyl)-N-(3-sulfamoylphenyl)benzamide, 2-(4-chloro-2-methyl) Toxyphenoxy)-4-(perfluoroethyl)-N-(3-sulfamoylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-5-(trifluoromethyl)benzamide, 5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)benzamide, 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)benzamide, 2,4-Dichloro-6-(4-chloro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)benzamide, 2,4-Dichloro-6-(4-fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4,6-bis(trifluoromethyl)benzamide, 2-(4-fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)-4,6-Bis(trifluoromethyl)benzamide, 5-Chloro-2-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4-(trifluoromethoxy)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4-(trifluoromethyl)benzamide, 4,5-Dichloro-2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)-N-(3-sulfamoylphenyl)benzamide, 5-Fluoro-2-(4-fluoro-2-methylphenoxy)- N-(3-sulfamoylphenyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-4-cyano-N-(3-sulfamoylphenyl)benzamide, N-(3-sulfamoylphenyl)-2-(4-(trifluoromethoxy)phenoxy)-4-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-(triduteromethoxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-pheni, N-(3-carbamoyl-4-fluorophenyl)-3 -(difluoromethyl)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzamide, 4-[[2-fluoro-6-[2-(triduteromethoxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethoxy)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-6-[2-chloro-4-(trifluoromethoxy)phenoxy]-2-fluoro-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-methyl-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluorophenyl)-2,3,4-Trifluoro-6-[2-Methoxy-4-(trifluoromethoxy)phenoxy]benzamide, N-(2-Carbamoyl-4-pyridyl)-3-fluoro-5-[2-Methoxy-4-(trifluoromethoxy)phenoxy]-2-(trifluoromethyl)pyridine-4-carboxamide, 4-[[6-[2-(difluoromethoxy)-4-(trifluoromethoxy)phenoxy]-2-fluoro-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-Carbamoyl-4-fluoro-phenyl)-6-[3-chloro-4-(trifluoromethoxy)phenoxy]-2-fluoro-3-(trifluoromethyl)benzamide, N-(3-Carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[4-(trifluoromethoxy )phenoxy]-3-(trifluoromethyl)benzamide, N-(4-carbamoyl-3-fluoro-phenyl)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, 4-[[2-fluoro-6-[2-(triduteromethoxy)-4-(trifluoromethoxy)phenoxy]-4-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[3-fluoro-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-[2-methoxy-4-(trifluoromethoxy)phenoxy]-5-(1,1,2,2,2-Pentafluoroethyl)benzamide, 4-[[4-(difluoromethoxy)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-fluoro-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, 4-[[4-cyclopropyl-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-5-fluoro-2-[2-methoxy-4-(trifluoromethoxy)phenoxy]-4-(trifluoro Oromethyl)benzamide, 5-[[2-fluoro-6-[2-(triduteromethoxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluorophenyl)-2-fluoro-6-(4-fluorophenoxy)-3-(trifluoromethyl)benzamide, 4-(2-fluoro-6-(2-methoxy-4-(trifluoromethoxy)phenoxy)-3-(trifluoromethyl)benzamide)picolinamide, or 4-[[2-fluoro-6-[3-fluoro-2-methoxy-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide;, (40) Combined Na V 1.7 and Na V 1.8 Blockers, e.g., DSP-2230, Lohocla201, or BL-1021; (41) 5-HT3 antagonists, e.g., ondansetron; (42) TPRV1 receptor agonists, such as capsaicin (NeurogesX®, Qutenza®), and pharmaceutically acceptable salts and solvates thereof; (43) Nicotinic receptor antagonists, e.g., varenicline; (44) N-type calcium channel antagonists, e.g., Z-160; (45) Nerve growth factor antagonists, e.g., tanezumab; (46) Endopeptidase stimulants, e.g., senlevotase; (47) Angiotensin II antagonists, e.g., EMA-401; (48) Acetaminophen (but not limited to intravenous acetaminophen (e.g., Ofrmev®)); (49) Bupivacaine (including, but not limited to, bupivacaine liposome injection suspension (e.g., Exparel®), bupivacaine ER (Posimir), bupivacaine collagen (Xaracoll), and transdermal bupivacaine (Eladur®)), and (50) A combination of bupivacaine and meloxicam (e.g., HTX-011).

[0211] In one embodiment, additional suitable therapeutic agents are selected from V-116517, pregabalin, sustained-release pregabalin, ezogabine (Potiga®), ketamine / amitriptyline topical cream (Amiket®), AVP-923, perampanel (E-2007), ralfinamide, transdermal bupivacaine (Eladur®), CNV1014802, JNJ-10234094 (Carisbamate), BMS-954561, or ARC-4558.

[0212] In another embodiment, additional suitable therapeutic agents are selected from N-(6-amino-5-(2,3,5-trichlorophenyl)pyridine-2-yl)acetamide; N-(6-amino-5-(2-chloro-5-methoxyphenyl)pyridine-2-yl)-1-methyl-1H-pyrazole-5-carboxamide; or 3-((4-(4-(trifluoromethoxy)phenyl)-1H-imidazole-2-yl)methyl)oxetane-3-amine.

[0213] In another embodiment, additional therapeutic agents are selected from GlyT2 / 5HT2 inhibitors, e.g., Operanserin (VVZ149), TRPV modulators, e.g., CA008, CMX-020, NEO6860, FTABS, CNTX4975, MCP101, MDR16523, or MDR652, EGR1 inhibitors, e.g., Brivoglide (AYX1), NGF inhibitors, e.g., tanezumab, facinumab, ASP6294, MEDI7352, Mu opioid agonists, e.g., cebranopadol, NKTR181 (oxycodegol), CB-1 agonists, e.g., NEO1940 (AZN1940), imidazoline 12 agonists, e.g., CR4056, or p75NTR-Fc modulators, e.g., LEVI-04.

[0214] In another embodiment, the additional therapeutic agent is oryceridine or ropivacaine (TLC590).

[0215] In another embodiment, the additional therapeutic agent is Na V 1.7 Blockers, e.g., ST-2427 or ST-2578, as disclosed in WO2010 / 129864, WO2015 / 157559, WO2017 / 059385, WO2018 / 183781, WO2018 / 183782, WO2020 / 072835, and WO2022 / 036297 (the entire contents of each application are incorporated herein by reference). In some embodiments, additional therapeutic agents are Na disclosed in WO2020 / 072835. V 1.7 Blockers. In some embodiments, additional therapeutic agents are disclosed in WO2022 / 036297. V 1.7 It is an antiblocker.

[0216] In another embodiment, additional therapeutic agents include ASP18071, CC-8464, ANP-230, ANP-231, NOC-100, NTX-1175, ASN008, NW3509, AM-6120, AM-8145, AM-0422, BL-017881, NTM-006, Opiranserin (Unafra®), Brivolizide, SR419, NRD.E1, LX9211, LY3016859, ISC-17536, NFX-88, LAT-8881, AP-235, NYX 2925, CNTX-6016, S-600918, S-637880, RQ-00434739, KLS-2031, MEDI It is either 7352 or XT-150.

[0217] In another embodiment, additional therapeutic agents include Olinvyk, Zynrelef, Seglentis, Neumentum, Nevakar, HTX-034, CPL-01, ACP-044, HRS-4800, Tarlige, BAY2395840, LY3526318, Eliapixant, TRV045, RTA901, NRD1355-E1, MT-8554, LY3556050, AP-325, tetrodotoxin, Otenaproxesul, CFTX-1554, Funapide, iN1011-N17, JMKX000623, ETX-801, or ACD440.

[0218] In another embodiment, additional therapeutic agents include WO2021 / 257490, WO2021 / 257420, WO2021 / 257418, WO2020 / 014246, WO2020 / 092187, WO2020 / 092667, WO2020 / 261114, CN112457294, CN112225695, CN111808019, WO2021 / 032074, WO2020 / 151728, WO2020 / 140959, WO2022 / 037641, WO2022 These are compounds disclosed in / 037647, CN112300051, CN112300069, WO2014 / 120808, WO2015 / 089361, WO2019 / 014352, WO2021 / 113627, WO2013 / 086229, WO2013 / 134518, WO2014 / 211173, WO2014 / 201206, WO2016 / 141035, WO2021 / 252818, WO2021 / 252822, and WO2021 / 252820.

[0219] In some embodiments, the additional therapeutic agent is a compound disclosed in WO2013 / 086229. In some embodiments, the additional therapeutic agent is a compound disclosed in WO2013 / 134518. In some embodiments, the additional therapeutic agent is a compound disclosed in WO2014 / 211173. In some embodiments, the additional therapeutic agent is a compound disclosed in WO2014 / 201206. In some embodiments, the additional therapeutic agent is a compound disclosed in WO2016 / 141035. In some embodiments, the additional therapeutic agent is a compound disclosed in WO2021 / 252818. In some embodiments, the additional therapeutic agent is a compound disclosed in WO2021 / 252822. In some embodiments, the additional therapeutic agent is a compound disclosed in WO2021 / 252820. In some embodiments, the additional therapeutic agent is a compound disclosed in WO2020 / 072835. In some embodiments, additional therapeutic agents are compounds disclosed in WO2022 / 036297.

[0220] In another embodiment, the additional therapeutic agent is Na as identified above.V 1.7 and Na V 1.8 These are sodium channel inhibitors (also known as sodium channel blockers), such as 1.8-blockers.

[0221] The amount of additional therapeutic agents present in the composition of the present invention may be less than or equal to the amount typically administered in a composition containing the therapeutic agent as the sole active agent. The amount of additional therapeutic agents in the currently disclosed compositions may range from about 10% to 100% of the amount typically present in a composition containing the agent as the sole therapeutic active agent.

[0222] The compounds and salts of the present invention, or pharmaceutically acceptable compositions thereof, may also be incorporated into compositions for coating implantable medical devices such as prostheses, prosthetic valves, vascular grafts, stents, and catheters. Therefore, in another embodiment, the present invention includes compositions for coating implantable devices, generally comprising the compounds or salts of the present invention described above, as well as the classes and subclasses herein, and carriers suitable for coating such implantable devices. In yet another embodiment, the present invention includes implantable devices coated with compositions comprising the compounds or salts of the present invention described above, as well as the classes and subclasses herein, and carriers suitable for coating such implantable devices. General preparations of suitable coatings and coated implantable devices are described in U.S. Patents 6,099,562, 5,886,026, and 5,304,121. The coatings are typically biocompatible polymer materials such as hydrogel polymers, polymethyldisiloxanes, polycaprolactones, polyethylene glycols, polylactic acid, ethylene vinyl acetates, and mixtures thereof. The coating may be further covered with a suitable top coating of fluorosilicone, polysaccharide, polyethylene glycol, phospholipid, or a combination thereof, as needed, to impart sustained-release properties to the composition.

[0223] Another aspect of the present invention is a biological sample or subject in which Na V1.8 With regard to inhibiting activity, the method includes administering to a subject or contacting the biological sample with the compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. As used herein, the term “biological sample” includes, but is not limited to, cell cultures or extracts thereof, biopsy materials obtained from mammals or extracts thereof, and blood, saliva, urine, feces, semen, tears, or other bodily fluids or extracts thereof.

[0224] Na in biological samples V 1.8 Inhibition of activity is useful for a variety of purposes known to those skilled in the art. Examples of such purposes include, but are not limited to, the study of sodium channels in biological and pathological phenomena, and the comparative evaluation of novel sodium channel inhibitors.

[0225] Synthesis of the Compound of the Present Invention The compounds of the present invention can be prepared from known materials by the methods described in the examples, other similar methods, and other methods known to those skilled in the art. As those skilled in the art will understand, the functional groups of the intermediate compounds in the following methods may need to be protected by suitable protecting groups. Protecting groups may be added or removed according to standard techniques well known to those skilled in the art. The use of protecting groups is described in detail in TGMWuts et al., Greene's Protective Groups in Organic Synthesis (4th ed. 2006).

[0226] Radiolabeled analogues of the compound of the present invention In another aspect, the present invention relates to radiolabeled analogues of the compounds of the present invention. As used herein, the term “radiolabeled analogue of the compounds of the present invention” means a compound that is identical to the compounds of the present invention described herein, except that one or more atoms are replaced with radioisotopes of atoms present in the compounds of the present invention, including all embodiments thereof.

[0227] As used herein, the term “radioisotope” refers to an isotope of an element known to undergo spontaneous radioactive decay. Examples of radioisotopes include: 3 H, 14 C, 32 P, 35 S, 18 F, 36 Examples include Cl, as well as isotopes whose decay modes have been identified in the Table of Nuclides (January 1980) by VS Shirley & C.M. Lederer, Isotopes Project, Nuclear Science Division, Lawrence Berkeley Laboratory.

[0228] Radiolabeled analogues can be used in several beneficial ways, including various types of assays such as substrate tissue distribution assays. For example, tritium (3 H ) Label and / or carbon-14 ( 14 C) Labeled compounds can be useful in various types of assays, such as substrate tissue distribution assays, due to their relatively simple preparation and excellent detection capabilities.

[0229] In another aspect, the present invention relates to pharmaceutically acceptable salts of radiolabeled analogs of compounds of the present invention, according to any of the embodiments described herein.

[0230] In another aspect, the present invention relates to a pharmaceutical composition comprising a radiolabeled analogue or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle, in accordance with any of the embodiments described herein relating to the compound of the present invention.

[0231] In another aspect, the present invention relates to a method for inhibiting voltage-gated sodium channels in a subject, comprising administering an effective amount of a radiolabeled analogue, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, in accordance with any of the embodiments described herein relating to the compounds of the present invention, and a method for treating or reducing the severity of various diseases and disorders, including pain.

[0232] In another aspect, the present invention relates to radiolabeled analogues, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof for use in relation to the compounds of the present invention, according to any of the embodiments described herein.

[0233] In another aspect, the present invention relates to radiolabeled analogues or pharmaceutically acceptable salts thereof for the manufacture of pharmaceuticals, and the use of pharmaceutical compositions thereof, in accordance with any of the embodiments described herein relating to the compounds of the present invention.

[0234] In another embodiment, radiolabeled analogues, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof may be used in combination therapy in relation to the compounds of the present invention, according to any of the embodiments described herein.

[0235] Listed embodiments Further embodiments of this disclosure are described in the following numbered clauses. 1. Compound of formula (I), [ka] , or a pharmaceutically acceptable salt thereof, in the formula, X 2a However, N, N + -O - , or CR 2a And, X 3a However, N or N + -O - And, X 5a However, N, N + -O -, or CR 5a And, X 6a However, N, N + -O - , or CR 6a And, R d However, (CH2) m (CHR e ) n (CH2) p H is, m, n, and p are each independently either 0 or 1. R e However, it is H, OH, halo, C1-C6 alkoxy, or C1-C6 haloalkoxy. R 2a and R 6a Each of these is independently H, halo, C1-C6 alkyl, or C1-C6 haloalkyl. R 5a However, it is H, halo, CH2OH, C1-C6 alkyl, or C1-C6 haloalkyl, R 4b1 and R 4b2 Each of these is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl. R 5b1 and R 5b2 Each of these is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or C1-C6 haloalkyl. X 3c However, N or CR 3c And, X 4c However, N or CR 4c And, X 5c However, N or CR 5c And, X 6c However, N or CR 6c And, R 2c However, H, OH, halo, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -L 1 -L 2-(C3-C6 cycloalkyl), and the cycloalkyl is substituted with 1-2 halos as needed. L 1 However, it is a bond or O, L 2 However, it is a bond or C1-C6 alkylene, R 3c However, it is either H, halo, C1-C6 alkyl, or C1-C6 haloalkyl, or X 3c However, CR 3c And R 2c and R 3c However, together with the carbon atoms to which they bond, they form a ring as shown in the following equation: [ka] ; Z1 and Z2 are independently either O or CH2. Each R is independently H or halo. R 4c However, it is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, R 5c However, it is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl, R 6c However, it is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl, However, X 2a , X 3a , X 5a , and X 6a Two or fewer of these are N or N + -O - And, X 3c , X 4c , X 5c , and X 6c A compound of formula (I), or a pharmaceutically acceptable salt thereof, provided that one or less of the elements is N. 2. The compound is of formula (IA) [ka] , A compound as described in Clause 1, or a pharmaceutically acceptable salt thereof, having the above characteristics. 3. The compound is of formula (IA-1) [ka] , A compound as described in Clause 1, or a pharmaceutically acceptable salt thereof, having the above characteristics. 4. The compound is of formula (IB) [ka] , A compound as described in Clause 1, or a pharmaceutically acceptable salt thereof, having the above characteristics. 5. The compound is of formula (IB-1) [ka] , A compound as described in Clause 1, or a pharmaceutically acceptable salt thereof, having the above characteristics. 6.X 2a However, CR 2a And R 2a A compound described in any one of clauses 1, 2, and 4, or a pharmaceutically acceptable salt thereof, wherein H is present. 7.X 3a The compound described in any one of clauses 1, 2, 4, and 6, or a pharmaceutically acceptable salt thereof, wherein N is present. 8.X 3a However, N + -O - The compound described in any one of clauses 1, 2, 4, and 6, or a pharmaceutically acceptable salt thereof. 9.X 5a However, N or CR 5a And R 5a A compound listed in any one of items 1, 2, 4, and 6-8, or a pharmaceutically acceptable salt thereof, wherein the compound is H, halo, or CH2OH. 10.X 5a However, the compound described in Clause 9, or a pharmaceutically acceptable salt thereof, is N. 11.X 5a However, CR 5a And R 5aThe compounds listed in item 9, or pharmaceutically acceptable salts thereof, wherein the compound is H, F, or CH2OH. 12.X 6a However, N or CR 6a And R 6a A compound listed in any one of items 1, 2, 4, and 6-11, or a pharmaceutically acceptable salt thereof, wherein H is present. 13.X 6a However, CR 6a And R 6a A compound listed in item 12, or a pharmaceutically acceptable salt thereof, which is H. 14.R 4b1 A compound listed in any one of items 1 to 13, which is H or C1-C6 alkyl, or a pharmaceutically acceptable salt thereof. 15.R 4b1 The compound described in Clause 14, or a pharmaceutically acceptable salt thereof, which is H or CH3. 16.R 4b2 A compound listed in any one of items 1 to 15, which is H or C1-C6 alkyl, or a pharmaceutically acceptable salt thereof. 17.R 4b2 The compound described in Clause 16, or a pharmaceutically acceptable salt thereof, which is H or CH3. 18.R 5b1 The compound described in any one of clauses 1 to 17, which is a C1-C6 alkyl or C1-C6 haloalkyl, or a pharmaceutically acceptable salt thereof. 19.R 5b1 However, the compounds described in Clause 18, or pharmaceutically acceptable salts thereof, which are CH3 or CF3. 20.R 5b2 The compound described in any one of clauses 1 to 19, which is a C1-C6 alkyl or C1-C6 haloalkyl, or a pharmaceutically acceptable salt thereof. 21.R 5b2 However, the compounds described in Clause 20, or pharmaceutically acceptable salts thereof, which are CH3 or CF3. 22.R 2cA compound described in any one of clauses 1 to 21, wherein the compound is OH, halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, or a pharmaceutically acceptable salt thereof. 23.R 2c The compounds described in Clause 22, or pharmaceutically acceptable salts thereof, wherein the compound is OH, Cl, CH3, OCH3, OCD3, OCH2CH3, OCH(CH3)2, OCH2CH2F, or OCH2CHF2. 24.X 3c However, N or CR 3c And R 3c The compound described in any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the compound is H, halo, C1-C6 alkyl, or C1-C6 haloalkyl. 25.X 3c However, the compound described in Clause 24, or a pharmaceutically acceptable salt thereof, is N. 26.X 3c However, CR 3c And R 3c The compounds described in Clause 24, or pharmaceutically acceptable salts thereof, wherein the compound is H, F, CH3, CHF2, or CF3. 27.X 3c However, CR 3c And R 2c and R 3c A compound described in any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein these atoms, together with the carbon atoms to which they are bonded, form a ring of the following formula. [ka] . 28. A compound described in Clause 27, or a pharmaceutically acceptable salt thereof, wherein the ring is of the following formula. [ka] . 29.X 4c However, CR 4c And R 4cA compound described in any one of clauses 1 to 28, wherein the compound is H, halo, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, or a pharmaceutically acceptable salt thereof. 30.X 4c However, CR 4c And R 4c The compounds described in Clause 29, or pharmaceutically acceptable salts thereof, which are H, F, CHF2, OCH2CH3, OCHF2, OCF3. 31.X 5c However, CR 5c And R 5c A compound described in any one of clauses 1 to 30, or a pharmaceutically acceptable salt thereof, wherein H is present. 32.X 6c However, CR 6c And R 6c A compound described in any one of clauses 1 to 31, or a pharmaceutically acceptable salt thereof, wherein H is present. 33.R d However, (CH2) p A compound described in any one of clauses 1 to 32, or a pharmaceutically acceptable salt thereof, which is H. 34.R d The compound described in Clause 33, or a pharmaceutically acceptable salt thereof, which is H or CH3. 35.R d However, (CHR e ) n (CH2) p A compound described in any one of clauses 1 to 32, or a pharmaceutically acceptable salt thereof, which is H. 36.R d The compounds described in Clause 35, or pharmaceutically acceptable salts thereof, which are CH2F, CH2OH, or CH(OH)CH3. 37.R d However, (CH2) m (CHR e ) n A compound described in any one of clauses 1 to 32, or a pharmaceutically acceptable salt thereof, which is H. 38.R d The compounds described in Clause 37, or pharmaceutically acceptable salts thereof, which are CH2OCH3 or CH2CH2OCH3. 39. A compound selected from Table A, or a pharmaceutically acceptable salt thereof. 40. A compound described in any one of clauses 1 to 39, which is in a non-salt form. 41. A pharmaceutical composition comprising a therapeutically effective amount of a compound described in any one of clauses 1 to 39 or a pharmaceutically acceptable salt thereof, or a compound described in clause 40, and one or more pharmaceutically acceptable carriers or vehicles. 42. A pharmaceutical composition comprising a compound described in any one of Clauses 1 to 39 or a pharmaceutically acceptable salt thereof, or a compound described in Clause 40, and one or more pharmaceutically acceptable carriers or vehicles. 43. A method for inhibiting voltage-gated sodium channels in a subject, comprising administering to the subject a compound described in any one of Clauses 1 to 39 or a pharmaceutically acceptable salt thereof, a compound described in Clause 40, or a pharmaceutical composition described in Clause 41 or 42. 44. Voltage-gated sodium channels, Na V 1.8 The method described in Article 43. 45. A method for treating or reducing the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or cardiac arrhythmia, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt thereof described in any one of clauses 1 to 39, a compound described in clause 40, or a pharmaceutical composition described in clause 41 or 42 to a subject. 46. ​​The method of Article 45, wherein the method includes treating neuropathic pain or reducing its severity in a subject. 47. The method according to Clause 46, wherein neuropathic pain includes postherpetic neuralgia. 48. The method according to Clause 46, wherein neuropathic pain includes small fiber neuropathy. 49. Neuropathic pain, including idiopathic small fiber neuropathy, as described in item 46. 50. The method according to Clause 46, wherein neuropathic pain includes diabetic neuropathy. 51. The method according to Clause 50, wherein diabetic neuropathy includes diabetic peripheral neuropathy. 52. The method according to Clause 45, wherein the method includes treating musculoskeletal pain or reducing its severity in a subject. 53. The method according to Clause 52, wherein musculoskeletal pain includes pain of osteoarthritis. 54. The method of Article 45, wherein the method includes treating acute pain or reducing its severity in a subject. 55. The method described in Clause 54, wherein acute pain includes acute postoperative pain. 56. The method of the provisions of Article 45, wherein the method includes treating postoperative pain or reducing its severity in a subject. 57. Postoperative pain, including pain from aponeurosis excision, as described in Clause 56. 58. The method described in Clause 56, wherein postoperative pain includes pain from abdominal wall reconstruction. 59. Postoperative pain, including pain from hernia repair, as described in Clause 56. 60. The method according to Clause 45, wherein the method includes treating visceral pain or reducing its severity in a subject. 61. The method according to any one of the clauses 43 to 60, wherein the subject is treated simultaneously with, or before, treatment with, one or more additional therapeutic agents administered before or after, treatment with a compound, a pharmaceutically acceptable salt, or a pharmaceutical composition. 62. Use as a pharmaceutical agent of any one of the compounds described in Clauses 1 to 39 or a pharmaceutically acceptable salt thereof, the compounds described in Clause 40, or the pharmaceutical compositions described in Clause 41 or 42. [Examples]

[0236] A common method. 1 The 1H NMR spectrum was obtained as a solution in a suitable deuterated solvent such as dimethyl sulfoxide-d6 (DMSO-d6).

[0237] Compound purity, retention time, and electrospray mass spectrometry (ESI-MS) data were determined by LC / MS analysis.

[0238] LC / MS analysis was performed using a Waters Acquity UPLC BEH C8 column (50 × 2.1 mm, 1.7 μm particles) (pn: 186002877) along with a Guard column (2.1 × 5 mm, 1.7 μm particles) (pn: 186003978), and a dual gradient run of 2–98% mobile phase B over 4.45 minutes. Mobile phase A = H2O (10 mM ammonium formate containing 0.05% ammonium hydroxide). Mobile phase B = acetonitrile. Flow rate = 0.6 mL / min, injection volume = 2 μL, and column temperature = 45°C.

[0239] X-ray powder diffraction analysis A: X-ray powder diffraction (XRPD) analysis was performed in transmission mode at room temperature using a PANalytical Empyrean system equipped with a sealed tube source and a PIXcel 1D Medipix-2 detector (Malvern PANalytical Inc., Westborough, Massachusetts). The X-ray generator was operated with copper emission (1.54060 Å) at a voltage of 45 kV and a current of 40 mA. The powder sample was placed on a 96-well sample holder with Mylar film and filled into the instrument. The sample was scanned over a range of approximately 5° to approximately 40°²θ with a step size of 0.0131303° and 8.67 seconds × 5 (unstable omega = 0, ±1, ±2) per step.

[0240] X-ray powder diffraction analysis B: X-ray powder diffraction (XRPD) analysis was performed in transmission mode at room temperature using a PANalytical Empyrean system equipped with a sealed tube source and a PIXcel 3D Medipix-3 detector (Malvern PANalytical Inc., Westborough, Massachusetts). The X-ray generator was operated with copper emission (1.54060 Å) at a voltage of 45 kV and a current of 40 mA. The powder sample was placed on a 96-well sample holder with Mylar film and filled into the instrument. The sample was scanned over a range of approximately 3° to approximately 40°²θ with a step size of 0.0131303° and a time of 49 seconds per step.

[0241] Abbreviation Unless otherwise stated, or as the context indicates, the following abbreviations should be understood to have the following meanings: [Table 2-1] [Table 2-2] Example 1 [ka]

[0242] Step 1: NEt3 (7.7 mL, 55.2 mmol) was added to a solution of ethyl 2-diazo-3-oxopentanoate (6.69 g, 39.3 mmol) in DCM (80 mL) while stirring under nitrogen at 0°C. Trimethylsilyl trifluoromethanesulfonate (8.5 mL, 47.0 mmol) was added dropwise over 5 minutes, and the mixture was stirred at 0°C for a further 30 minutes. The reaction mixture was diluted with pentane (100 mL), the layers were separated, and the organic phase was washed with diluted sodium bicarbonate aqueous solution (100 mL) and then with brine (100 mL). The organic layer was dried (MgSO4) and concentrated under vacuum to obtain ethyl(Z)-2-diazo-3-trimethylsilyloxy-penta-3-enoate (9.4 g, 99%) as a red oil. 1¹H NMR (500 MHz, chloroform-d): δ 5.33 (q, J = 7.0 Hz, 1H), 4.25 (q, J = 7.1 Hz, 2H), 1.67 (d, J = 7.0 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H), 0.22 (s, 9H) ppm.

[0243] Step 2: To a stirred solution of 1,1,1-trifluoropropan-2-one (8 mL, 89.4 mmol) in 80 mL of DCM at -78°C, TiCl4 (1 M in DCM, 70 mL, 70.00 mmol) was added via a cannula. To the resulting solution, a solution of ethyl(Z)-2-diazo-3-trimethylsilyloxy-penta-3-enoate (31.3% w / w, 36.1 g, 46.6 mmol) in 40 mL of DCM was added dropwise over 15 minutes. After stirring for 100 minutes, the reaction mixture was carefully quenched with water, the temperature was slowly increased, and then extracted with DCM. The combined organic layers were dried (MgSO4), filtered, and concentrated under vacuum. The solution was purified by silica gel chromatography (330 g SiO2, 0-20% ethyl in heptane) to obtain ethyl rac-(4R,5R)-2-diazo-6,6,6-trifluoro-5-hydroxy-4,5-dimethyl-3-oxohexanoate (8.82 g, 67%) as the main diastereoisomer, which was then stored as a solution in toluene. 1 H NMR (500 MHz,chloroform-d) δ 4.33 (q, J = 7.1 Hz, 2H), 4.14 (q, J = 7.0 Hz, 1H), 3.98 (s, 1H), 1.43 (q, J = 1.2 Hz, 3H), 1.35 (t, J = 7.1 Hz, 3H), 1.31 (dq, J = 7.0, 1.4 Hz, 3H) ppm. ESI-MS m / z calculated value 282.08273, measured value 283.1 (M+1) + ; 281.0 (M-1) - .

[0244] Step 3: A solution of rhodium tetraacetate (245 mg, 0.55 mmol) in benzene (32 mL) was heated under reflux for 10 minutes. Then, a solution of ethyl rac-(4R,5R)-2-diazo-6,6,6-trifluoro-5-hydroxy-4,5-dimethyl-3-oxohexanoate (10 g, 35.4 mmol) in benzene (13 mL) was slowly added via an addition funnel under reflux for 60 minutes. The mixture was concentrated under vacuum to obtain ethyl rac-(4R,5R)-4,5-dimethyl-3-oxo-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (9.0 g, 100%) as a green residue containing the residual catalyst and as a mixture of epimers at the position adjacent to the ester. This substance was used in the next step without further purification. 1 ¹H NMR (500 MHz, chloroform-d): δ 4.83 - 4.57 (m, 1H), 4.38 - 4.16 (m, 2H), 2.60 (dddd, J = 9.3, 8.2, 5.6, 1.4 Hz, 1H), 1.73 - 1.63 (m, 3H), 1.30 (t, J = 7.1 Hz, 3H), 1.24 (ddq, J = 6.4, 4.1, 1.9 Hz, 3H) ppm.

[0245] Step 4: DIPEA (29.680 g, 40 mL, 229.64 mmol) was added to a stirred solution of ethyl rac-(4R,5R)-4,5-dimethyl-3-oxo-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (48 g, 188.83 mmol) in DCM (400 mL) at -78°C. A solution of trifluoromethylsulfonyltrifluoromethanesulfonate (53.440 g, 32 mL, 189.41 mmol) in DCM (200 mL) was added to the reaction mixture at the same temperature over 1 hour. The reaction mixture was stirred at 0°C for 30 minutes and then quenched with 100 mL of saturated NaHCO3 aqueous solution. The organic layer was separated, and the aqueous layer was extracted with DCM (160 mL). The combined organic layers were dried (MgSO4) and concentrated under vacuum to obtain ethylrac-(4R,5R)-2,3-dimethyl-2-(trifluoromethyl)-4-(trifluoromethylsulfonyloxy)-3H-furan-5-carboxylate (71 g, 97%). 1 ¹H NMR (400 MHz, chloroform-d): δ 4.38 - 4.32 (m, 2H), 3.29 - 3.23 (m, 1H), 1.64 (s, 3H), 1.37 - 1.33 (m, 6H) ppm.

[0246] Step 5: To a stirred solution of ethyl rac-(4R,5R)-2,3-dimethyl-2-(trifluoromethyl)-4-(trifluoromethylsulfonyloxy)-3H-furan-5-carboxylate (26 g, 67.311 mmol) in toluene (130.00 mL), (3,4-difluoro-2-methoxyphenyl)boronic acid (14 g, 74.5 mmol), followed by K3PO4 (2 M, 200.00 mmol in 100 mL), was added under an argon atmosphere. After degassing the reaction mixture, tetrakis(triphenylphosphine)palladium(0) (4 g, 3.46 mmol) was added. After further degassing, the reaction mixture was heated at 100°C for 2 hours. The reaction mixture was diluted with water, and the aqueous layer was extracted with ELISA (2 × 100 mL). The combined organic layers were concentrated under vacuum. Purification by silica gel chromatography (SiO2, heptane with 0-10% ethyl) yielded ethyl 4-(3,4-difluoro-2-methoxyphenyl)-2,3-dimethyl-2-(trifluoromethyl)-3H-furan-5-carboxylate (24.4 g, 93%) as a 6:1 diastereomer mixture. The major isomer is considered to be ethyl rac-(4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-2,3-dimethyl-2-(trifluoromethyl)-3H-furan-5-carboxylate. Major isomers: 1 H NMR (400 MHz,chloroform-d) δ 6.88 - 6.79 (m, 2H), 4.17 - 4.09 (m, 2H), 3.90 (s, 3H), 3.46 (q, J = 7.4 Hz, 1H), 1.67 (s, 3H), 1.12 (t, J = 7.4 Hz, 3H), 1.06 (dd, J = 5.4, 2.7 Hz, 3H) ppm. Trace isomers: 1¹H NMR (400 MHz, Chromo-d) δ 6.88 - 6.79 (m, 2H), 4.17 - 4.09 (m, 2H), 3.88 (s, 3H), 3.76 - 3.71 (m, 1H), 1.51 (s, 3H), 1.12 (t, J = 7.4 Hz, 3H), 0.99 (dd, J = 5.4, 2.7 Hz, 3H) ppm. ESI-MS m / z calculated value 380.1047, measured value 381.02 (M+1) + .

[0247] ステップ6: To an ice-cold solution of ethyl rac-(4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-2,3-dimethyl-2-(trifluoromethyl)-3H-furan-5-carboxylate (110 g, 243.0 mmol) in DCM (360 mL), BBr3 (1 M, 370.0 mmol in 370 mL) was added dropwise. Upon completion of the addition, the mixture was quenched by adding an aqueous sodium bicarbonate solution. The aqueous layer was extracted with DCM, the combined organic layers were dried (MgSO4), filtered, and concentrated under vacuum. The residue was dissolved in DCM (430 mL) at ambient temperature, and TFA (40 mL, 519.2 mmol) was added. The reaction mixture was heated to 45°C. Upon completion of the reaction, the mixture was quenched by adding an aqueous sodium bicarbonate solution, the aqueous layer was extracted with DCM, dried (MgSO4), filtered, and concentrated under vacuum to obtain the desired product as a 5:1 mixture of diastereomers. Recrystallization was carried out by solubilizing the crude material in the smallest possible amount of DCM and adding a layer of heptane on top of this solution (liquid-liquid diffusion). After about 1 hour, 56.5 g (dr97:3 syn:anti) was obtained from the first and second crystallizations, and a further 4.6 g (dr96:4 syn:anti) was obtained from the third crystallization. By combining the first to third recrystallization batches, 6,7-difluoro-1,2-dimethyl-2-(trifluoromethyl)-1H-flu[2,3-c]chromen-4-one (61g, 78%) was obtained, and the major isomer is considered to be rac-(1S,2R)-6,7-difluoro-1,2-dimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-flu[2,3-c]chromen-4-one. ESI-MS m / z calculated value: 320.04718, measured value: 321.5 (M+1) + ; 319.6 (M-1) - .

[0248] Step 7: rac-(1S,2R)-6,7-difluoro-1,2-dimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-flu[2,3-c]chromen-4-one (1348 g, 4.366 mol) was separated by chiral SFC using a (R,R)-Whelk-O1 column from Regis Technologies, 5 μm particle size, 15 cm × 3 cm, on a MultiGram III SFC instrument from Berger Instruments, using a mobile phase consisting of MeOH (containing 5 mM ammonia) and CO2.

[0249] First eluted isomer (retention time = 1.85 min): (1R,2S)-6,7-difluoro-1,2-dimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-flu[2,3-c]chromen-4-one (only the analytical sample was collected). 1 H NMR (400 MHz, DMSO-d6) δ 7.57 (ddd, J = 9.0, 5.5, 2.0 Hz, 1H), 7.51 (ddd, J = 10.3, 9.0, 7.0 Hz, 1H), 4.03 (q, J = 7.2 Hz, 1H), 1.65 (s, 3H), 1.45 (dt, J = 6.9, 2.2 Hz, 3H) ppm. ESI-MS m / z calculated value 320.04718, measured value 321.3 (M+1) + ; 319.4 (M-1) - .

[0250] Second eluted isomer (retention time = 2.38 min): (1S,2R)-6,7-difluoro-1,2-dimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-fl[2,3-c]chromen-4-one (366.99 g, 26%). 1H NMR (400 MHz, DMSO-d6) δ 7.57 (ddd, J = 9.0, 5.5, 2.0 Hz, 1H), 7.50 (ddd, J = 10.3, 9.0, 7.0 Hz, 1H), 4.03 (q, J = 7.2 Hz, 1H), 1.65 (s, 3H), 1.45 (dt, J = 6.9, 2.2 Hz, 3H) ppm. ESI-MS m / z calculated value 320.04518, measured value 321.4 (M+1) + ; 319.4 (M-1) - .

[0251] Step 8: A solution of (1S,2R)-6,7-difluoro-1,2-dimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-flu[2,3-c]chromen-4-one (0.89 kg, 2.78 mol) and 20% palladium-carbon hydroxide (50% wet, 0.39 kg, 0.278 mol) in MeOH (12 L) was stirred overnight under hydrogen at a pressure of 40 psi. After the overnight reaction, it was observed that the reaction temperature rose to 37°C, and the mixture was cooled to 24°C. Hydrogenation was continued for a total of 48 hours. The mixture was filtered through Celite while washing with MeOH (20 L), and the filtrate was concentrated under vacuum. The residue was dissolved in toluene (4 L), concentrated under vacuum, and this process was repeated. The residue was dried overnight at 40°C under vacuum to obtain methyl(2S,3S,4S,5R)-3-(3,4-difluoro-2-hydroxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (1.0 kg, 100%) with 91% purity as a beige solid. 1H NMR (400 MHz, DMSO-d6) 10.20 (br s, 1H), 6.94 (br t, J = 7.4 Hz, 1H), 6.79-6.69 (m, 1H), 5.10 (d, J = 6.0 Hz, 1H), 4.20 (dd, J = 6.1, 8.2 Hz, 1H), 3.43 (s, 3H), 2.94 (quin, J = 7.7 Hz, 1H), 1.46 (s, 3H), 0.77 (br d, J = 6.8 Hz, 3H) ppm.

[0252] Step 9: Potassium carbonate (2.0 kg, 14.4 mol) and iodomethane (800 mL, 12.8 mol) were sequentially added to a solution of methyl (2S,3S,4S,5R)-3-(3,4-difluoro-2-hydroxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (1.0 kg, 2.82 mol) in acetonitrile (10 L) under nitrogen while stirring at ambient temperature. After stirring overnight, additional iodomethane (120 mL, 2 mmol) was added. After stirring overnight, additional iodomethane (60 mL, 0.85 mmol) was added, and the mixture was stirred for a further 3 days. The reaction mixture was diluted with MTBE (30 L), treated with Celite (1 kg), and filtered through a Celite (1 kg) bed while washing with MTBE (10 L). The filtrate was filtered a second time through Celite (1 kg) while washing with MTBE (4 L), and the filtrate was concentrated under vacuum. The residue was dissolved in toluene (4 L), concentrated under vacuum, and this process was repeated. The residue was dried overnight under vacuum at 40°C to obtain methyl (2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (0.99 kg, 95% purity at 90%) as a brown solid. 1H NMR (400 MHz, DMSO-d6) 7.14-7.00 (m, 2H), 5.14 (d, J = 6.0 Hz, 1H), 4.15 (dd, J = 6.2, 8.4 Hz, 1H), 3.88 (d, J = 1.7 Hz, 3H), 2.97 (quin, J = 7.8 Hz, 1H), 1.48 (s, 3H), 0.72 (br d, J = 6.6 Hz, 3H) ppm.

[0253] Steps 10 and 11: Sodium methoxide (25% in methanol, 65 mL, 0.28 mol) was added to a solution of methyl (2S,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (0.98 kg, 2.66 mol) in THF (10 L) while stirring under nitrogen at ambient temperature. After 5 hours, MeOH (1 L), water (1 L), and lithium hydroxide monohydrate (0.168 kg, 4.0 mol) were added sequentially, and the mixture was stirred overnight. The reaction mixture was poured into 1 M HCl (4.4 L, 4.4 mol) and then extracted with MTBE (20 L). The aqueous layer was further extracted with MTBE (2 × 5 L), the combined organic layers were washed with brine (2 L), dried, filtered with (Na2SO4), and then treated with activated carbon (50 g, 5% w / w) with stirring for 1 hour. The mixture was filtered through Celite while washing with MTBE (2 × 4 L), and the filtrate was concentrated under vacuum. The residue was dissolved in toluene (4 L), concentrated under vacuum, then dissolved in MTBE (4 L), and concentrated again under vacuum to obtain (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (1.06 kg at 77.7% purity) as an amber-colored oil, which was used without further purification.

[0254] Step 12: Crude (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (2.09 kg, 4.54 mol at 77% purity) was dissolved in MTBE (25 L) in a 100 L Chemglass reactor and then stirred at 84 rpm at ambient temperature. A mixture of (R)-1-phenylethylamine (0.704 kg, 5.81 mol) and MTBE (2 L), followed by the addition of MTBE, was added to the reactor to obtain a total volume of 30 L. After 2 hours, an additional MTBE (2 L) was added to the reaction mixture. After a total of 3.5 hours, the mixture was filtered while washing with MTBE (2 L). The reactor was rinsed with MTBE (4 L), and the solid was rinsed using it, which was then compressed and dried on a Buchner funnel for 2 hours. The solid product cake was loosened and then dried overnight in a Buchner funnel under a nitrogen stream and vacuum. The isolated solid was dried for 24 hours in a convection oven at 40°C to obtain (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (R)-1-phenylethane-1-amine salt (1.86 kg at 95.7% purity, 74% in 3 steps) as a grayish-white solid. 1 H NMR, 400 MHz, DMSO-d6) 8.34 (br s, 2H), 7.46-7.41 (m, 2H), 7.36-7.27 (m, 3H), 7.16-7.11 (m, 1H), 7.10-7.03 (m, 1H), 4.58 (d, J = 9.9 Hz, 1H), 4.23 (q, J = 6.7 Hz, 1H), 3.99 (dd, J = 7.8, 9.8 Hz, 1H), 3.90 (d, J = 2.0 Hz, 3H), 2.60 (quin, J = 7.5 Hz, 1H), 1.50 (s, 3H), 1.40 (d, J = 6.7 Hz, 3H), 0.71–0.59 (m, 3H) ppm.

[0255] Step 13: A suspension of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (1R)-1-phenylethaneamine salt (10.6 g, 22.29 mmol) in MTBE (250 mL) was mixed with HCl (200 mL, 2 M, 400.0 mmol). The layers were separated, the organic layer was washed with water (200 mL), dried, filtered, and concentrated under vacuum to obtain (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (8.4 g, 99%) as oil. 1 H NMR (400 MHz,chloroform-d) δ 6.96 (ddd, J = 7.9, 5.6, 2.0 Hz, 1H), 6.88 (td, J = 9.2, 7.3 Hz, 1H), 4.96 (d, J = 10.5 Hz, 1H), 4.15 (dd, J = 10.5, 8.0 Hz, 1H), 4.02 (d, J = 2.8 Hz, 3H), 2.74 (p, J = 7.6 Hz, 1H), 1.64 (t, J = 1.2 Hz, 3H), 0.79 (dq, J = 7.4, 2.3 Hz, 3H) ppm.

[0256] Steps 14 and 15: Oxalyl chloride (738 μL, 8.460 mmol) was added dropwise to a solution of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (1.5 g, 4.234 mmol) and DMF (31 μL, 0.4004 mmol) in dichloromethane (10 mL). After stirring at ambient temperature for 30 minutes, the solution was concentrated under vacuum. The residue was redissolved in dichloromethane (10 mL) to form a mixture of rac-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine (904 mg, 4.654 mmol) and triethylamine (706 μL, 5.065 mmol). The mixture was stirred at ambient temperature for 1 hour. The reaction mixture was partitioned into ethyl acetate (30 mL) and water (30 mL). The aqueous layer was further extracted with ethyl acetate (50 mL). The combined organic extract was washed with brine (1 × 20 mL), dried, filtered, and concentrated under vacuum. It was purified by reverse-phase preparative HPLC (Waters Sunfire C18, 10 μM, 100 Å column, 0%~100% MeCN in water containing 0.1% ammonia), and after lyophilization, a mixture of two diastereoisomers of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide was obtained.

[0257] A mixture of two diastereoisomers of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide was separated by chiral SFC on a Minigram SFC instrument from Berger Instruments using a chiral cell OJ-H column from Daicel, 5 μm particle size, 25 cm × 10 mm (mobile phase: 12% MeOH (containing 20 mM ammonia), 88% CO2; flow rate: 10 mL / min):

[0258] First eluted isomer (retention time = 2.99 min): (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (700 mg, 60%). ESI-MS m / z calculated value 530.184, measured value 531.2 (M+1) + ;Retention time: 3.56 minutes.

[0259] Second eluted isomer (retention time = 3.63 min): (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (700 mg, 60%). ESI-MS m / z calculated value 530.184, measured value 531.2 (M+1) + ;Retention time: 3.56 minutes.

[0260] Step 16: TFA (1.743 mL, 22.62 mmol) was added to a solution of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (600 mg, 1.112 mmol) (first eluted isomer from SFC separation) in DCM (20 mL), and the mixture was stirred at ambient temperature for 2 hours. The mixture was concentrated under vacuum and freeze-dried from MeCN and water to obtain a white solid. The solution was purified by reverse-phase preparative HPLC (Waters Sunfire C18, 10 μM, 100 Å column, 0% to 100% MeCN in water containing 0.1% ammonia), and after lyophilization, (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (1,304 mg, 55%) was obtained. 1 H NMR (500 MHz, DMSO-d6) δ 10.48 (s, 1H), 8.73 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 8.6 Hz, 1H), 7.23 - 7.13 (m, 2H), 5.11 (d, J = 10.3 Hz, 1H), 4.61 (s, 1H), 4.25 (dd, J = 10.3, 7.6 Hz, 1H), 3.95 (d, J = 2.1 Hz, 3H), 3.63 (dd, J = 11.0, 4.4 Hz, 2H), 3.48 (dd, J = 11.0, 6.5 Hz, 2H), 2.77 (p, J = 7.6 Hz, 1H), 1.61 (s, 3H), 0.79 - 0.69 (m, 3H) ppm. ESI-MS m / z calculated value 490.1527, measured value 491.6 (M+1) + ;Retention time: 2.98 minutes.

[0261] (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (600 mg, 1.106 mmol) (second eluted isomer from SFC separation) was treated in the same manner, and after lyophilization, (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((S)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (2,340 mg, 61%) was obtained. 1 H NMR (500 MHz, DMSO-d6) δ 10.36 (s, 1H), 8.67 (dd, J = 2.5, 0.7 Hz, 1H), 7.98 (dd, J = 8.5, 2.6 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.17 (dd, J = 9.4, 6.3 Hz, 2H), 5.32 (d, J = 4.9 Hz, 1H), 5.09 (d, J = 10.3 Hz, 1H), 4.63 (t, J = 5.9 Hz, 1H), 4.54 (dt, J = 6.7, 4.4 Hz, 1H), 4.24 (dd, J = 10.3, 7.7 Hz, 1H), 3.95 (d, J = 2.1 Hz, 3H), 3.63 (ddd, J = 11.0, 6.0, 4.1 Hz, 1H), 3.45 (ddd, J = 11.0, 6.9, 5.8 Hz, 1H), 2.77 (p, J = 7.5 Hz, 1H), 1.61 (s, 3H), 0.82 - 0.65 (m, 3H) ppm. ESI-MS m / z calculated value 490.1527, measured value 491.6 (M+1) + ;Holding time: 2.99 minutes.

[0262] The absolute stereochemistry of 1 and 2 was determined by single-crystal X-ray crystal structure analysis of 1.

[0263] Compound 1 was analyzed by X-ray powder diffraction analysis method A and determined to be amorphous (see Figure 1).

[0264] The following compounds were prepared using the method described in Example 1, except that rac-6-((4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl)pyridine-3-amine was used instead of rac-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine in amide coupling step 14. In step 15, the compounds were purified by chiral SFC using a Minigram SFC instrument from Berger Instruments with a chiral cell OD-H column from Daicel Corporation, 5 μm particle size, 25 cm × 10 mm (mobile phase: 12% MeOH (containing 20 mM ammonia), 88% CO2; flow rate: 10 mL / min). [Table 3]

[0265] The following compounds were prepared using the method described in Example 1, except that (1R,2S)-6,7-difluoro-1,2-dimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-fl[2,3-c]chromen-4-one was used in place of (1S,2R)-6,7-difluoro-1,2-dimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-fl[2,3-c]chromen-4-one in hydrogenation step 8, and (S)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine was used as the coupling partner in step 14. SFC separation step 15 was not required: [Table 4]

[0266] The following compounds were prepared using the method described in Example 1, except that ethyl iodide was used instead of methyl iodide in alkylation step 9. The conditions used in epimerization / hydrolysis steps 10 and 11 followed the first part of the conditions described in step 4 of Example 5. In step 14, (S)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine and (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine were used as coupling partners for compounds 6 and 7, respectively. SFC separation step 15 was not required: [Table 5]

[0267] Compound 7 was analyzed by X-ray powder diffraction method B and determined to be amorphous (see Figure 2).

[0268] The following compounds were prepared using a method similar to that described in Example 1, except that the conditions used for alkylation step 9 with methyl iodide and for amide coupling step 14 followed the conditions described in step 1 of Example 2, using (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine as the coupling partner. SFC separation step 15 was not required: [Table 6]

[0269] Compound 8 was analyzed by X-ray powder diffraction method B and determined to be amorphous (see Figure 3).

[0270] The following compounds were prepared using the method described in Example 1, except that 2-iodopropane was used instead of methyl iodide in step 9 and the reaction was carried out at 75°C. Epimerization / hydrolysis steps 10 and 11 were carried out in one step according to the conditions described in step 3 of Example 6. Steps 12 and 13 were omitted, and in amide coupling step 14, 2-(2,2-dimethyl-1,3-dioxolan-4-yl)pyrimidine-5-amine was used as the coupling partner. In step 15, purification was performed by chiral SFC on a Berger Instruments Minigram SFC instrument using a Daicel Corporation chiral pack IB column, 5 μm particle size, 25 cm × 20 mm (mobile phase: 20% MeOH (containing 20 mM ammonia), 80% CO2. Flow rate: 100 mL / min). [Table 7]

[0271] The following compounds were prepared using the method described in Example 1, except that steps 12 and 13 were omitted and 2-(2,2-dimethyl-1,3-dioxolan-4-yl)pyrimidine-5-amine was used as the coupling partner in the amide coupling step 14. In step 15, the compounds were purified by chiral SFC using a Minigram SFC instrument from Berger Instruments with a chiral cell OD-H column from Daicel Corporation, 5 μm particle size, 25 cm × 10 mm (mobile phase: 22% MeOH (containing 20 mM ammonia), 78% CO2; flow rate: 10 mL / min). [Table 8]

[0272] The following compounds were prepared using the method described in Example 1, except that (3-fluoro-2-methoxyphenyl)boronic acid was used instead of (3,4-difluoro-2-methoxyphenyl)boronic acid in Suzuki Step 5. In amide coupling step 14, (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine was used instead of 6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine, and the coupling conditions were those used in Step 1 of Example 2. The compounds did not require chiral SFC separation step 15. [Table 9]

[0273] The following compounds were prepared using the method described in Example 1, except that 6-(((tert-butyldimethylsilyl)oxy)methyl)pyridine-3-amine was used as the coupling partner in the amide coupling step 14. The SFC separation step 15 was not required, and the deprotection step 16 was carried out at ambient temperature for 3 days using excess HCl (37% w / v) in MeOH as the solvent. [Table 10]

[0274] The following compounds were prepared using the method described in Example 1, except that methyl (5-aminopyrimidine-2-yl)benzoate was used as the coupling partner in amide coupling step 14. SFC separation step 15 was not required, and deprotection step 16 was carried out overnight at ambient temperature using an excess of 2M sodium hydroxide solution and 1,4-dioxane as the solvent. [Table 11]

[0275] The following compounds were prepared using the method described in Example 1, except that 6-(1-((tert-butyldimethylsilyl)oxy)-2-fluoroethyl)pyridine-3-amine was used as the coupling partner in amide coupling step 14. Chiral SFC separation step 15 was performed on a Waters Prep-100 SFC instrument using a Daicel chiral pack IB column, 5 μm particle size, 25 cm × 20 mm (mobile phase: 5% IPA (containing 20 mM ammonia), 95% CO2; flow rate: 100 mL / min). The conditions used in deprotection step 16 were those described in step 3 of Example 2, which utilizes THF as the solvent instead of 2-MeTHF.

[0276] Compound 16 was analyzed by X-ray powder diffraction method B and determined to be crystalline (see Figure 4). [Table 12] Example 2 [ka]

[0277] Step 1: T3P (1000 μL, 1.571 mmol, 50% w / v) was added to a mixture of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (130 mg, 0.3486 mmol), rac-6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-amine (108 mg, 0.3824 mmol), and Et3N (100 μL, 0.7175 mmol) in 1.5 mL of ethyl phosphate. The clear mixture was stirred at ambient temperature for 2 hours. The mixture was partitioned into ethyl phosphate and water and passed through a phase separation cartridge. The organic filtrate was concentrated under vacuum to obtain a clear oil. Purification by silica gel chromatography (12 g of SiO2, 0-30% ELISA in hexane) yielded a clear oil mixture of two diastereoisomers of (2R,3S,4S,5R)-N-(6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (211 mg, 92%). ESI-MS m / z calculation: 618.2548, measured value: 619.0 (M+1). + ; 617.0 (M-1) - ;Retention time: 4.3 minutes.

[0278] Step 2: Two diastereoisomers of (2R,3S,4S,5R)-N-(6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (210 mg, 0.3191 mmol) were separated on a Minigram SFC instrument from Berger Instruments using a chiral cell OD-H column from Daicel, 5 μm particle size, 25 cm × 10 mm (mobile phase: 15% MeOH (containing 20 mM ammonia), 85% CO2; flow rate: 10 mL / min):

[0279] First eluted isomer (retention time = 2.24 min): rel-(2R*,3S*,4S*,5R*)-N-(6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (83 mg, 84%). ESI-MS m / z calculated value 618.2548, measured value 619.0 (M+1) + ; 617.0 (M-1) - ;Retention time: 4.3 minutes.

[0280] Second eluted isomer (retention time = 3.01 min): rel-(2R*,3S*,4S*,5R*)-N-(6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (82 mg, 83%). ESI-MS m / z calculated value 618.2548, measured value 619.0 (M+1) + ; 617.0 (M-1) - ;Retention time: 4.3 minutes.

[0281] Step 3: A THF solution of TBAF (650 μL, 1 M, 0.6500 mmol) was added at 0°C to a stirred solution of rel-(2R*,3S*,4S*,5R*)-N-(6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (80 mg, 0.1293 mmol) (first eluted isomer from SFC separation) in 2-MeTHF (4 mL). The reaction mixture was stirred at ambient temperature over the weekend (convenient). The reaction mixture was quenched with saturated NaHCO3 aqueous solution (10 mL), stirred for 10 minutes, and extracted with ethyl acetate (2 × 10 mL). The combined organic extracts were dried (MgSO4), filtered, and concentrated under vacuum. The solution was purified by reverse-phase preparative HPLC (Waters Sunfire C18, 10 μM, 100 Å column, 0% to 100% MeCN in water containing 0.1% ammonia), and after lyophilization, rel-(2R*,3S*,4S*,5R*)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-(1-hydroxy-2-methoxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (20, 52 mg, 79%) was obtained. 1H NMR (400 MHz, DMSO-d6) δ 10.38 (s, 1H), 8.66 (dd, J = 2.5, 0.7 Hz, 1H), 8.01 (dd, J = 8.5, 2.5 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.21 - 7.13 (m, 2H), 5.47 (d, J = 5.0 Hz, 1H), 5.09 (d, J = 10.3 Hz, 1H), 4.73 - 4.64 (m, 1H), 4.29 - 4.19 (m, 1H), 3.95 (d, J = 2.2 Hz, 3H), 3.57 (dd, J = 10.0, 3.9 Hz, ESI-MS m / z calculated value 504.16837, measured value 505.0 (M+1) + ; 503.0 (M-1) - ;Retention time: 3.16 minutes.

[0282] rel-(2R*,3S*,4S*,5R*)-N-(6-(1-((tert-butyldimethylsilyl)oxy)-2-methoxyethyl)pyridine-3-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (80 mg, 0.1293 mmol) (second eluted isomer from SFC separation) was treated in the same manner, and after lyophilization, rel-(2R*,3S*,4S*,5R*)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-(1-hydroxy-2-methoxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (21, 54 mg, 82%) was obtained. 1H NMR (400 MHz, DMSO-d6) δ 10.38 (s, 1H), 8.68 (dd, J = 2.5, 0.7 Hz, 1H), 7.99 (dd, J = 8.5, 2.5 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.21 - 7.13 (m, 2H), 5.47 (d, J = 4.4 Hz, 1H), 5.09 (d, J = 10.3 Hz, 1H), 4.69 (d, J = 6.2 Hz, 1H), 4.24 (dd, J = 10.3, 7.7 Hz, 1H), 3.95 (d, J = 2.2 Hz, 3H), 3.57 (dd, J = 10.0, 3.9 Hz, 1H), 3.44 (dd, J = 10.0, 6.9 Hz, 1H), 3.24 (s, 3H), 2.77 (p, J = 7.6 Hz, 1H), 1.61 (s, 3H), 0.74 (d, J = 7.0 Hz, 3H) ppm. ESI-MS m / z calculated value 504.16837, measured value 505.0 (M+1) + ;503.0 (M-1) - ;Retention time: 3.16 minutes.

[0283] Compound 21 was analyzed by X-ray powder diffraction method B and determined to be amorphous (see Figure 5).

[0284] The following compounds were prepared using the method described in Example 2, except that 6-(1-((tert-butyldimethylsilyl)oxy)-3-methoxypropyl)pyridine-3-amine was used as the coupling partner in amide coupling step 1. In step 2, purification was performed by chiral SFC on a Waters Prep-100 SFC instrument using a Daicel chiral pack IB column, 5 μm particle size, 25 cm × 20 mm (mobile phase: 5% MeOH (containing 20 mM ammonia), 95% CO2; flow rate: 100 mL / min). [Table 13] Example 3 [ka]

[0285] Step 1: Triethylamine (8.05 g, 11.2 mL, 78.8 mmol) was added at 0°C to a stirred solution of ethyl 2-diazo-3-oxobutanoate (5.0 g, 31.4 mmol) in DCM (50 mL). TBSOTf (9.24 g, 8.2 mL, 34.3 mmol) was slowly added, and the reaction mixture was stirred at 0°C for 30 minutes. The reaction mixture was washed with 30% NaHCO3 solution (200 mL). The organic layer was separated, washed with water (500 mL), dried, filtered, and concentrated under vacuum to obtain ethyl 3-((tert-butyldimethylsilyl)oxy)-2-diazobuta-3-enoate (8.22 g, 97%), which was used in the next step without further purification.

[0286] Step 2: A solution of 1,1,1-trifluoropropan-2-one (33.8 g, 27 mL, 301.2 mmol) in DCM (150 mL) was cooled to -78°C. TiCl4 (56.8 g, 33 mL, 299.2 mmol) was added dropwise to the stirred reaction mixture. After maintaining the reaction at -78°C for 10 minutes, a solution of ethyl 3-((tert-butyldimethylsilyl)oxy)-2-diazobuta-3-enoate (64 g, 236.7 mmol) in DCM (150 mL) was added. The reaction was maintained at -78°C for 1 hour. A saturated NaHCO3 solution was added, and the mixture was diluted with DCM. The organic layer was separated, dried (MgSO4), filtered, and concentrated under vacuum. Purification by silica gel chromatography (SiO2, 0-30% ethyl in hexane) yielded ethyl 2-diazo-6,6,6-trifluoro-5-hydroxy-5-methyl-3-oxohexanoate (39 g, 61%) as a pale yellow liquid. 1¹H NMR (400 MHz, chloroform-d): δ 4.92 (s, 1H), 4.32 (q, J = 7.1 Hz, 2H), 3.63 (d, J = 15.5 Hz, 1H), 2.84 (d, J = 15.5 Hz, 1H), 1.41 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H) ppm.

[0287] Step 3: Rhodium(II) acetate (643 mg, 1.45 mmol) was packed into an oven-dried two-necked flask. Toluene (970 mL) was added, and the solution was stirred at 100°C for 10 minutes. The solution was briefly removed from the oil bath, while a solution of ethyl 2-diazo-6,6,6-trifluoro-5-hydroxy-5-methyl-3-oxohexanoate (39 g, 145.4 mmol) in toluene (200 mL) was added dropwise. The reaction mixture was heated under reflux for 1 hour. The mixture was filtered through filter paper, and the filtrate was concentrated under vacuum to obtain ethyl 5-methyl-3-oxo-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (30.89 g, 88%) as a mixture of epimers at the ester's adjacent position. 1 ¹H NMR (400 MHz, chloroform-d): δ 4.68 (s, 1H), 4.35 - 4.17 (m, 2H), 2.89 (d, J = 18.8, 1H), 2.58 (d, J = 18.8, 1H), 1.70 (s, 3H), 1.30 (t, J = 7.2, Hz, 3H) ppm.

[0288] Step 4: Trifluoromethanesulfonic anhydride (6.0 mL, 35.7 mmol) was added dropwise at -78°C to a solution of ethyl 5-methyl-3-oxo-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (6.5 g, 27.1 mmol) and DIPEA (14 mL, 80.4 mmol) in DCM (150 mL). After stirring the reaction mixture for 2.5 hours, saturated NH4Cl aqueous solution (75 mL) was added. The mixture was heated to ambient temperature. The aqueous layer was extracted with DCM (2 × 30 mL). The combined organic extract was dried (MgSO4), filtered, and concentrated under vacuum to obtain ethyl 5-methyl-5-(trifluoromethyl)-3-(((trifluoromethyl)sulfonyl)oxy)-4,5-dihydrofuran-2-carboxylate (10.1 g), which was used directly in the following reaction.

[0289] Step 5: K3PO4 (13 mL of 2 M aqueous solution, 26.0 mmol) was added to a stirred solution of (3,4-difluoro-2-methoxyphenyl)boronic acid (2.0 g, 10.6 mmol) and ethyl 5-methyl-5-(trifluoromethyl)-3-(((trifluoromethyl)sulfonyl)oxy)-4,5-dihydrofuran-2-carboxylate (3 g, 7.90 mmol) in toluene (80 mL). The mixture was degassed by bubbling nitrogen through the solution for 20 minutes. Pd(PPh3)4 (466 mg, 0.40 mmol) was added, and the reaction was heated at 100 °C for 1 hour. The mixture was filtered through a Celite pad. The filtrate was diluted with water (50 mL), and the aqueous phase was separated. The aqueous phase was extracted with ELISA (50 × 2 mL). The combined organic extracts were dried (MgSO4), filtered, and concentrated under vacuum. Purification by silica gel chromatography (SiO2, hexane with 0-2% ethyl) yielded ethyl 3-(3,4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (2.5 g, 85%) as a bright yellow liquid. 1H NMR (400 MHz,chloroform-d) δ 6.87 (pd, J = 8.8, 6.2 Hz, 2H), 4.15 (q, J = 7.1 Hz, 2H), 3.89 (s, 3H), 3.42 (d, J = 17.4 Hz, 1H), 2.93 (d, J = 17.4 Hz,1H), 1.65 (s, 3H), 1.14 (t, J = 7.1 Hz, 3H) ppm. ESI-MS m / z calculated value 366.08905, measured value 367.4 (M+1) + ;Holding time: 1.01 minutes.

[0290] Step 6: EtOH (200 mL) was added to a mixture of ethyl 3-(3,4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (5.51 g, 15.0 mmol) and Pd / C (10 wt% packed, 2.2 g, 2.067 mmol). The mixture was degassed and stirred under an H2 balloon for 96 hours. The catalyst was removed by filtration, and the solids were washed with EtOH (50 mL). The filtrate was concentrated under vacuum. An additional amount of Pd / C (10 wt% packed, 2.2 g, 2.07 mmol) was added to the residue, followed by the addition of EtOH (200 mL). The reaction mixture was stirred under an H2 balloon at ambient temperature for 24 hours. The catalyst was removed by filtration, and the solids were washed with EtOH (50 mL). The filtrate was concentrated under vacuum. Further amounts of Pd / C (10% by weight, 2.2 g, 2.07 mmol) were added to the residue, followed by the addition of EtOH (200 mL). The reaction mixture was stirred at ambient temperature under an H2 balloon for 4 days. The catalyst was removed by filtration, and the solids were washed with EtOH (50 mL). The filtrate was concentrated under vacuum to obtain ethyl rac-(2S,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (5.19 g, 94%) as a white solid and as a single diastereomer. 1H NMR (500 MHz,chloroform-d) δ 6.89 - 6.86 (m, 1H), 6.82 - 6.77 (m, 1H), 4.93 (d, J = 8.9 Hz, 1H), 4.23 (dt, J = 13.0, 7.6 Hz, 1H), 4.08 (d, J = 2.9 Hz, 3H), 3.85 - 3.71 (m, 2H), 2.82 (t, J = 12.5 Hz, 1H), 2.04 (dd, J = 12.0, 6.7 Hz, 1H), 1.53 (s, 3H), 0.94 (t, J = 7.1 Hz, 3H) ppm; 19 F NMR (471 MHz, chloroform-d): δ -80.15, -136.84 (d, J = 19.4 Hz), -154.77 (d, J = 19.6 Hz) ppm.

[0291] Step 7: Ethyl rac-(2S,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (5.19 g, 14.09 mmol) was dissolved in ethanol (100 mL). Cs2CO3 (7.1 g, 21.79 mmol) was added, and the suspension was stirred at 50°C for 2 hours. The reaction mixture was concentrated under vacuum, and the residue was partitioned into 1 M HCl and MTBE. The aqueous layer was extracted twice with MTBE. The combined organic extract was dried (MgSO4), filtered, and concentrated under vacuum to obtain rac-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (5.1063 g, 96%) as a colorless oil. 1H NMR (500 MHz, クロロホルム-d) δ 6.99 - 6.96 (m, 1H), 6.92 - 6.87 (m, 1H), 4.68 (d, J = 10.5 Hz, 1H), 4.00 (d, J = 2.7 Hz, 3H), 3.90 (ddd, J = 12.0, 10.6, 8.2 Hz, 1H), 2.58 (t, J = 12.5 Hz, 1H), 2.31 (dd, J = 13.0, 8.2 Hz, 1H), 1.60 (s, 3H) ppm; 19 F NMR (471 MHz, Chromo-d) δ -81.56, -136.40 (d, J = 19.6 Hz), -153.60 (d, J = 19.5 Hz) ppm. ESI-MS m / z calculated value 340.0734, measured value 339.5 (M⁻¹) - Duration: 0.52 minutes.

[0292] ステップ8: Oxalyl chloride (70 μL, 0.8024 mmol) was carefully added to an ice-cold solution of rac-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (150 mg, 0.3968 mmol) and DMF (2-methyl-THF solution, 50 μL, 0.86 M, 0.04300 mmol) in 2-methyltetrahydrofuran (5 mL). The reaction mixture was stirred and heated to room temperature for 45 minutes. The reaction mixture was concentrated under vacuum, and the residue was dissolved in 2-methyltetrahydrofuran (5 mL). This solution was added to an ice-cold solution of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine (90 mg, 0.4634 mmol) and TEA (250 μL, 1.794 mmol) in 2-methyltetrahydrofuran (5 mL). The resulting mixture was stirred and heated to ambient temperature for 1 hour. The reaction mixture was quenched with water (2 mL) and the layers were separated. The aqueous phase was extracted with ELISA (2 × 5 mL). The combined organic extracts were dried (MgSO4), filtered, and concentrated under vacuum. Purification by silica gel chromatography (24 g of SiO2, 0-100% siRNA in heptane, packed from DCM) yielded rel-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R*)-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (120.4 mg, 59%) as a white solid and as a mixture of two diastereoisomers. 1H NMR (500 MHz, DMSO-d6) δ 10.15 (s, 1H), 8.70 - 8.69 (m, 1H), 8.03 (dt, J = 8.4, 2.6 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.22 - 7.15 (m, 2H), 5.07 (t, J = 6.8 Hz, 1H), 4.65 (d, J = 10.1 Hz, 1H), 4.33 (dd, J = 8.2, 6.7 Hz, 1H), 4.05 (q, J = 10.0 Hz, 1H), 3.87 (d, J = 2.0 Hz, 3H), 3.83 (ddd, J = 8.0, 19F NMR (471 MHz, DMSO-d6) δ -80.12, -138.13 (d, J = 21.1 Hz), -154.77 (d, J = 21.2 Hz) ppm.ESI-MS m / z calculated value 516.16833, measured value 517.5(M+1) + ; 515.6(M-1) - ;Retention time: 0.99 minutes.

[0293] Step 9: Two diastereoisomers of rel-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide were separated by chiral SFC on a Waters Prep-100 SFC instrument using a Daicel chiral pack IA column, 5 μm particle size, 25 cm × 20 mm (mobile phase: 15% MeOH (containing 20 mM ammonia), 85% CO2; flow rate: 100 mL / min):

[0294] First eluted isomer (retention time = 0.73 min): rel-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (42 mg, 60%) as a white solid. ESI-MS m / z calculated value 516.16833, measured value 517.2 (M+1) + ; 515.3 (M-1) - ;Retention time: 3.41 minutes.

[0295] Second eluted isomer (retention time = 0.95 min): rel-(2S,3R,5S)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R*)-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (51 mg, 73%) as a white solid. ESI-MS m / z calculated value 516.16833, measured value 517.2 (M+1). + ; 515.3(M-1) - ;Retention time: 3.41 minutes.

[0296] Step 10: TFA (225 μL, 2.920 mmol) was added to a solution of rel-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R*)-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (42 mg, 0.081 mmol) (first eluted isomer from SFC separation) in DCM (5 mL), and the mixture was stirred at ambient temperature for 18 hours. The mixture was concentrated under vacuum and azeotropically mixed twice in DCM. Reverse-phase preparative HPLC (Waters Sunfire The solution was purified using a C18, 10 μM, 100 Å column and water containing 0.1% ammonia (0% to 100% MeCN), and after lyophilization, rel-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (24, 24.6 mg, 62%) was obtained as a white solid. 1 H NMR (500 MHz, DMSO-d6) δ 10.09 (s, 1H), 8.64 (d, J = 2.2 Hz, 1H), 7.97 (dd, J = 8.5, 2.5 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.22 - 7.15 (m, 2H), 5.32 (d, J = 4.9 Hz, 1H), 4.66 - 4.62 (m, 2H), 4.54 (dt, J = 6.6, 4.5 Hz, 1H), 4.05 (q, J = 10.1 Hz, 1H), 3.88 (d, J = 1.9 Hz, 3H), 3.63 (ddd, J = 10.3, 6.0, 4.2 Hz, 1H), 3.48 - 3.43 (m, 1H), 2.47 (s, 1H), 2.45 (s, 1H), 1.56 (s, 3H) ppm; 19F NMR (471 MHz, DMSO-d6) δ -80.12, -138.14 (d, J = 21.0 Hz), -154.77 (d, J = 21.0 Hz) ppm.ESI-MS m / z calculated value 476.13705, measured value 474.4 (M+1) + ; 475.5 (M-1) - ;Retention time: 2.77 minutes.

[0297] rel-(2S,3R,5S)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R*)-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (51 mg, 0.099 mmol) (second eluted isomer from SFC separation) was treated in the same manner, and after lyophilization, rel-(2S,3R,5S)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (25, 32.0 mg, 66%) was obtained as a white solid. 1 H NMR (500 MHz, DMSO-d6) δ 10.08 (s, 1H), 8.65 (d, J = 2.5 Hz, 1H), 7.96 (dd, J = 8.5, 2.5 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.22 - 7.15 (m, 2H), 5.32 (d, J = 4.9 Hz, 1H), 4.66 - 4.62 (m, 2H), 4.54 (dt, J = 6.7, 4.5 Hz, 1H), 4.05 (q, J = 10.0 Hz, 1H), 3.88 (d, J = 1.9 Hz, 3H), 3.64 (ddd, J = 10.4, 6.0, 4.2 Hz, 1H), 3.45 (ddd, J = 11.0, 6.7, 5.9 Hz, 1H), 2.47 (s, 1H), 2.45 (s, 1H), 1.57 (s, 3H) ppm; 19F NMR (471 MHz, DMSO-d6) δ -80.12, -138.14 (d, J = 21.1 Hz), -154.77 (d, J = 21.1 Hz) ppm.ESI-MS m / z calculated value 476.13705, measured value 477.4(M+1) + ;475.4(M-1) - ;Retention time: 2.77 minutes.

[0298] The following compounds were prepared using the method described in Example 3, except that (S)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine was used instead of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine in amide coupling step 8. In step 9, purification was performed by chiral SFC using a Chiral Pack IA column from Daicel Corporation, with a particle size of 5 μm and a diameter of 25 cm × 20 mm, on a Prep-100 SFC instrument from Waters: [Table 14]

[0299] The following compounds were prepared using the method described in Example 3, except that rac-2-(2,2-dimethyl-1,3-dioxolan-4-yl)pyrimidine-5-amine was used instead of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine in amide coupling step 8. In Suzuki coupling step 5, Pd(PPh3)4 was used as a catalyst together with Na2CO3 as the base and a mixture of toluene, water, and methanol as the solvent, and the reaction was carried out at 80°C for 16 hours. In Step 9, a mixture of four stereoisomers of rel-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(2-(1,2-dihydroxyethyl)pyrimidine-5-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, which had known relative stereochemistry for the THF ring (i.e., (2R,3S,5R)) but unknown relative stereochemistry between the THF ring and the dihydroxyethyl substituent, was subjected to chiral SFC on a Waters Prep-100 SFC instrument using a Daicel Corporation chiral cell OJ column, 5 μm particle size, 25 cm × 21.2 mm (40°C; mobile phase: 6% MeOH (20 mM NH3), 94% CO2; flow rate: 70 mL / min). [Table 15-1] [Table 15-2]

[0300] The following compounds were prepared using the method described in Example 3, except that 2-(2-ethoxy-3,4-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of (3,4-difluoro-2-methoxyphenyl)boronic acid in the Suzuki coupling step 5. For compounds 32 and 33, (S)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine was used instead of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine in the amide coupling step 8. In the Suzuki coupling step 5, Pd(PPh3)4 was used as a catalyst together with Na2CO3 as the base and a mixture of toluene, water, and methanol as the solvent, and the reaction was carried out at 80°C for 16 hours. In step 9, purification was performed by chiral SFC on a Minigram SFC instrument from Berger Instruments using a (R,R)-Whelk-O1 column from Daicel, with a particle size of 5 μm and a size of 25 cm × 21.1 mm (mobile phase: 30% MeOH (containing 20 mM ammonia), 70% CO2; flow rate: 100 mL / min). Deprotection step 10 was carried out at ambient temperature for 1.5 hours using 12 M HCl in THF as the solvent: [Table 16-1] [Table 16-2]

[0301] Compound 35 was analyzed by X-ray powder diffraction method B and determined to be amorphous (see Figure 6). Example 4 [ka]

[0302] Step 1: A stirred solution of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-((R)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (1,343.7 mg, 0.7008 mmol) in DCM (9 mL) was placed under a nitrogen atmosphere and cooled in an ice bath. Boron tribromide (in DCM) (2.2 mL of 1 M, 2.200 mmol) was added, and the reaction mixture was stirred for 2 hours. The reaction product was quenched by adding MeOH (2 mL) and stirred overnight at ambient temperature. The mixture was concentrated under vacuum. The residue was dissolved in MeOH (3 mL), and the pH was adjusted to pH 9 with 2 M sodium hydroxide aqueous solution. The solution was purified by reverse-phase preparative HPLC (Waters Sunfire C18, 10 μM, 100 Å column, 0% to 100% MeCN in water containing 0.1% ammonia) to obtain (2R,3S,4S,5R)-3-(3,4-difluoro-2-hydroxyphenyl)-N-(6-((R)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (36, 259.8 mg, 78%). 1H NMR (500 MHz, DMSO-d6) δ 10.45 (s, 1H), 10.40 (s, 1H), 8.65 (d, J = 2.2 Hz, 1H), 8.00 (dd, J = 8.7, 2.3 Hz, 1H), 7.42 (d, J = 8.6 Hz, 1H), 7.03 (t, J = 6.8 Hz, 1H), 6.85 (q, J = 8.6 Hz, 1H), 5.33 (d, J = 4.9 Hz, 1H), 5.09 (d, J = 10.3 Hz, 1H), 4.64 (t, J = 5.9 Hz, 1H), 4.57 - 4.50 (m, 1H), 4.28 - 4.19 (m, 1H), 3.66 - 3.57 (m, 1H), 3.49 - 3.38 (m, 1H), 2.83 (p, J = 7.4 Hz, 1H), 1.58 (s, 3H), 0.70 (d, J = 6.4 Hz, 3H) ppm. ESI-MS m / z calculated value 476.13705, measured value 477.3 (M+1) + Duration: 2.46 minutes.

[0303] ステップ2: K2CO3 (18 mg, 0.1302 mmol) was added to a mixture of 1-fluoro-2-iodoethane (10 μL, 0.1230 mmol) and (2R,3S,4S,5R)-3-(3,4-difluoro-2-hydroxyphenyl)-N-(6-((R)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (36, 40 mg, 0.08396 mmol) in DMF (2 mL). The mixture was stirred at 60°C for 6 hours and 30 minutes. The mixture was diluted with MeOH and purified by reverse-phase preparative HPLC (Waters Sunfire C18, 10 μM, 100 Å column, 0% to 100% MeCN in water containing 0.1% ammonia) to obtain (2R,3S,4S,5R)-3-(3,4-difluoro-2-(2-fluoroethoxy)phenyl)-N-(6-((R)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (37 mg, 18.48 mg, 41%). 1 H NMR (500 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.64 (dd, J = 2.5, 0.8 Hz, 1H), 8.00 (dd, J = 8.5, 2.5 Hz, 1H), 7.42 (d, J = 8.6 Hz, 1H), 7.27 - 7.09 (m, 2H), 5.32 (d, J = 4.9 Hz, 1H), 5.11 (d, J = 10.6 Hz, 1H), 4.79 (dt, J = 4.9, 2.4 Hz, 1H), 4.69 (dt, J = 5.0, 2.4 Hz, 1H), 4.63 (t, J = 5.9 Hz, 1H), 4.54 (dt, J = 6.8, 4.5 Hz, 1H), 4.49 - 4.27 (m, 3H), 3.70 - 3.59 (m, 1H), 3.45 (ddd, J = 10.9, 6.8, 5.7 Hz, 1H), 2.78 (p, J = 7.4 Hz, 1H), 1.59 (s, 3H), 0.81 - 0.68 (m, 3H) ppm. ESI-MS m / z calculated value 522.15894, measured value 523.3 (M+1)+ ;Holding time: 3.0 minutes.

[0304] The following compounds were prepared using the method described in Example 4, except that 2-bromo-1,1-difluoroethane was used instead of 1-fluoro-2-iodoethane in alkylation step 2. [Table 17]

[0305] The following compounds were prepared using the method described in Step 1 of Example 4, except that (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(2-(hydroxymethyl)pyrimidine-5-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (15) was used as the starting material. [Table 18] Example 5 [ka]

[0306] Step 1: In a 2L three-necked round-bottom flask with a thermometer positioned to the side, saturated NaHCO3 solution (120 mL) and dioxane (400 mL) were used to prepare ethyl rac-(4R,5R)-4,5-dimethyl-5-(trifluoromethyl)-3-(((trifluoromethyl)sulfonyl)oxy)-4,5-dihydrofuran-2-carboxylate (39.05 g, 101.1 mmol), (4-fluoro-2-methoxy-3-methylphenyl)boronic acid (20.4 g, 110.9 mmol), and PdCl2(PPh3). 2(A mixture of 1.4 g (1.995 mmol) was added. The orange mixture was heated internally to 50°C for 20 minutes. The reaction mixture was cooled to ambient temperature and diluted with HCl (100 mL) and water (100 mL). The layers were separated, and the aqueous phase was extracted with HCl (4 × 100 mL). The combined organic extracts were washed with brine (1 × 50 mL), dried, filtered, and concentrated under vacuum to a volume of approximately 100 mL. Charcoal (10 g) was added, and the mixture was stirred for 2 hours. The mixture was filtered, and the residual cake was further washed with HCl. The filtrate was collected and concentrated under vacuum to obtain 50 g of crude product. The solution was purified by flash chromatography (330 g of SiO2, heptane containing 0-30% ethyl rac-(4S,5R)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (27.348 g, 72%) as a pale yellow oil. 1 H NMR (500 MHz,chloroform-d) δ 6.98 - 6.88 (m, 1H), 6.81 (t, J = 8.7 Hz, 1H), 4.20 - 4.07 (m, 2H), 3.66 (s, 3H), 3.58 - 3.49 (m, 1H), 2.21 (d, ESI-MS m / z calculated value 376.12976, measured value 377.5 (M+1) + ;Retention time: 1.09 minutes.

[0307] Step 2: Ethyl rac-(4S,5R)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (27.35 g, 72.67 mmol), followed by DCM (200 mL), was added to a 1 L three-necked flask fitted with a thermometer. The reaction mixture was cooled to 5°C in an ice bath. While maintaining an internal temperature of approximately 5°C, boron tribromide (112 mL, 1 M solution in DCM, 112.0 mmol) was added via a cannula over 30 minutes. The reaction mixture was stirred for 1 hour. The mixture was quenched by slowly adding water (100 mL) (to induce foaming) and saturated sodium bicarbonate solution (100 mL). The mixture was stirred for 30 minutes. The aqueous phase was collected and washed with DCM (3 × 50 mL). The combined organic extracts were washed with saturated sodium bicarbonate solution (5 × 100 mL), dried (MgSO4), filtered, and concentrated under vacuum to obtain a yellow waxy solid. The waxy solid was redissolved in SiO4 (100 mL). Charcoal (15 g) was added, and the mixture was stirred overnight at ambient temperature. The mixture was filtered through a Celite pad. The filtrate was collected, dried (MgSO4), filtered, and concentrated under vacuum to obtain a waxy solid, which was a mixture of rac-(1S,2R)-7-fluoro-1,2,6-trimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-flu[2,3-c]chromen-4-one and ethylrac-(4S,5R)-3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (27.7 g) in an approximately 1:1 ratio.

[0308] The mixture was dissolved in DCM (200 mL), and TFA (9.8 mL, 127.2 mmol) was added at ambient temperature while stirring. The reaction mixture was heated under reflux and stirred for 2.5 hours. The mixture was cooled to ambient temperature and quenched with saturated sodium bicarbonate aqueous solution (100 mL). The organic phase was washed with saturated sodium bicarbonate aqueous solution (4 × 100 mL), dried (Na₂SO₄), and concentrated in vacuum to obtain a waxy solid. The waxy solid was redissolved in siRNA (200 mL), and activated carbon (10 g) was added. The mixture was stirred overnight at ambient temperature. The mixture was filtered through a Celite cartridge while washing with siRNA (3 × 100 mL). The filtrate was concentrated in vacuum to obtain a waxy solid. The solution was purified by flash chromatography (50% ethyl acetate in 120 g of SiO2 and heptane) to obtain rac-(1S,2R)-7-fluoro-1,2,6-trimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-flu[2,3-c]chromen-4-one (24.18 g, 100%). 1 H NMR (500 MHz,chloroform-d) δ 7.25 - 7.23 (m, 1H), 7.05 (t, J = 8.7 Hz, 1H), 3.65 (q, J = 7.4 Hz, 1H), 2.39 (d, J = 2.0 Hz, 3H), 1.67 (q, J = 1.0 Hz, 3H), 1.58 (t, J = 2.2 Hz, 3H) ppm. ESI-MS m / z calculated value 316.07227, measured value 317.4 (M+1) + ; 315.4 (M-1) - ;Retention time: 0.94 minutes.

[0309] Step 3: rac-(1S,2R)-7-fluoro-1,2,6-trimethyl-2-(trifluoromethyl)-1,2-dihydro-4H-flu[2,3-c]chromen-4-one (1.5 g, 3.273 mmol) was dissolved in ELISA (20 mL) and stirred with activated carbon (300 mg, 24.98 mmol) for 18 hours. The mixture was filtered through a Celite pad. The liquid was concentrated under vacuum to obtain a yellow solid. The solid was dissolved in methanol (20 mL) and added to a 100 mL flask containing dihydroxypalladium (460 mg, 20% w / w, 0.6551 mmol). The resulting mixture was stirred under atmospheric pressure with hydrogen for 120 hours. The mixture was filtered through a Celite cartridge while washing with MeOH. The filtrate was concentrated under vacuum to a volume of approximately 20 mL and added to a flask containing dihydroxypalladium (230 mg, 20% w / w, 0.3276 mmol). The resulting mixture was stirred for 12 hours under a hydrogen balloon atmosphere. The reaction mixture was filtered through a Celite cartridge while washing with MeOH. The filtrate was concentrated under vacuum to obtain a mixture of isomers of methyl 3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (939.3 mg, 82%) as a grayish-white solid, of which methyl rac-(2S,3S,4S,5R)-3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate was the major isomer. 1¹H NMR (500 MHz, chloroform-d) δ 7.20 (t, J = 7.7 Hz, 1H), 6.57 (t, J = 8.9 Hz, 1H), 4.88 (d, J = 6.1 Hz, 2H), 4.28 (dd, J = 8.4, 6.1 Hz, 1H), 3.56 (s, 3H), 2.81 (p, J = 7.8 Hz, 1H), 2.14 (d, J = 1.6 Hz, 3H), 1.4 (3H), 0.92 (dq, J = 7.6, 1.9 Hz, 3H) ppm; no alcohol OH groups were observed. ESI-MS m / z calculated value 350.11414, measured value 349.0 (M-1) - ;Holding time: 0.95 minutes.

[0310] Step 4: Potassium tert-butoxide (11.40 g, 101.6 mmol) was added to a stirred solution of a mixture of isomers of methyl 3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (8.896 g, 25.39 mmol). Of these, methyl rac-(2S,3S,4S,5R)-3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate was the major isomer in tetrahydrofuran (125 mL) at 0°C. After 15 minutes, the mixture was quenched by adding 1 M HCl (350 mL) and diluted with saturated brine (100 mL) and DCM (100 mL). The aqueous layer was extracted with DCM (3 × 100 mL). The combined organic extracts were dried (MgSO4), filtered, and concentrated under vacuum. The residue was dissolved in DCM (71 mL) and treated with TFA (26.62 g, 17.99 mL, 233.5 mmol). The reaction mixture was stirred at ambient temperature for 2 hours. The mixture was concentrated under vacuum, and the residue was azeotropically dissolved in DCM (2 × 50 mL). The residue was partitioned into DCM (100 mL) and water (50 mL), and the layers were separated. The organic layer was washed with water (3 x 50 mL), the organic extract was dried (MgSO4), filtered, and concentrated under vacuum to obtain a mixture of rac-(2R,3S,4S,5R)-3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2S,3S,4S,5R)-3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (9.753 g, 100%) as a brown oil, which was used directly in the next step. ESI-MS m / z calculated value 336.09848, measured value 335.5 (M-1) - ;Retention time: 0.56 minutes.

[0311] Step 5: K2CO3 (1.65 g, 11.94 mmol) and iodoethane (1 mL, 12.50 mmol) were added in a sealed vial to a solution of a mixture of rac-(2R,3S,4S,5R)-3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2S,3S,4S,5R)-3-(4-fluoro-2-hydroxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (1 g, 2.974 mmol) in acetonitrile (10 mL). The vial was sealed and heated at 80°C for 5 hours. The reaction mixture was cooled to ambient temperature and diluted with DCM. The mixture was filtered, and the solid was further washed with DCM. The filtrate was collected and concentrated under vacuum to obtain a mixture of ethyl rac-(2R,3S,4S,5R)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate and ethyl rac-(2S,3S,4S,5R)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (1.038 g, 89%). ESI-MS m / z calculated value: 392.16107, measured value: 393.6 (M+1) + ;Retention time: 0.99 minutes.

[0312] Step 6: LiOH (3.3 mL, 2 M, 6.600 mmol) was added to a stirred solution of ethyl rac-(2R,3S,4S,5R)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate and rac-(2S,3S,4S,5R)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (1 g, 2.549 mmol) in methanol (15 mL) and water (4 mL). The mixture was stirred at ambient temperature for 18 hours. The LiOH was removed under vacuum and the mixture was diluted to pH 1 with 1 M HCl. The mixture was extracted with DCM (2 × 10 mL). The combined organic extracts were dried by passing them through a phase separation cartridge and concentrated in a vacuum to obtain a mixture of rac-(2R,3S,4S,5R)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2S,3S,4S,5R)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (778.9 mg, 84%). ESI-MS m / z calculated value: 364.12976, measured value: 363.6 (M-1) - ;Retention time: 0.62 minutes.

[0313] Step 7: DMF (2.5 μL, 0.0323 mmol) and oxalyl chloride (27.5 μL, 0.315 mmol) were added to a solution of a mixture of rac-(2R,3S,4S,5R)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2S,3S,4S,5R)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (76 mg, 0.209 mmol) in DCM (2 mL) cooled to 0°C. At the end of the addition, the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated under vacuum. The residue was taken in 2 mL of 2-MeTHF and added dropwise to a solution of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine (48.8 mg, 0.2512 mmol) and TEA (90 μL, 0.6457 mmol). The reaction mixture was stirred at ambient temperature for 2 hours. The mixture was concentrated under vacuum and packed onto a solid support. Purification by flash chromatography (0-100% siRNA in SiO2, heptane) yielded a mixture of isomers:

[0314] First eluted isomer: A mixture of rel-(2R,3S,4S,5R)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2S,3R,4R,5S)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (23 mg, 41%). 1H NMR (400 MHz,chloroform-d) δ 8.54 (dd, J = 2.6, 0.7 Hz, 1H), 8.35 (s, 1H), 8.12 (dd, J = 8.6, 2.6 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.19 (dd, J = 8.7, 6.3 Hz, 1H), 6.86 (t, J = 8.7 Hz, 1H), 5.16 (t, J = 6.7 Hz, 1H), 5.00 (d, J = 11.1 Hz, 1H), 4.42 (ddd, J = 8.0, 6.8, 1.1 Hz, 1H), 4.13 (dd, J = 11.0, 7.9 Hz, 1H), 3.95 - 3.75 (m, 3H), 2.76 (p, J = 7.7 Hz, 1H), 2.20 (d, J = 2.1 Hz, 3H), 1.69 (s, 3H), 1.51 (dd, J = 1.5, 0.7 Hz, 3H), 1.48 (t, J = 0.7 Hz, 3H), 1.39 (t, J = 7.0 Hz, 3H), 0.83 - 0.76 (m, 3H) ppm. ESI-MS m / z calculated value 540.22473, measured value 541.2 (M+1) + ; 539.3 (M-1) - ;Retention time: 1.09 minutes.

[0315] Second eluted isomer: A mixture of rel-(2S,3S,4S,5R)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2R,3R,4R,5S)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (13.3 mg, 24%). 1H NMR (400 MHz,chloroform-d) δ 8.45 (ddd, J = 18.1, 2.6, 0.7 Hz, 1H), 8.22 (d, J = 2.8 Hz, 1H), 7.85 (ddd, J = 24.6, 8.5, 2.6 Hz, 1H), 7.44 (dd, J = 8.6, 1.1 Hz, 1H), 7.12 (dd, J = 8.7, 6.7 Hz, 1H), 6.63 (td, J = 8.8, 1.7 Hz, 1H), 5.15 (t, J = 6.7 Hz, 1H), 4.92 (d, J = 6.6 Hz, 1H), 4.41 (ddd, J = 8.3, 6.7, 1.5 Hz, 1H), 4.36 (dd, J = 8.8, 6.6 Hz, 1H), 4.01 - 3.79 (m, 3H), 2.90 (p, J = 7.8 Hz, 1H), 2.17 (d, J = 2.1 Hz, 3H), 1.59 (d, J = ESI-MS m / z calculated value 540.22473, measured value 541.2 (M+1) + ; 539.3 (M-1) - Retention time: 1.06 minutes. These isomers were separated by chiral SFC.

[0316] Step 8: A mixture of rel-(2R,3S,4S,5R)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2S,3R,4R,5S)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (23 mg, 0.042 mmol) (first eluted isomer from Step 7) from Minigram, Berger Instruments. Separation was performed on an SFC instrument using a Lux i-Cellulose-5 column from Phenomenex, Inc., with a particle size of 5 μm and a diameter of 25 cm × 20 mm (mobile phase: 15% MeOH (containing 20 mM ammonia), 85% CO2; flow rate: 100 mL / min) via chiral SFC:

[0317] First eluted isomer (retention time = 3.41 min): rel-(2R,3S,4S,5R)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (10 mg, 87%). ESI-MS m / z calculated value 540.22473, measured value 541.2 (M+1) + ; 539.3 (M-1) - ;Retention time: 3.73 minutes.

[0318] Second eluted isomer (retention time = 4.48 min): rel-(2S,3R,4R,5S)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (9 mg, 78%). ESI-MS m / z calculated value 540.22473, measured value 541.2 (M+1) + ; 539.3 (M-1) - ;Retention time: 3.73 minutes.

[0319] Step 9: TFA (10 μL, 0.130 mmol) was added to a solution of rel-(2R,3S,4S,5R)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (10 mg, 0.0185 mmol) (first eluted isomer from SFC separation) in THF (800 μL) and water (200 μL). The reaction mixture was stirred at 60°C for 6 hours and then at 40°C for a further 16 hours. The mixture was concentrated under vacuum. The tetrahydrofuran-2-carboxamide was purified by reverse-phase HPLC-MS using a Waters X-bridge C18 OBD column (150 × 19 mm, 5 mm particle size) to obtain rel-(2R,3S,4S,5R)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (40 mg, 2.5 mg, 27%). 1H NMR (400 MHz, methanol-d4) δ 8.67 (dd, J = 2.5, 0.7 Hz, 1H), 8.04 (dd, J = 8.6, 2.5 Hz, 1H), 7.52 (dt, J = 8.5, 0.7 Hz, 1H), 7.20 (dd, J = 8.7, 6.3 Hz, 1H), 6.86 (t, J = 8.8 Hz, 1H), 5.03 (d, J = 10.8 Hz, 1H), 4.71 (dd, J = 6.7, 4.2 Hz, 1H), 4.34 (dd, J = 10.8, 7.9 Hz, 1H), 3.96 - 3.82 (m, 2H), 3.79 (dd, J = 11.3, 4.2 Hz, 1H), 3.65 (dd, J = 11.3, 6.7 Hz, 1H), 2.77 (p, J = 7.6 Hz, 1H), 2.19 (d, J = 2.1 Hz, 3H), 1.67 (d, J = 1.1 Hz, 3H), 1.43 (t, J = 7.0 Hz, 3H), 0.80 (dq, J = 7.4, 2.3 Hz, 3H) ppm; no alcohols (OH) or amides (NH) were observed. ESI-MS m / z calculated value 500.19342, measured value 501.2 (M+1) + ; 499.2 (M-1) - ;Retention time: 3.17 minutes.

[0320] rel-(2S,3R,4R,5S)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (9 mg, 0.01665 mmol) (second eluted isomer from SFC separation) was treated in the same manner to obtain rel-(2S,3R,4R,5S)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-3-(2-ethoxy-4-fluoro-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (41 mg, 2.2 mg, 26%). 1H NMR (400 MHz,methanol-d4) δ 8.67 (dd, J = 2.5, 0.7 Hz, 1H), 8.04 (dd, J = 8.5, 2.5 Hz, 1H), 7.52 (dt, J = 8.6, 0.7 Hz, 1H), 7.20 (dd, J = 8.7, 6.3 Hz, 1H), 6.86 (t, J = 8.8 Hz, 1H), 5.03 (d, J = 10.8 Hz, 1H), 4.71 (dd, J = 6.6, 4.2 Hz, 1H), 4.35 (dd, J = 10.8, 7.9 Hz, 1H), 3.98 - 3.82 (m, 2H), 3.79 (dd, J = 11.3, 4.2 Hz, 1H), 3.65 (dd, J = 11.3, 6.7 Hz, 1H), 2.77 (p, J = 7.6 Hz, 1H), 2.19 (d, J = 2.1 Hz, 3H), 1.67 (d, J = 1.1 Hz, 3H), 1.43 (t, J = 7.0 Hz, 3H), 0.80 (dt, J = 7.2, 2.4 Hz, 3H) ppm; no alcohols (OH) or amides (NH) were observed. ESI-MS m / z calculated value 500.19342, measured value 501.3 (M+1) + ; 499.3 (M-1) - ;Retention time: 3.19 minutes.

[0321] The following compounds were prepared using the method described in Example 5, except that in Step 7, (S)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine was used instead of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine. In Step 8, the compounds were purified by chiral SFC using a Lux i-cellulose-5 column from Daicel Corporation, 5 mm particle size, 25 cm × 20 mm (mobile phase: 15% MeOH (containing 20 mM ammonia), 85% CO2; flow rate: 100 mL / min) on a Waters Prep-100 SFC instrument. [Table 19]

[0322] The following compounds were prepared using the method described in Example 5, except that hydrogenation step 3 was carried out using 60 psi of hydrogen. In step 5, methyl iodide was used as the alkylating agent instead of ethyl iodide. In step 7, for compounds 44 and 45, (S)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine was used instead of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine. In step 8, purification was performed by chiral SFC on a Minigram SFC instrument from Berger Instruments using a (R,R)-Whelk-O1 column from Daicel, 5 μm particle size, 25 cm × 21.1 mm (mobile phase: 5-25% MeOH (containing 20 mM ammonia), 95-75% CO2. Flow rate: 100 mL / min). In step 9, DCM was used as the solvent instead of a mixture of THF and water: [Table 20-1] [Table 20-2] Example 6 [ka]

[0323] Step 1: A mixture of ethyl rac-(4R,5R)-4,5-dimethyl-5-(trifluoromethyl)-3-(((trifluoromethyl)sulfonyl)oxy)-4,5-dihydrofuran-2-carboxylate (1.44 g, 3.169 mmol), 2-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (900 mg, 2.592 mmol), Pd(Ph3)4 (148 mg, 0.1281 mmol), and an aqueous solution of K2CO3 (2.6 mL, 2 M, 5.200 mmol) in 1,4-dioxane (25 mL) was heated at 100°C for 2 hours. The mixture was concentrated in vacuum and packed into a solid support. Purification by flash chromatography (0-25% ethyl in SiO2 and heptane) yielded ethylrac-(4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (708 mg, 66%) as a colorless oil. 1 H NMR (400 MHz,chloroform-d)δ 7.25 (ddt, J = 7.3, 6.2, 1.2 Hz, 1H), 6.95 (td, J = 53.6, 0.7 Hz, 1H), 6.94 (tt, J = 8.7, 0.9 Hz, 1H), 4.17 (qd, J = 7.1, 1.3 Hz, 2H), 3.77 (s, 3H), 3.62 - 3.53 (m, 1H), 1.71 (q, J = 1.0 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H), 1.07 (dq, J = 7.1, 2.2 Hz, 3H) ppm. ESI-MS Calculated m / z value: 412.11093, measured value: 413.2 (M+1) + ;Holding time: 1.05 minutes.

[0324] Step 2: A solution of ethyl rac-(4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (3.5 g, 8.488 mmol) in MeOH (100 mL) was added to a two-necked flask containing magnesium (2.07 g, 85.17 mmol). The reaction mixture was heated at 70°C for 3 hours. The mixture was concentrated under vacuum and partitioned into aqueous AcOH and ethyl phosphate. The aqueous layer was separated and extracted twice with ethyl phosphate. The combined organic phase was washed with aqueous NaHCO3 and then washed twice with water. The organic phase was dried (MgSO4) and concentrated in a vacuum to obtain a mixture of methyl rac-(2S,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate and methyl rac-(2R,3R,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (2.87 g, 84%) as an orange oil. 1 ¹H NMR (400 MHz, chloroform-d) δ 7.43 - 7.32 (m, 1H), 7.01 - 6.95 (m, 1H), 7.09 - 6.80 (m, 1H), 4.89 (d, J = 10.2 Hz, 1H), 4.21 - 4.15 (m, 1H), 3.84 (s, 3H), 3.71 (s, 3H), 2.73 (p, J = 7.7 Hz, 1H), 1.63 (q, J = 1.2 Hz, 3H), 0.78 (ddq, J = 7.2, 4.7, 2.3 Hz, 3H) ppm.

[0325] Step 3: Potassium tert-butoxide (1.66 g, 14.79 mmol) was added in a water bath at ambient temperature to a solution of a mixture of methyl rac-(2S,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate and methyl rac-(2R,3R,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (2.87 g, 7.169 mmol) in 2-MeTHF (35 mL). An exothermic reaction of approximately 3°C was observed during the addition. The reaction mixture was stirred for 2 hours, after which an additional amount of potassium tert-butoxide (860 mg) was added. The mixture was stirred for a further 1 hour at ambient temperature. The reaction products were quenched with a diluted HCl solution. The aqueous layer was separated, washed with ethyl acetate, dried, and concentrated under vacuum to obtain a mixture of rac-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2S,3R,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (3.32 g, 74%) as an orange oil. 1 ¹H NMR (400 MHz, chloroform-d) δ 7.43 - 7.35 (m, 1H), 6.98 (ddd, J = 13.4, 9.3, 4.2 Hz, 1H), 6.93 (t, J = 53.6 Hz, 1H), 4.93 (d, J = 10.3 Hz, 1H), 4.18 - 4.14 (m, 1H), 3.84 (s, 3H), 2.76 (p, J = 7.7 Hz, 1H), 1.67 - 1.62 (m, 3H), 0.82 - 0.75 (m, 3H) ppm; no OH acids were observed. ESI-MS m / z calculated value 386.09528, measured value 385.1 (M-1) - ;Retention time: 0.57 minutes.

[0326] Step 4: T3P (310 μL, 50% w / w, 0.5208 mmol) was added to a mixture of rac-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2S,3R,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (100 mg, 0.2589 mmol) in ethyl acetate (2 mL), a solution of (S)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine (78 mg, 0.4016 mmol), and triethylamine (110 μL, 0.7892 mmol). The reaction mixture was stirred at 50°C for 30 minutes, and then at ambient temperature overnight. The reaction mixture was partitioned into RINKAN and water and passed through Whatmann phase separation filter paper. The organic phase was concentrated under vacuum and packed onto silica. The mixture was purified by flash chromatography (0-75% ELISA in SiO2 and heptane) to obtain a mixture of rel-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2S,3R,4R,5S)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (50 mg, 34%). 1H NMR (400 MHz,chloroform-d) δ 8.56 (t, J = 2.5 Hz, 1H), 8.38 (s, 1H), 8.13 (dt, J = 8.7, 2.9 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.11 - 6.76 (m, 2H), 5.18 (t, J = 6.7 Hz, 1H), 5.01 (d, J = 10.6 Hz, 1H), 4.43 (ddd, J = 8.4, 6.7, 0.8 Hz, 1H), 4.16 - 4.08 (m, 1H), 3.98 - 3.88 (m, 1H), 3.84 (d, J = 0.6 Hz, 4H), 2.78 (p, J = 7.7 Hz, 1H), 1.69 (s, 3H), 1.50 - 1.45 (m, 6H), 0.84 - 0.75 (m, 3H) ppm; NH amide was not observed. ESI-MS m / z calculated value 562.19025, measured value 563.2 (M+1) + ; 561.3 (M-1) - ;Holding time: 1.02 minutes.

[0327] Step 5: A mixture of rel-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2S,3R,4R,5S)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (50 mg, 0.089 mmol) was processed on a Minigram SFC instrument from Berger Instruments using Daicel. Separation was performed by chiral SFC using a chiral pack AS-H column from Corporation, 5 μm particle size, 25 cm × 10 mm (mobile phase: 15% MeOH (containing 20 mM ammonia), 85% CO2, flow rate: 10 mL / min).

[0328] First eluted isomer (retention time = 2.14 min): rel-(2S,3R,4R,5S)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (15 mg, 60%). ESI-MS m / z calculated value 562.19025, measured value 563.2 (M+1) + ; 561.2 (M-1) - ;Holding time: 3.5 minutes.

[0329] Second eluted isomer (retention time = 3.60 min): rel-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (12 mg, 48%). ESI-MS m / z calculated value 562.19025, measured value 563.2 (M+1) + ; 561.2 (M-1) - ;Holding time: 3.49 minutes.

[0330] Step 6: TFA (10 μL, 0.1298 mmol) was added to a solution of rel-(2S,3R,4R,5S)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (15 mg, 0.02667 mmol) (first eluted isomer from SFC separation) in THF (800 μL) and water (200 μL). The reaction mixture was stirred overnight at 60°C. The mixture was concentrated under vacuum. The tetrahydrofuran-2-carboxamide was purified by reverse-phase HPLC-MS using a Waters X-bridge C18 OBD column (150 × 19 mm, 5 mm particle size) to obtain rel-(2S,3R,4R,5S)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (48 mg, 6 mg, 41%). 1H NMR (400 MHz,methanol-d4) δ 8.71 (dd, J = 2.6, 0.8 Hz, 1H), 8.08 (dd, J = 8.5, 2.5 Hz, 1H), 7.64 - 7.58 (m, 1H), 7.55 (dt, J = 8.6, 0.7 Hz, 1H), 7.21 - 6.89 (m, 2H), 5.09 (d, J = 10.4 Hz, 1H), 4.74 (dd, J = 6.6, 4.2 Hz, 1H), 4.36 (dd, J = 10.4, 8.1 Hz, 1H), 3.87 (s, 3H), 3.86 - 3.62 (m, 2H), 2.83 (p, J (= 7.7 Hz, 1H), 1.70 (d, J = 1.2 Hz, 3H), 0.90 - 0.82 (m, 3H) ppm; no alcohols (OH) or amides (NH) were observed. ESI-MS m / z calculated value 522.15894, measured value 522.9 (M+1) + ; 521.0 (M-1) - ;Retention time: 3.04 minutes.

[0331] rel-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (12 mg, 0.02133 mmol) (second eluted isomer from SFC separation) was treated in the same manner to obtain rel-(2R,3S,4S,5R)-3-(3-(difluoromethyl)-4-fluoro-2-methoxyphenyl)-N-(6-((S*)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (49 mg, 34%). 1H NMR (400 MHz,methanol-d4) δ 8.69 (dd, J = 2.6, 0.8 Hz, 1H), 8.06 (dd, J = 8.5, 2.5 Hz, 1H), 7.63 - 7.57 (m, 1H), 7.53 (dt, J = 8.6, 0.7 Hz, 1H), 7.20 - 6.87 (m, 2H), 5.08 (d, J = 10.4 Hz, 1H), 4.72 (dd, J = 6.6, 4.2 Hz, 1H), 4.34 (dd, J = 10.4, 8.1 Hz, 1H), 3.86 (s, 3H), 3.84 - 3.61 (m, 2H), 2.82 (p, J (= 7.7 Hz, 1H), 1.69 (d, J = 1.2 Hz, 3H), 0.88 - 0.80 (m, 3H) ppm; no alcohols (OH) or amides (NH) were observed. ESI-MS m / z calculated value 522.15894, measured value 522.9 (M+1) + ; 521.0 (M-1) - ;Retention time: 3.01 minutes.

[0332] The following compounds were prepared using the method described in Example 6, except that (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine was used instead of (S)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine in amide coupling step 4. In step 5, purification was performed by chiral SFC using a Minigram SFC instrument from Berger Instruments with a (R,R)-Whelk-O1 column from Daicel, 5 μm particle size, 25 cm × 21.1 mm (mobile phase: 5-55% MeOH, 95-45% CO2; flow rate: 100 mL / min). The conditions used in step 6 were similar to those described in step 16 of Example 1: [Table 21]

[0333] The following compounds were prepared using the method described in Example 6. The product of Step 1 was prepared in three steps using the conditions described in Steps 1, 2, and 3 of Example 11, with 1-bromo-3-(difluoromethyl)-4-fluoro-2-methoxybenzene as the coupling partner. In the amide coupling step 4, methyl 5-aminopicolinate was used as the amine coupling partner. The ester formed in Step 4 was reduced overnight at 50°C using excess NaBH4 in MeOH as the solvent, under conditions well known in the art. Deprotection step 6 was not required: [Table 22]

[0334] The following compounds were prepared using the method described in Example 6. The product of Step 1 was prepared in three steps using the conditions described in Steps 1, 2, and 3 of Example 11, with 1-bromo-3-(difluoromethyl)-4-fluoro-2-methoxybenzene as the coupling partner. In the amide coupling step 4, methyl (5-aminopyrimidine-2-yl)benzoate was used as the amine coupling partner. Chiral SFC separation step 5 was performed on a Waters Prep-100 SFC instrument using a Daicel chiral pack IG column, 5 μm particle size, 25 cm × 20 mm (mobile phase: 17% MeOH (containing 20 mM ammonia), 83% CO2; flow rate: 100 mL / min). Deprotection step 6 was performed over 16 hours at 30°C using an excess 2 M LiOH solution in MeOH as the solvent, under conditions well known in the art: [Table 23]

[0335] The following compounds were prepared using the method described in Example 6. The product of Step 1 was prepared in three steps using the conditions described in Steps 1, 2, and 3 of Example 11, with 1-bromo-3-(difluoromethyl)-4-fluoro-2-methoxybenzene as the coupling partner. In the amide coupling step 4, 1-(5-aminopyridine-2-yl)ethane-1-one was used as the amine coupling partner. Chiral SFC separation step 5 was performed on a Minigram SFC instrument from Berger Instruments using a chiral pack IG column from Daicel, with a particle size of 5 μm, 25 cm × 10 mm (mobile phase: 25% IPA (containing 20 mM ammonia), 75% CO2; flow rate: 10 mL / min). Deprotection step 6 was performed at ambient temperature for 30 minutes and replaced by a ketone reduction step using 3 equivalents of NaBH4 in MeOH as the solvent, under conditions well known in the art. The first eluted isomer in SFC separation (step 5) is a mixture of epimers at the hydroxyethyl position, which is not further separated and is referred to herein as compound 56. The second eluted isomer in SFC separation (step 5) is a mixture of epimers at the hydroxyethyl position, compounds 57 and 58, which were further separated by chiral SFC on a Minigram SFC instrument from Berger Instruments using a chiral pack IG column from Daicel, 5 μm particle size, 25 cm × 10 mm (mobile phase: 25% IPA (containing 20 mM ammonia), 75% CO2; flow rate: 10 mL / min): [Table 24-1] [Table 24-2] Example 7 [ka]

[0336] Step 1: A solution of rel-(2R,3S,4S,5R)-N-(6-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (11.5 mg, 0.02184 mmol) prepared as described for the precursor of compound 45 in Example 5, in DCM (2 mL) was cooled in an ice bath. m-CPBA (19.9 mg, 0.08072 mmol) was added all at once, and the mixture was slowly warmed in the ice bath. The reaction mixture was stirred for 24 hours. The reaction mixture was quenched with saturated bicarbonate (2 ml). The aqueous layer was washed with DCM (3 × 2 ml). The organic phases were combined and passed through a phase separator cartridge. The liquid was concentrated under vacuum to obtain rel-2-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)-5-((2R,3S,4S,5R)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide)pyridine 1-oxide (15.4 mg, 100%) as a yellow solid, which was used directly in the next step. ESI-MS m / z calculated value: 542.204, measured value: 543.7 (M+1) + ; 541.6 (M-1) - ;Retention time: 0.97 minutes.

[0337] Step 2: TFA (25 μL, 0.3245 mmol) was added to a stirred solution of rel-2-((S*)-2,2-dimethyl-1,3-dioxolan-4-yl)-5-((2R,3S,4S,5R)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide)pyridine 1-oxide (15.4 mg, 0.02441 mmol) in DCM (500 μL). The reaction mixture was stirred at ambient temperature for 24 hours. Purification by reverse-phase preparative HPLC (base elution) yielded rel-2-((S*)-1,2-dihydroxyethyl)-5-((2R,3S,4S,5R)-3-(4-fluoro-2-methoxy-3-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide)pyridine 1-oxide (3.2 mg, 24%) as a white solid. 1 H NMR (500 MHz, methanol-d4) δ 8.96 (d, J = 1.9 Hz, 1H), 7.78 - 7.73 (m, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.22 (dd, J = 8.7, 6.4 Hz, 1H), 6.91 (t, J = 8.8 Hz, 1H), 5.28 (dd, J = 5.4, 3.5 Hz, 1H), 5.06 (d, J = 10.6 Hz, 1H), 4.38 (dd, J = 10.6, 8.0 Hz, 1H), 3.93 (dd, J = 11.3, 3.4 Hz, 1H), 3.83 - 3.72 (m, 4H), 2.81 (p, J = 7.6 Hz, 1H), 2.25 (d, J = 2.0 Hz, 3H), 1.70 (s, 3H), 0.84 (dd, J = 6.9, 2.6 Hz, 3H) ppm; no alcohols (OH) or amides (NH) were observed. 19 F NMR (471 MHz, methanol-d4): δ -75.62, -117.82 ppm. ESI-MS m / z calculated value 502.1727, measured value 503.6 (M+1) + ; 501.6 (M-1) - ;Retention time: 2.9 minutes.

[0338] Using material 1 as the starting material, the following compounds were prepared using the method described in Example 7: [Table 25] Example 8 [ka]

[0339] Step 1: Tetrakis(triphenylphosphine)palladium(0) (1.3 g, 1.125 mmol) was added to a mixture of (2-chloro-4-(trifluoromethoxy)phenyl)boronic acid (5 g, 20.80 mmol), ethyl 5-methyl-5-(trifluoromethyl)-3-(((trifluoromethyl)sulfonyl)oxy)-4,5-dihydrofuran-2-carboxylate (8 g, 21.49 mmol), and aqueous sodium carbonate solution (28.2 mL, 2 M, 56.40 mmol) in dioxane (85 mL). The reaction mixture was heated at 100 °C for 3 hours. The mixture was partitioned into ethyl phosphate and water. The organic layer was washed with brine, dried, filtered, and concentrated under vacuum. The solution was purified by flash chromatography (120 g of SiO2, heptane containing 0-40% ethyl) to obtain ethyl 3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (6.46 g, 74%). 1 H NMR (500 MHz,chloroform-d) δ 7.34 (dd, J = 2.3, 1.0 Hz, 1H), 7.32 - 7.24 (m, 1H), 7.16 (dtd, J = 8.5, 2.0, 0.9 Hz, 1H), 4.14 (q, J = 7.2 Hz, ESI-MS m / z calculated value 418.04065, actual value 418.8 (M+1)+ ;Retention time: 1.13 minutes.

[0340] Step 2: A pressure tube was packed with magnesium powder (2.35 g, 96.69 mmol) and purged with nitrogen. MeOH (20 mL) was added to the reaction vessel, followed by a solution of ethyl 3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (2 g, 4.777 mmol) in MeOH (20 mL). The reaction mixture was degassed with nitrogen, and then a few drops of 1,2-dibromoethane (80 mg, 0.4258 mmol) were added. The reaction mixture was vigorously stirred and heated at 50°C for 5 hours. The mixture was cooled to ambient temperature and quenched by slowly pouring it into a cooled 1 M HCl solution. The mixture was stirred for 30 minutes until a clear solution was obtained. The mixture was partitioned using TBME. The separated aqueous layer was washed with TBME (×3). The combined organic phases were passed through a phase separator cartridge. The filtrate was concentrated under vacuum to obtain a mixture of diastereoisomers. The two main diastereoisomers were methylrac-(2S,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate and methylrac-(2R,3R,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (2.85 g, 73%), which were used directly in the next step. ESI-MS m / z calculation: 406.04065, retention time: 1.09 and 1.11 minutes for the two main diastereoisomers.

[0341] Step 3: Sodium methoxide (310 μL in MeOH, 25% w / v, 1.435 mmol) was added under nitrogen at ambient temperature to a stirred solution containing a mixture of methyl rac-(2S,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate and methyl rac-(2R,3R,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (3.8 g, 9.343 mmol) in THF (40 mL). After 5 hours, methanol (0.2 ml) and LiOH (7.3 mL of 2 M aqueous solution, 14.60 mmol) were added, and the reaction mixture was stirred overnight at ambient temperature. The reaction product was poured into a 1 M HCl solution. The mixture was extracted with TBME (2 × 30 ml). The combined organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated under vacuum to obtain a mixture containing two major diastereoisomers, rac-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2S,3R,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (3.244 g, 88%). ESI-MS m / z calculated value: 392.025, measured value: 391.0 (M-1) - Retention time: 0.63 and 0.66 minutes for the two main diastereoisomers.

[0342] Step 4: Dimethylformamide (0.3 μL, 0.003874 mmol) and oxalyl chloride (78 μL, 0.8941 mmol) were added to an ice-cold, stirred solution of a mixture of diastereoisomers containing rac-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2S,3R,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (167 mg, 0.4253 mmol) in 2-methyltetrahydrofuran (2 mL). The reaction mixture was stirred and heated to ambient temperature for 1.5 hours. The reaction mixture was concentrated under vacuum. The residue was taken in 2 mL of 2-methyltetrahydrofuran and added to an ice-cold solution of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine (90 mg, 0.4634 mmol) and TEA (178 μL, 1.277 mmol) in a mixture of 2 mL of 2-methyltetrahydrofuran and 0.1 mL of NMP. The resulting mixture was stirred and heated to ambient temperature for 18 hours. The reaction mixture was quenched with water (5 mL) and the layers were separated. The aqueous phase was extracted with SiO2 (2 × 10 mL). The combined organic extracts were washed with brine (5 mL), dried, filtered, and concentrated under vacuum. Purification by column chromatography (12 g of SiO2, 0-50% SiO2 in heptane) yielded a mixture of isomers:

[0343] First eluted isomer: a mixture of rel-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (95 mg, 28%) as a white solid and in a mixture of approximately 3:1 with dechlorination by-products. ESI-MS m / z calculated value: 568.12, measured value: 570.1 (M+1) + ;Retention time: 1.09 minutes.

[0344] Second eluted isomer: A mixture of rel-(2S,3R,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (59 mg, 21%) as a white solid. 1H NMR (500 MHz,chloroform-d) δ 8.58 (dd, J = 22.6, 2.5 Hz, 1H), 8.32 (d, J = 2.9 Hz, 1H), 8.12 (ddd, J = 25.0, 8.6, 2.6 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 8.6 Hz, 1H), 7.33 (dd, J = 2.5, 1.0 Hz, 1H), 7.24 - 7.16 (m, 1H), 5.22 (t, J = 6.7 Hz, 1H), 4.97 (dd, J = 9.5, 1.3 Hz, 1H), 4.46 (dd, J = 8.4, 6.7 Hz, 1H), 4.22 (dt, J = 11.4, 8.9 Hz, 1H), 3.96 (dd, J = 8.3, 6.7 Hz, 1H), 2.95 (dd, J = 13.9, 8.4 Hz, 1H), 2.27 - 2.15 (m, 1H), 1.69 - 1.62 (m, 3H), 1.54 (s, 3H), 1.51 (s, 3H) ppm. ESI-MS m / z calculated value 568.12, measured value 570.1 (M+1) + Retention time: 1.09 minutes. The SFC separation and deprotection of these second eluted isomers are illustrated in the table following Example 8.

[0345] Step 5: A mixture of rel-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide and rel-(2S,3R,5S)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (95 mg, 0.120 mmol) (first eluted isomer from Step 4) from Minigram by Berger Instruments. Separation was performed on an SFC instrument using a chiral SFC with a Daicel (R,R)-Whelk-O1 column, 5 μm particle size, 25 cm × 21.1 mm (mobile phase: 30% MeOH (containing 20 mM ammonia), 70% CO2; flow rate: 100 mL / min):

[0346] First eluted isomer (retention time = 2.66 min): rel-(2S,3R,5S)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (28 mg, 36%) as a colorless oil. 1H NMR (500 MHz,chloroform-d) δ 8.55 (d, J = 2.5 Hz, 1H), 8.27 (s, 1H), 8.14 (dd, J = 8.6, 2.6 Hz, 1H), 7.54 - 7.49 (m, 2H), 7.32 (dd, J = 2.5, 1.0 Hz, 1H), 7.22 (ddd, J = 8.7, 2.5, 1.1 Hz, 1H), 5.19 (t, J = 6.7 Hz, 1H), 4.83 (d, J = 10.6 Hz, 1H), 4.45 (dd, J = 8.3, 6.7 Hz, 1H), 4.12 (td, J = 11.2, 8.2 Hz, 1H), 3.94 (dd, J = 8.3, 6.7 Hz, 1H), 2.55 (dd, J = 13.2, 8.2 Hz, 1H), 2.46 (dd, J = 13.2, 11.7 Hz, 1H), 1.69 (s, 3H), 1.54 (s, 3H), 1.51 (s, 3H) ppm. ESI-MS m / z calculated value 568.12, measured value 569.2 (M+1) + ; 567.1 (M-1) - ;Holding time: 1.12 minutes.

[0347] Second eluted isomer (retention time = 3.76 min): rel-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (27 mg, 38%) as a colorless oil. 1H NMR (500 MHz, クロロホルム-d) δ 8.46 (d, J = 2.4 Hz, 1H), 8.18 (s, 1H), 8.04 (dd, J = 8.6, 2.6 Hz, 1H), 7.42 (dd, J = 8.7, 1.8 Hz, 2H), 7.22 (dd, J = 2.5, 1.0 Hz, 1H), 7.13 (ddd, J = 8.6, 2.5, 1.1 Hz, 1H), 5.10 (t, J = 6.7 Hz, 1H), 4.74 (d, J = 10.5 Hz, 1H), 4.35 (dd, J = 8.3, 6.7 Hz, 1H), 4.03 (td, J = 11.2, 8.2 Hz, 1H), 3.84 (dd, J = 8.3, 6.8 Hz, 1H), 2.46 (dd, J = 13.3, 8.2 Hz, 1H), 2.36 (dd, J = 13.2, 11.7 Hz, 1H), 1.59 (s, 3H), 1.44 (s, 3H), 1.41 (s, 3H) ppm. ESI-MS m / z calculated value 568.12, measured value 569.2 (M+1) + 567.1 (M-1) - Duration: 1.12 minutes.

[0348] ステップ6: TFA (200 μL, 2.596 mmol) was added to a solution of rel-(2S,3R,5S)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (32 mg, 0.04950 mmol) (first eluted isomer from SFC separation) in DCM (3 mL). The reaction mixture was stirred at ambient temperature for 18 hours. The mixture was concentrated under vacuum. The solution was purified by reverse-phase preparative HPLC (Waters Sunfire C18, 10 μM, 100 Å column, 0% to 100% MeCN in water containing 0.1% ammonia) to obtain rel-(2S,3R,5S)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (61 mg, 7.9 mg, 26%). 1 H NMR (500 MHz, DMSO-d6) δ 10.09 (s, 1H), 8.62 (d, J = 2.5 Hz, 1H), 7.94 (dd, J = 8.5, 2.6 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.62 - 7.57 (m, 1H), 7.48 - 7.44 (m, 1H), 7.43 (d, J = 8.5 Hz, 1H), 5.32 (d, J = 4.9 Hz, 1H), 4.73 (d, J = 9.9 Hz, 1H), 4.64 (t, J = 5.9 Hz, 1H), 4.56 - 4.51 (m, 1H), 4.28 - 4.18 (m, 1H), 3.64 (ddd, J = 10.5, 6.0, 4.2 Hz, 1H), 3.45 (dt, J = 11.0, 6.2 Hz, 1H), 2.59 (dd, J = 13.0, 8.1 Hz, 1H), 2.44 (t, J = 12.3 Hz, 1H), 1.59 (s, 3H) ppm; 19F NMR (471 MHz, DMSO-d6): δ -56.96, -79.96 ppm. ESI-MS m / z calculated value 528.0887, measured value 529.2 (M+1). + ; 527.1 (M-1) - ;Holding time: 3.15 minutes.

[0349] rel-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (27 mg, 0.04604 mmol) (second eluted isomer from SFC separation) was treated in the same manner to obtain rel-(2R,3S,5R)-3-(2-chloro-4-(trifluoromethoxy)phenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (62 mg, 8.1 mg, 33%). 1 H NMR (500 MHz, DMSO-d6) δ 10.10 (s, 1H), 8.61 (d, J = 2.5 Hz, 1H), 7.95 (dd, J = 8.5, 2.5 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.59 (d, J = 2.6 Hz, 1H), 7.52 - 7.44 (m, 1H), 7.43 (d, J = 8.5 Hz, 1H), 5.33 (d, J = 4.5 Hz, 1H), 4.73 (d, J = 9.9 Hz, 1H), 4.64 (t, J = 5.9 Hz, 1H), 4.54 (dt, J = 7.4, 4.0 Hz, 1H), 4.24 (td, J = 10.7, 10.2, 8.2 Hz, 1H), 3.68 - 3.58 (m, 1H), 3.45 (dt, J = 11.4, 5.9 Hz, 1H), 2.59 (dd, J = 13.0, 8.1 Hz, 1H), 2.48 - 2.39 (m, 1H), 1.59 (s, 3H) ppm; 19F NMR (471 MHz, DMSO-d6): δ -56.96, -79.96 ppm. ESI-MS m / z calculated value 528.0887, measured value 529.2 (M+1). + ; 527.1 (M-1) - ;Holding time: 3.15 minutes.

[0350] The following compounds were prepared using the method described in Example 8, with the second eluted isomer obtained from column chromatography in amide coupling step 4. In step 5, purification was performed by chiral SFC on a Minigram SFC instrument from Berger Instruments using a Daicel chiral cell OD-H column, 5 μm particle size, 25 cm × 10 mm (mobile phase: 15% MeOH (containing 20 mM ammonia), 85% CO2; flow rate: 10 mL / min). [Table 26] Example 9 [ka]

[0351] Step 1: Ethyl rac-(4R,5R)-4,5-dimethyl-5-(trifluoromethyl)-3-(((trifluoromethyl)sulfonyl)oxy)-4,5-dihydrofuran-2-carboxylate (42 g, 108.7 mmol) and 1,4-dioxane (500 mL) were added to a 1-liter three-necked flask with a thermometer and air conditioner condenser positioned to the side. The stirred mixture was degassed and flushed with nitrogen. KOAc (32 g, 326.1 mmol), followed by bis(pinacolate)diborone (32 g, 126.0 mmol). The reaction mixture was drained and returned to the flask, filled with nitrogen (x3). Pd(dppf)Cl2 (4 g, 5.467 mmol) was added, and the mixture was heated at 80°C for 20 hours. The reaction mixture was cooled to ambient temperature and partitioned into ethyl acetate (300 mL) and water (100 mL). The mixture was filtered through a Celite pad, washing with ethyl acetate (5 × 100 ml) until no more product could be removed. The filtrate phase was separated. The aqueous layer was extracted with ethyl acetate (100 mL × 2). The combined organic layers were passed through Whatmann phase separation filter paper. The filtrate was concentrated under vacuum to obtain 47 g of brown oil. Purification by flash chromatography (Florisil, 100% heptane) yielded ethylrac-(4S,5R)-4,5-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (47 g, 95%) as a thick, viscous yellow oil. 1 H NMR (500 MHz,chloroform-d) δ 4.33 - 4.23 (m, 2H), 3.27 - 3.18 (m, 1H), 1.55 (d, J = 1.1 Hz, 3H), 1.32 (s, 12H), 1.28 (d, J = 2.3 Hz, 3H), 1.24 (s, 3H) ppm. ESI-MS m / z calculated value 364.1669, measured value 365.3 (M+1) + ;Holding time: 1.1 minutes.

[0352] Step 2: An aqueous solution of K3PO4 (8 mL, 2 M, 16.00 mmol) was added to a solution of rac-(4S,5R)-4,5-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (3 g, 7.414 mmol), 1-bromo-3,4-difluoro-2-methylbenzene (1.4 g, 6.763 mmol), and Pd(dppf)Cl2.CH2Cl2 (350 mg, 0.4286 mmol) in 1,4-dioxane (60 mL). The mixture was degassed and placed under a nitrogen atmosphere. The reaction was stirred at 100°C for 2 hours. The mixture was partitioned into water and ethyl acetate. The aqueous layer was extracted three times with ethyl acetate. The organic phases were combined and passed through Whatmann phase separation filter paper. The filtrate was concentrated under vacuum to obtain a brown oil. It was purified by flash chromatography (24 g of SiO2, heptane with 0-100% ethyl) to obtain ethyl rac-(4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (2.213 g, 67%) as a pale yellow oil. 1 H NMR (500 MHz, methanol-d4) δ 7.10 (dt, J = 10.3, 8.4 Hz, 1H), 6.90 (s, 1H), 4.14 - 4.00 (m, 2H), 3.54 (d, J = 8.2 Hz, 1H), 2.19 (d, J = 2.7 ESI-MS m / z calculated value 364.10977, measured value 365.2 (M+1) + ;Retention time: 1.08 minutes.

[0353] Step 3: A pressure tube was filled with magnesium powder (200 mg, 8.229 mmol) and purged with nitrogen. A solution of ethyl rac-(4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)-4,5-dihydrofuran-2-carboxylate (2.02 g, 5.545 mmol) in MeOH (30 mL) was added to the pressure vessel. The mixture was degassed and placed under a nitrogen atmosphere. A few drops of 1,2-dibromoethane (5 μL, 0.058 mmol) were added. The reaction mixture was vigorously stirred and heated at 70°C for 6 hours. Three further consecutive amounts of magnesium powder (200 mg, 8.229 mmol) were added, followed by one drop of 1,2-dibromoethane (5 μL, 0.058 mmol). The mixture was stirred overnight at 70°C for 88 hours. The reaction mixture was cooled to 0°C before opening the pressure vessel. The cooled mixture was added dropwise to an ice-cold 1M HCl solution. The reaction was stirred at 0°C for 30 minutes until all Mg solids were dissolved. The mixture was concentrated under vacuum to remove MeOH. The resulting aqueous solution was extracted with ethyl acetate (×3). The combined organic extract was passed through Whatmann phase separation filter paper. The filtrate was concentrated under vacuum to obtain a mixture of methyl rac-(2R,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate and methyl rac-(2S,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (1.487 g, 76%) as a colorless oil. ESI-MS m / z calculated value: 352.10977, measured value: 353.3 (M+1) + Holding time: 0.94, 1.00, 1.01, and 1.04 minutes.

[0354] Step 4: To a cooled solution of a mixture of methyl rac-(2R,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate and methyl rac-(2S,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (1.487 g, 4.221 mmol) in 2-MeTHF (20 mL), potassium tert-butoxide (1.4 g, 12.48 mmol) was added, causing a temperature increase of approximately 5°C. The reaction mixture turned yellow upon the addition of potassium t-butoxide. The reaction mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with ethyl acetate and 1N NaOH. The aqueous layer was separated. The organic layer was further washed with 1M NaOH (×2). The combined organic layers were passed through Whatmann phase separation filter paper. The filtrate was concentrated under vacuum to obtain a mixture of two major diastereoisomers, rac-(2S,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (1.01 g, 71%), as a colorless oil. ESI-MS m / z calculated value: 338.09415, measured value: 337.0 (M-1) - Retention time: 1.20 and 1.27 minutes for the two main diastereoisomers.

[0355] Step 5: DMF (2 μL, 0.026 mmol) and oxalyl chloride (154.2 mg, 106.0 μL, 1.215 mmol) were carefully added to an ice-cold, stirred solution of a mixture of rac-(2S,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid and rac-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (200 mg, 0.591 mmol) in 2-MeTHF (5 mL). The mixture was heated to ambient temperature for 30 minutes. The reaction mixture was concentrated under vacuum. The residue was taken in 2-MeTHF (5 mL) and added to an ice-cold solution of (R)-6-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-amine (155 mg, 0.710 mmol) and triethylamine (384 μL, 2.755 mmol) in 2-methyltetrahydrofuran (5 mL). The resulting mixture was stirred and heated to ambient temperature for 18 hours. The reaction mixture was quenched by adding water (5 mL) and the layers were separated. The aqueous layer was extracted with ELISA (2 × 10 mL). The combined organic extract was passed through Whatmann phase separation filter paper. The filtrate was concentrated under vacuum to obtain the oil.Purified by flash chromatography (0-50% ELISA:EtOH (3:1) containing 2% NH4OH in 4g of SiO2 and heptane) to obtain rel-(2S,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, rel-(2R,3S,4R,5S)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetra A mixture of diastereoisomers was obtained containing hydrofuran-2-carboxamide, rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide, and rel-(2S,3R,4R,5S)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (191.4 mg, 63%). ESI-MS m / z calculated value: 514.1891, measured value: 515.3 (M+1). + ; 513.4 (M-1) - Holding time: 3.60 and 3.67 minutes.

[0356] Step 6: The diastereoisomer mixture obtained in Step 5 was separated by chiral SFC on a Minigram SFC instrument from Berger Instruments using a (R,R)-Whelk-O1 column, 5 μm particle size, 25 cm × 21 mm mobile phase: 5-45% MeOH (containing 20 mM ammonia), 95-55% CO2. Flow rate: 100 mL / min.

[0357] First eluted isomer (retention time = 3.43 min): rel-(2S,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (16 mg, 26%). ESI-MS m / z calculated value 514.1891, measured value 515.0 (M+1) + ; 513.2 (M-1) - ;Retention time: 3.66 minutes.

[0358] Second eluted isomer (retention time = 3.98 min): rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (23 mg, 41%). ESI-MS m / z calculated value 514.1891, measured value 515.1 (M+1) + ; 513.2 (M-1) - ;Retention time: 3.59 minutes.

[0359] Third eluted isomer (retention time = 5.29 min): rel-(2R,3S,4R,5S)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (14 mg, 27%). ESI-MS m / z calculated value 514.1891, measured value 515.1 (M+1) + ; 513.2 (M-1) - ;Retention time: 3.66 minutes.

[0360] Fourth eluted isomer (retention time = 6.44 min): rel-(2S,3R,4R,5S)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (35 mg, 50%). ESI-MS m / z calculated value 514.1891, measured value 515.2 (M+1) + ; 513.2 (M-1) - ;Retention time: 3.59 minutes.

[0361] Step 7: TFA (100 μL, 1.298 mmol) was added to a stirred solution of rel-(2S,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (16 mg, 0.025 mmol) (first eluted isomer from SFC separation) in DCM (5 mL). The reaction mixture was stirred overnight at ambient temperature. The mixture was concentrated under vacuum. The residue was azeotropically mixed twice in DCM, quenched with 1 M NaOH solution, and partitioned in DCM. The aqueous layer was extracted in DCM (×3). The combined organic phase was passed through a phase separator cartridge and concentrated under vacuum. The rel-(2S,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (65 mg, 6.4 mg, 51%) was purified by reverse-phase HPLC-MS using a Waters X-bridge C18 OBD column (150 × 19 mm, 5 mm particle size) to obtain rel-(2S,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (65 mg, 6.4 mg, 51%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.04 (s, 1H), 8.61 (dd, J = 2.5, 0.8 Hz, 1H), 7.96 (dd, J = 8.5, 2.5 Hz, 1H), 7.48 - 7.38 (m, 2H), 7.32 (q, J = 9.1 Hz, 1H), 5.32 (d, J = 4.7 Hz, 1H), 4.68 - 4.59 (m, 2H), 4.56 - 4.49 (m, 1H), 3.83 - 3.73 (m, 1H), 3.62 (dt, J = 10.3, 4.9 Hz, 1H), 3.44 (dt, J = 11.9, ESI-MS m / z calculated value 474.1578, measured value 475.2 (M+1) + ; 473.2 (M-1) - ;Retention time: 2.93 minutes.

[0362] rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (23 mg, 0.038 mmol) (second eluted isomer from SFC separation) was treated in the same manner to obtain rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (66 mg, 10.6 mg, 55%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.39 (s, 1H), 8.65 (dd, J = 2.5, 0.8 Hz, 1H), 7.99 (dd, J = 8.5, 2.5 Hz, 1H), 7.45 - 7.38 (m, 1H), 7.26 (q, J = 9.0 Hz, 1H), 7.17 (dd, J = 8.8, 3.5 Hz, 1H), 5.33 (d, J = 4.8 Hz, 1H), 5.16 (d, J = 10.4 Hz, 1H), 4.63 (t, J = 5.9 Hz, 1H), 4.58 - 4.50 (m, 1H), 4.17 (dd, J = 10.5, 7.5 Hz, 1H), 3.67 - 3.57 (m, 1H), 3.49 - 3.38 (m, 1H), 2.85 (p, J = 7.5 Hz, 1H), 2.28 (d, J = 1.9 Hz, 3H), 1.63 (s, 3H), 0.68 (d, J = 7.4 Hz, 3H) ppm. ESI-MS m / z calculated value 474.1578, measured value 475.2 (M+1) + ; 473.2 (M-1) - ;Retention time: 3.02 minutes.

[0363] rel-(2R,3S,4R,5S)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (14 mg, 0.025 mmol) (the third eluted isomer from SFC separation) was treated in the same manner to obtain rel-(2R,3S,4R,5S)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (67 mg, 7.5 mg, 63%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.05 (s, 1H), 8.61 (dd, J = 2.6, 0.7 Hz, 1H), 7.97 (dd, J = 8.5, 2.5 Hz, 1H), 7.48 - 7.37 (m, 2H), 7.32 (q, J = 9.1 Hz, 1H), 5.32 (s, 1H), 4.64 (d, J = 9.3 Hz, 2H), 4.53 (s, 1H), 3.83 - 3.73 (m, 1H), 3.66 - 3.59 (m, 1H), 3.44 (dt, J = 11.1, 5.8 Hz, 1H), 2.58 (m, 1H), 2.25 (d, J = 1.9 Hz, 3H), 1.60 (s, 3H), 0.95 (d, J = 7.0 Hz, 3H) ppm. ESI-MS m / z calculated value 474.1578, measured value 475.2 (M+1) + ; 473.2 (M-1) - ;Retention time: 2.93 minutes.

[0364] rel-(2S,3R,4R,5S)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-2,2-dimethyl-1,3-dioxolan-4-yl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (35 mg, 0.047 mmol) (the fourth eluted isomer from SFC separation) was treated in the same manner to obtain rel-(2S,3R,4R,5S)-3-(3,4-difluoro-2-methylphenyl)-N-(6-((R*)-1,2-dihydroxyethyl)pyridine-3-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (68 mg, 9.6 mg, 42%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.37 (s, 1H), 8.67 (dd, J = 2.6, 0.7 Hz, 1H), 7.97 (dd, J = 8.5, 2.5 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.26 (q, J = 9.1 Hz, 1H), 7.17 (dd, J = 8.8, 3.5 Hz, 1H), 5.32 (d, J = 4.9 Hz, 1H), 5.16 (d, J = 10.5 Hz, 1H), 4.63 (t, J = 5.9 Hz, 1H), 4.54 (dt, J = 6.8, 4.5 Hz, 1H), 4.17 (dd, J = 10.5, 7.5 Hz, 1H), 3.62 (ddd, J = 10.5, 6.0, 4.1 Hz, 1H), 3.44 (ddd, J = 10.9, 6.9, 5.8 Hz, 1H), 2.85 (p, J = 7.5 Hz, 1H), 2.28 (d, J = 1.9 Hz, 3H), 1.63 (s, 3H), 0.68 (d, J = 6.6 Hz, 3H) ppm. ESI-MS m / z calculated value 474.157...

Claims

1. Compound of formula (I), 【Chemistry 1】 , or a pharmaceutically acceptable salt thereof, in the formula, X 2a However, N, N + -O - , or CR 2a And, X 3a However, N or N + -O - And, X 5a is N, N + -O - , or C-R 5a ​ X 6a However, N, N + -O - , or CR 6a And, R d However, (CH 2 ) m (CHR e ) n (CH 2 ) p It is H, m, n, and p are each independently 0 or 1. R e However, H, OH, halo, C 1 -C 6 Alkoxy, or C 1 -C 6 It is a haloalkoxy, R 2a and R 6a These are H, Haro, and C, each operating independently. 1 -C 6 Alkyl, or C 1 -C 6 It is a haloalkyl, R 5a However, H, Haro, CH 2 OH, C 1 -C 6 Alkyl, or C 1 -C 6 It is a haloalkyl, R 4b1 and R 4b2 H and C are independent of each other. 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, or C 1 -C 6 It is a haloalkyl, R 5b1 and R 5b2 H and C are independent of each other. 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, or C 1 -C 6 It is a haloalkyl, X 3c However, N or C-R 3c And, X 4c However, N or C-R 4c And, X 5c However, N or C-R 5c And, X 6c However, N or C-R 6c And, R 2c However, H, OH, halo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenil, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy or -L 1 -L 2 - (C 3 -C 6 The cycloalkyl group is either unsubstituted or substituted with one or two halos. L 1 However, it is a bond or O, L 2 However, bonding or C 1 -C 6 It is alkylene, R 3c is H, halo, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl, or X 3c is C-R 3c , and R 2c and R 3c together with the carbon atom to which they are attached form a ring of the following formula, 【Chemistry 2】 ; Z 1 and Z 2 Each of them independently is either O or CH 2 And, Each R is independently H or halo. R 4c is H, halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, or C 1 -C 6 haloalkoxy. R 5c However, H, Haro, C 1 -C 6 Alkyl, or C 1 -C 6 It is a haloalkyl, R 6c However, H, Haro, C 1 -C 6 Alkyl, or C 1 -C 6 It is a haloalkyl, However, X 2a , X 3a , X 5a , and X 6a Two or fewer of these are N or N + -O - And, X 3c , X 4c , X 5c , and X 6c A compound of formula (I), or a pharmaceutically acceptable salt thereof, provided that one or less of the elements is N.

2. The aforementioned compound is of formula (I-A) 【Transformation 3】 , A compound according to claim 1, or a pharmaceutically acceptable salt thereof, having the above.

3. The aforementioned compound is of formula (I-A-1) 【Chemistry 4】 , A compound according to claim 1, or a pharmaceutically acceptable salt thereof, having the above.

4. The aforementioned compound is of formula (I-B) 【Transformation 5】 , A compound according to claim 1, or a pharmaceutically acceptable salt thereof, having the above.

5. The aforementioned compound is of formula (I-B-1) 【Transformation 6】 , A compound according to claim 1, or a pharmaceutically acceptable salt thereof, having the above.

6. X 2a However, C-R 2a And R 2a The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein H is present.

7. X 3a The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein N is present.

8. X 5a However, N or C-R 5a And R 5a However, H, halo, or CH 2 The compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is an OH group.

9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X 5a is C-R 5a and R 5a is H, F, or CH2OH.

10. X 6a However, N or C-R 6a And R 6a The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein H is present.

11. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X 6a is C-R 6a and R 6a is H.

12. R 4b1 However, H or C 1 -C 6 The compound according to claim 1, which is alkyl, or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 4b1 is H or CH 3.

14. R 4b2 However, H or C 1 -C 6 The compound according to claim 1, which is alkyl, or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 4b2 is H or CH 3.

16. R 5b1 However, C 1 -C 6 Alkyl or C 1 -C 6 A compound according to claim 1, which is a haloalkyl compound, or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 5b1 is CH3 or CF3.

18. R 5b2 However, C 1 -C 6 Alkyl or C 1 -C 6 A compound according to claim 1, which is a haloalkyl compound, or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 5b2 is CH3 or CF3.

20. R 2c But, OH, Halo, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, or C 1 -C 6 A compound according to claim 1, which is a haloalkoxy, or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 2c is OH, Cl, CH 3, OCH 3, OCD 3, OCH 2 CH 3, OCH(CH 3) 2, OCH 2 CH 2 F, or OCH 2 CHF 2.

22. X 3c However, N or C-R 3c And R 3c However, H, Haro, C 1 -C 6 Alkyl, or C 1 -C 6 A compound according to claim 1, which is a haloalkyl compound, or a pharmaceutically acceptable salt thereof.

23. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X 3c is C-R 3c and R 3c is H, F, CH 3, CHF 2, or CF 3.

24. X 4c However, C-R 4c And R 4c However, H, Haro, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy, or C 1 -C 6 A compound according to claim 1, which is a haloalkoxy, or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X 4c is C-R 4c and R 4c is H, F, CHF 2, OCH 2 CH 3, OCHF 2, OCF 3.

26. X 5c However, C-R 5c And R 5c The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein H is present.

27. X 6c However, C-R 6c And R 6c The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein H is present.

28. R d However, (CH 2 ) p The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein H.

29. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R d is H or CH3.

30. R d However, (CHR e ) n (CH 2 ) p The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein H.

31. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R d is CH₂F, CH₂OH, or CH(OH)CH₃.

32. R d However, (CH 2 ) m (CHR e ) n The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein H.

33. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Rd is CH₂OCH₃ or CH₂CH₂OCH₃. 【Request Item 34】 【Table 1-1】 Table 1-2 Table 1-3 Table 1-4 Table 1-5 Table 1-6 Table 1-7 Table 1-8 Table 1-9 Table 1-10 Table 1-11 Table 1-12 Table 1-13 Table 1-14 Table 1-15 A compound selected from, or a pharmaceutically acceptable salt thereof.

35. A compound selected from the following: 【Chemistry 7-1】 【Chemistry 7-2】 or a pharmaceutically acceptable salt thereof.

36. formula: 【Transformation 8】 Compounds thereof, or pharmaceutically acceptable salts thereof.

37. formula: 【Chemistry 9】 Compounds thereof, or pharmaceutically acceptable salts thereof.

38. formula: 【Chemistry 10】 Compounds thereof, or pharmaceutically acceptable salts thereof.

39. formula: 【Chemistry 11】 Compounds thereof, or pharmaceutically acceptable salts thereof.

40. formula: 【Chemistry 12】 Compounds thereof, or pharmaceutically acceptable salts thereof.

41. formula: 【Chemistry 13】 Compounds thereof, or pharmaceutically acceptable salts thereof.

42. The compound according to any one of claims 1 to 41, which is in a non-salt form.

43. The non-salt form, formula: 【Chemistry 14】 A compound of [this].

44. A pharmaceutical composition comprising a therapeutically effective amount of the compound described in claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or vehicles.

45. A pharmaceutical composition comprising the compound described in claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or vehicles.

46. A composition for use in a method of inhibiting voltage-gated sodium channels in a subject, comprising the compound described in claim 1 or a pharmaceutically acceptable salt thereof.

47. The composition according to claim 46, wherein the voltage-gated sodium channel is Na V 1.

8.

48. A composition for use in treating or reducing the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or cardiac arrhythmia, comprising the compound described in claim 1 or a pharmaceutically acceptable salt thereof.

49. The composition according to claim 48, wherein the method comprises treating the neuropathic pain or reducing its severity in the subject.

50. The composition according to claim 49, wherein the neuropathic pain includes postherpetic neuralgia, small fiber neuropathy, idiopathic small fiber neuropathy, or diabetic neuropathy.

51. The composition according to claim 50, wherein the neuropathic pain includes diabetic neuropathy, and the diabetic neuropathy includes diabetic peripheral neuropathy.

52. The composition according to claim 48, wherein the method comprises treating the musculoskeletal pain or reducing its severity in the subject.

53. The composition according to claim 52, wherein the musculoskeletal pain includes pain of osteoarthritis.

54. The composition according to claim 48, wherein the method comprises treating the acute pain or reducing its severity in the subject.

55. The composition according to claim 54, wherein the acute pain includes acute postoperative pain.

56. The composition according to claim 48, wherein the method comprises treating postoperative pain or reducing the severity thereof in the subject.

57. The composition according to claim 56, wherein the postoperative pain includes pain from aponeurosis excision, pain from abdominal wall reconstruction, or pain from hernia repair.

58. The composition according to claim 48, wherein the method comprises treating visceral pain or reducing its severity in the subject.

59. The composition according to claim 48, wherein the subject is treated simultaneously with treatment by the composition, or with one or more additional therapeutic agents administered before or after such treatment.

60. A composition comprising the compound described in claim 1 or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

Citation Information

Patent Citations

  • Carboxamides as modulators of sodium channels

    JP2020526561A

  • 2-amino-n-heteroaryl-nicotinamides as NAV1.8 inhibitors

    WO2020092667A1